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Resumo 
A doença de Machado-Joseph ou ataxia espinocerebelosa do tipo 3 (DMJ/SCA3) é uma 
doença de repetições trinucleotídicas, causada pela expansão de um segmento repetitivo 
CAG, instável e altamente polimórfico, localizado na região 3’ codificante do gene ATXN3. O 
segmento repetitivo, que normalmente contém 12-41 CAG, encontra-se expandido de 51 a 
86 CAGs nos doentes. A DMJ/SCA3 é uma doença neurodegenerativa, sendo a ataxia 
autossómica dominante mais frequente em todo o mundo. 
O mecanismo subjacente às doenças de poliglutaminas (poliQ), como a DMJ/SCA3, não é 
completamente compreendido. Pensa-se que as doenças de poliQ resultam de um ganho de 
função tóxico, inerente às propriedades nocivas da região expandida nas proteínas mutadas. 
Embora estas proteínas se caracterizem por uma expressão ubíqua, somente algumas 
populações específicas de neurónios são afectados, originando um padrão de morte neuronal 
específico de cada doença. 
O gene ATXN3 codifica a proteína ataxina-3 (ATXN3), uma proteína poliglutamínica, 
intracelular de 42 kDa, com propriedades de ubiquitina hidrolase, in vitro. A existência de 
interacções proteicas diferenciais pode estar na base da morte neuronal selectiva, 
característica da DMJ/SCA3. O objectivo deste trabalho foi a identificação de interactores 
moleculares da ataxina-3. 
Os primeiros interactores proteicos da ATXN3 identificados foram duas proteínas humanas 
homólogas do RAD23, os HHR23A e HHR23B. Estas duas proteínas funcionam como 
moduladoras do sistema ubiquitina-proteassoma, e participam no mecanismo de reparação 
do ADN por excisão nucleotídica (NER), através da interacção molecular com a proteína XPC 
(Xeroderma pigmentosum group C). Neste estudo usámos ensaios de yeast two-hybrid e de 
imunofluorêscencia em células de mamífero, para mostrar que a ATXN3 interactua e 
colocaliza com a proteína XPC. Em células irradiadas com raios ultra-violeta (UV) 
verificámos um aumento desta colocalização. 
A possibilidade de realizar estudos funcionais num organismo multicelular simples, e a 
existência no laboratório de uma estirpe de C. elegans com expressão silenciada do gene da 
ataxina-3 (atx-3), levaram-nos e seguida a avaliar a conservação, no memátode, das 
interacções proteicas observadas no humano, bem como a possível participação da ATXN3 
em vias de reparação do ADN. Neste trabalho, clonámos e expressámos pela primeira vez a 
proteína homóloga das HHR em C. elegans, a ZK20.3. Verificámos que a atx-3 interactua 
com a ZK20.3, evidenciando a conservação evolutiva da base estrutural necessária para esta 
interacção. Além disso, constatámos que o transcrito ZK20.3 é altamente expresso no 
nemátode adulto, tal como o descrito para atx-3. Analisámos, por RT-PCR semi-quantitativa, 
xii 
o efeito do mutagénico ENU (N-ethyl-N-nitrosourea) na expressão dos genes atx-3, ZK20.3 e 
xpc-1 em C. elegans. Neste estudo, mostrámos que a expressão do gene atx-3 é indutível 
pelo ENU, o que sugere uma participação da atx-3 na resposta do nemátode à 
genotoxicidade. Nos ensaios comportamentais, a diferença significativa verificada no 
número de descendestes dos animais mutantes, atx-3-/-, face aos wild-type, quando tratados 
com 1 mM ENU, parece indicar uma maior resistência da estirpe mutante a condições 
genotóxicas; estes resultados conjuntamente com a indução de expressão de atx-3 
verificada na presença de ENU, apontam para uma regulação negativa da atx-3 nos 
mecanismos de reparação do DNA.  
Foi recentemente verificada a acumulação de NEDD8 (neural precursor cell expressed 
developmentally down-regulated 8), uma proteína ubiquitina-like, nas inclusões proteicas 
existentes nos cérebros de doentes DMJ/SCA3. Neste estudo, utilizando ensaios in vitro e de 
imunofluorescência, verificámos que a ATXN3 normal interactua com a NEDD8. A interacção 
é independente dos domínios UIM (ubiquitin-interacting motif) da ATXN3, já que a presença 
do domínio josefina é suficiente e necessária para que a interacção ocorra. A conservação 
da interacção entre a ataxina-3 de C. elegans e a NEDD8, demonstra a sua importância 
biológica e funcional. Estudos de previsão estrutural, sugerem que a interacção da NEDD8 
com o domínio josefina é do tipo substrato-enzima. Os resultados obtidos in vitro com um 
substrato fluorogénico, NEDD8-AMC confirmaram as previsões estruturais, uma vez que a 
ATXN3 possuí actividade de desnedilase in vitro. A actividade de desnedilase é dependente 
da cisteína do centro catalítico, na posição 14 do domínio josefina, uma vez que, a mutação 
deste aminoácido elimina a actividade da proteína in vitro, embora não afecte a interacção 
com o NEDD8.  
As diferentes observações obtidas com este trabalho poderão ajudar a compreender melhor 
a(s) função(ões) da ATXN3 e o seu papel nos mecanismos biológicos nos quais parece estar 
envolvida.  
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Abstract 
Machado-Joseph disease or spinocerebellar ataxia type 3 (MJD/SCA3) is a trinucleotide 
repeat disease, caused by the expansion of an unstable and highly polymorphic CAG segment, 
localized in the 3’-coding region of ATXN3 gene. The repeat segment, which normally 
consists of 12-41 CAG, is expanded from 51 up to 86 CAGs in patients. MJD/SCA3 is a 
neurodegenerative disorder and is the most frequent autosomal dominant ataxia worldwide.  
Although the mechanism underlying polyglutamine (polyQ) diseases, including MJD, is poorly 
understood, it is believed that they are caused by a gain of toxic function, inherent to the 
expanded polyQ tract in the mutated protein. Despite the ubiquitous expression of 
polyglutamine proteins, only a specific subset of neurons is affected in the disease, leading 
to a pattern of neuronal loss that is specific of each disease. 
The ATXN3 gene encodes ataxin-3 (ATXN3), a 42-KDa intracellular polyglutamine protein 
with deubiquitylating properties in vitro. The establishment of differential interactions by 
ATXN3 may be the basis of the selective neuronal loss characteristic of MJD/SCA3. Our goal 
was to identify the molecular partners of ATXN3. The first interactors of human ATXN3 
identified were the human homologues of RAD23, HHR23A, and HHR23B. These proteins have 
been characterised as modulators of the ubiquitin-proteasome system (UPS) and as 
participants of the DNA damage recognition mechanism, in nucleotide excision repair (NER), 
through interaction with Xeroderma pigmentosum group C (XP-C) protein. Here, we used 
yeast two-hybrid assays and immunofluorescence analysis, in mammalian cells, to show that 
ATXN3 interacts and co-localizes with XPC protein. Using UV-radiation assays, we also show 
that their co-localization is enhanced in irradiated cells.  
The possibility to carry out functional studies in a multicellular yet simpler organism, and 
the availability of a C. elegans knockout strain for atx-3 in the lab, led us to proceed our 
studies in this model. We studied the conservation of the interactions observed with the 
human proteins, and the possible participation of ATXN3 in DNA repair. For the first time, 
we have cloned and expressed the C. elegans RAD23 protein homologue, ZK20.3. Moreover, 
we show that atx-3 interacts with ZK20.3, suggesting evolutionary conservation of the 
structural determinants relevant for this novel interaction. ZK20.3 is highly expressed in 
worm adults, as previously observed for atx-3. Using semi-quantitative RT-PCR, we analysed 
the effect of N-ethyl-N-nitrosourea (ENU) upon the expression of atx-3, ZK20.3 and xpc-1 in 
C. elegans. Here, we show that atx-3 is an ENU-responsive gene, suggesting a potential role 
of atx-3 in C. elegans’ response to mutagenics. Behavioural assays showed a significant 
difference between wild-type animal and atx-3-/- progeny, when exposed to 1 mM of ENU, 
suggesting that the absence of atx-3 confers higher resistance of animals to DNA-damaging 
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conditions. Altogether, these results are compatible with the involvement of atx-3 as an 
inducible negative regulator of the DNA repair mechanisms.  
Recently, the accumulation of the neural precursor cell expressed developmentally down-
regulated 8 (NEDD8), an ubiquitin-like protein, in the inclusions of MJD brains was reported. 
Here, we report a new molecular interaction between wild-type ATXN3 and NEDD8, using in 
vitro and immunofluorescence assays. We show that this interaction is independent of the 
ubiquitin-interacting motifs in ATXN3, since the presence of the Josephin domain is 
sufficient and necessary for the interaction to occur. The conservation of the interaction 
between the C. elegans ataxin-3 homologue (atx-3) and NEDD8 suggests its biological and 
functional relevance. Our molecular docking studies of the NEDD8 molecule to the Josephin 
domain of ATXN3 suggest that NEDD8 interacts with ATXN3 in a substrate-like mode. In 
agreement, using NEDD8-AMC hydrolase assays we show that ATXN3 displays deneddylase 
activity, in vitro, against a fluorogenic NEDD8–linked substrate. The insertion of a mutation 
in the active site of ATXN3, C14A, though not affecting the interaction with NEDD8, 
abrogates ATXN3 catalytic activity towards this substrate.  
The evidence generated in this work should contribute to a better understanding of the 
normal function(s) of ATXN3 and to elucidate its role in the pathways that it seems to be 
involved with.    
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Résumé 
La Maladie de Machado-Joseph (MJD/SCA3) est une maladie de trinucleotides, dont la cause 
est l’expansion d’une répétition CAG instable et très polymorphique, dans la région 3’ 
codante du gène ATXN3. Le segment répétitif, qui contient normalement 12-44 CAG, est 
expansé jusqu’à 61-87 CAG chez les patients. MJD/SCA3 est une maladie neurodégénérative 
autosomique dominante, et une des ataxies dominantes plus fréquentes dans le monde. 
Même si le méchanisme pathogénique des maladies de polyglutamines est très peu compris, 
on croît que ces maladies sont causées par un gain de fonction toxique inhérent à la 
protéine mutante. Malgré l’expression ubiqüe des protéines de polyglutamines, ces maladies 
sont caractérisées par des patrons spécifiques de mort neuronale. 
Le gène ATXN3 codifie la protéine ataxine-3 (ATXN3), une protéine intracellulaire de 42kDa 
avec activité de desubiquitination in vitro. L’établissement d’interactions différentielles par 
cette protéine peut expliquer pour la perte sélective de neurones qui caractérise la MJD, 
malgré l’expression généralisée de ATXN3. Le but de ce travail a été l’identification des 
interacteurs de ATXN3. Les premiers interacteurs moléculaires de ATXN3 identifiés on été 
des homologues humaines de RAD23, HHR23A et HHR23B. Ces protéines ont été 
caractérisées comme modulateurs du système ubiquitine-proteasome (UPS) et participent au 
mécanisme de reconnaissance de lésions du DNA dans le système de réparation par excision 
(NER), par l’interaction avec la protéine Xeroderma pigmentosum group C (XP-C). En ce 
travail, on montre par le système y2h et par l’analyse d’immunofluorescence dans des 
cellules HEK293 que ATXN3 et XPC interagissent et co-localisent, et que la radiation UV 
augmente cette co-localisation.  
En plus, on rapporte, pour la première fois, le clonage et analyse d’expression de 
l’homologue de RAD23 dans le C. elegans, ZK20.3, et on démontre que atx-3 (l’homologue 
de ATXN3) interagit avec ZK20.3, ce qui suggère la conservation évolutive des motifs 
structurels nécessaires à cette interaction. Le gène ZK20.3 s’exprime fortement dans les 
vers adultes, comme il a été observé pour l’ataxine-3. Par RT-PCR, on étudié l’effet de 
l’agent mutagénique ENU (N-ethyl-N-nitrosurée) dans l’expression des gènes atx-3, ZK20.3 
et xpc-1 dans les vers. Une induction de l’expression de atx-3 a été détectée chez les 
animaux traités à l’ENU, ce qui suggère un rôle pour l’atx-3 dans la réponse à la 
genotoxicité. La différence dans le nombre de descendants de C. elegans du type sauvage et 
knock-out pour atx-3 traités avec ENU suggère une résistance augmentée des mutants. Ces 
résultats semblent indiquer un rôle de l’ataxine-3 comme régulateur négatif de la réponse 
aux lésions de DNA. 
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Récemment, il a été démontré dans le cerveau de patients MJD/SCA3 que les inclusions 
intranucléaires ubiquitinées, caractéristiques des maladies de polyglutamines, contenaient 
aussi de la protéine NEDD8 (neural precursor cell expressed developmentally down-
regulated 8), une protéine ubiquitin-like (UBL). En cet étude, on a vérifié, par des essais in 
vitro et d’immunofluorescence, que l’ATXN3 normale interagit avec NEDD8. Cette 
interaction ne dépend pas des domaines UIM (ubiquitin-interaction motifs), vu que le 
domaine Josephin (JD) est suffisant et nécessaire pour l’interaction. La conservation de 
l’interaction entre l’ataxine-3 de C. elegans et NEDD8 démontre son importance biologique 
et fonctionnelle. Nos études de prévision structurelle suggèrent que l’interaction de NEDD8 
avec le JD est du type substrat-enzyme. Les résultats des études in vitro avec un substrat 
fluorescent NEDD8-AMC ont confirmé cette hypothèse, vu que ATXN3 démontre une activité 
deneddilase. Cette activité catalytique dépend de la cysteine 14 du centre actif, dans le JD, 
car la mutation de ce résidu élimine l’activité deneddilase de la protéine, même si elle ne 
modifie pas l’interaction entre ATXN3 et NEDD8. 
Les résultats de ce travail peuvent aider à mieux comprendre les fonctions physiologiques 
d’ATXN3 et son rôle spécifique chez les mécanismes biologiques qu’elle intègre. 
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Trinucleotide repeat disorders 
The identification of expanded trinucleotide repeats in various genes has been found to 
be the ultimate cause of a growing number of neurodegenerative disorders. The 
trinucleotide repeats expansions are dynamic, changing in size upon transmission to the 
offspring. The repeats usually show meiotic and mitotic instability. Ensuing their 
intergenerational instability, affected families experience anticipation or earlier age of 
onset and increased severity of the disease.   
To date, 16 neurological diseases are known to be caused by expansion of trinucleotide 
repeats (Orr and Zoghbi, 2007). Based on the repeat localization within the gene, the 
trinucleotide repeat disorders may be sub-divided in two classes: coding or noncoding. 
 
Non-coding trinucleotide repeat diseases 
The non-coding trinucleotide repeat diseases typically comprise large and highly 
variable repeat expansions, which result in multiple tissue dysfunction or degeneration. 
The diseases phenotypes are variable, possibly due to the pronounced degree of somatic 
heterogeneity. It has been discovered that the mutational event of this sub-class is 
based on the existence of pre-mutations, usually clinically silent intermediate size 
expansions from which the larger mutations are transmitted. Non-coding trinucleotide 
diseases may be caused by CGG, GCC, GAA, CTG and CAG repeats. Besides the sequence 
of the repeat, its location with respect to the gene, are determinant factors in the 
pathogenic mechanism underlying each disease. Non-coding trinucleotide diseases may 
result from the lost function of the respective proteins or acquired function of a toxic 
transcript. This group includes Fragile X syndrome (FRAXA), Fragile-XE syndrome 
(FRAXE), Friedreich ataxia (FA), myotonic dystrophy (DM), Fragile X-associated tremor 
ataxia syndrome (FXTAS), spinocerebellar ataxia type 8 (SCA8), spinocerebellar ataxia 
type 12 (SCA12) (Orr and Zoghbi, 2007) (Table 1). 
 
Coding trinucleotide repeat diseases 
The expansions associated with this sub-class are much smaller and, the repeat 
instability is a phenomenon less pronounced, but no less severe. This group includes 
diseases caused by the expansion of a repetitive segment of alanine (GCG) or glutamine 
(CAG). 
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Polyalanine diseases 
Expansions of trinucleotide repeats (GCG) encoding polyalanine tracts are the cause of 
several diseases, predominantly congenital malformation syndromes, skeletal dysplasia 
and nervous system anomalies. Typically, the expanded repeats result from in-frame 
duplications or insertions within the nucleotide sequence encoding the alanine stretch; 
the expanded alleles are stable mitotically and meiotically, with the only exception 
being a further expansion of one trinucleotide repeat in the PABPN1 gene involved in 
oculopharyngeal muscular dystrophy (OPMD). Other examples of such disorders are 
synpolydactyly syndrome (SPD), hand–foot–genital syndrome (HFGS), X-linked mental 
retardation and growth hormone deficit (XLMR+GHD) and X-linked mental retardation 
and abnormal genitalia (XLAG) (Amiel et al., 2004). 
 
Polyglutamine diseases 
The identification of the causative mutation of SBMA (spinal and bulbar muscular 
atrophy) or Kennedy disease, back in 1991, by Fischbeck et al. (1991) defined a new 
class of neurodegenerative diseases. This emerging class of triplet diseases includes, so 
far, nine polyglutamine (polyQ) diseases: SBMA/Kennedy disease, Huntington disease 
(HD), and seven spinocerebellar ataxias - SCA1, dentatorubral-pallidoluysian atrophy 
(DRPLA), SCA2, Machado-Joseph disease/SCA3, SCA6, SCA7 and SCA17 (Table 2). The 
expansion of a repetitive tract of CAG (cytosine-adenine-guanine) is located in the 
coding region of the genes of interest, hence producing proteins with long 
polyglutamine tracts. 
With the unique exception of SMBA, which is X-linked, all are autosomal dominant 
inherited disorders, with a late clinical onset characterized by progressive neuronal 
degeneration with loss of coordination, motor and, in some of these diseases, cognitive 
impairment (reviewed in Zoghbi and Orr, 2000). Clinically, the polyQ diseases often 
overlap and their strikingly similar mutations may suggest that a common pathogenic 
mechanism may underlie all polyQ diseases. The recent work of Lim et al. (2006), 
strengthened this close proximity between the different polyQ-associated ataxias, with 
the comprehensive definition of the “ataxia-ome”, where many ataxia-causing diseases 
were shown to share defined interaction clusters.  
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   Table 1. Features of unstable repeat diseases caused by expanded, non-coding triplets.  
 
   repeat intervals  
Disease (acronym)   MIM Main clinicopathology 
  
Repeat unit/location 
 Normal  Pathological 
 Gene product  
Fragile X syndrome  
(FRAXA) 309550 
Mental retardation, macroorchidsm, 
connective tissue defects, behavioral 
abnormalities 
 (CGC)n/5’UTR 
 
6-60 >200  
(full mutation) 
 
FMRP 
Fragile XE syndrome  
(FRAXE) 309548 Mental retardation 
 (CCG)n/5’ UTR 
 
4-39 200-900 
 
FMR2 
Friedreich ataxia  
(FRDA) 229300 
Sensory ataxia, cardiomyopathy, 
diabetes 
 (GAA)n/intron 1 
 
6-32 200, 1700 
 
Frataxin 
Myotonic dystrophy type 1 
(DM1) 160900 
Myotonia, weakness, cardiac 
conduction defects, insulin resistance, 
cataracts, testicular atrophy, and 
mental retardation in congenital form 
 (CTG)n/3’ UTR 
 
5-37 50-10,000 
 
DMPK 
(serine/threonine 
kinase) 
Fragile X-associated tremor 
ataxia syndrome (FXTAS) 309550 
Late onset ataxia, tremor, 
Parkinsonism, and dementia 
 (CGG) n/5’UTR 
 
6-60 60-200  
(pre-mutation) 
 
FMR1 RNA 
Spinocerebellar ataxia type 8 
(SCA8) 608768 Ataxia, dysarthria, nystagmus 
 
(CTG)n/3-prime 
terminal exon 
 
16-34 >74 
 
SCA8 RNA 
Spinocerebellar ataxia type 12 
(SCA12) 603516 Ataxia and seizures 
 (CAG)n/5’UTR 
 
7-45 55-78 
 
PPP2R2B  
(regulatory subunit of 
phosphatase PP2A) 
Huntington disease-like 2 
(HDL2) 606438 Similar to HD 
 
(CTG)n/splice acceptor 
site of an alternatively 
spliced exon 
 
7-28 66-78 
 
Junctophilin 
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No physiological function was determined for the majority of the proteins involved in 
the polyQ diseases, with the exception of the androgen receptor in SBMA, the voltage-
gated α1A subunit of calcium channel in SCA6, the transcription activator atrophin-1 in 
DRPLA, and the TATA-binding protein mutated in SCA17 (Table1).  
Apart from the existence of a polyQ tract, no other similar features were found, so far, 
among polyQ proteins, albeit the location of the polyQ tract within the protein differs 
from one disease gene to another. The expansion of the repetitive segment seems to 
confer toxic properties to the proteins, and evidence suggests the inherent misfolded 
state is linked with its toxicity and gain of function, leading to the abnormal protein-
protein interactions and aggregation. Despite the fact that both normal and mutated 
polyQ proteins show ubiquitous expression, both in the CNS and in peripheral tissues, 
the diseases are mainly confined to the CNS (except in SBMA and in a juvenile-onset 
SCA7 case), where only specific sub-types of neurons are affected, leading to very 
selective patterns of neurodegeneration (Zoghbi and Orr, 2000).   
The CAG repeats are highly polymorphic in the normal population, presenting somatic 
and germline instability; the expanded CAG repeats are particularly unstable, changing 
in size upon transmission (Richards, 2001). The repeat length correlates inversely with 
clinical age of onset and severity of the disease (Gusella and MacDonald, 2000); larger 
expansions are often associated with juvenile onset and more generalised 
neurodegeneration pattern (Holmberg et al., 1998; Andresen et al., 2007). The dynamic 
nature of these mutations, may in part justify the variability in expression, including the 
age-at-onset, and the severity of the disease. Moreover, due to this intergenerational 
repeat instability, affected families may display the phenomenon of anticipation, 
characterised by earlier age-at-onset, increased severity, and faster progression of the 
disease (reviewed in Orr and Zoghbi, 2007).  
 
 
Pathogenic mechanisms underlying polyQ disease  
 
The importance of polyQ domain 
As mentioned above, apart from the polyQ segment, the proteins involved in 
polyglutamine diseases show virtually no similarity. This, and the fact that the age-at-
onset and severity correlates with the polyQ length, suggests a major role for this 
domain itself in the pathogenesis. Based on this, most of the initial experiments  
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Table 2. Features of polyglutamines disease caused by expanded, coding CAG repeats. 
 
  CAG intervals   
Disease (acronym)   MIM Main clinicopathology 
  
Gene 
Normal  Pathological   
Protein product, MW Function 
Dentatorubropallydolluysian 
atrophy (DRPLA) 125370 
ataxia, seizures, 
choreoathetosis, 
dementia 
  ATN1 6-34 49-88   atrophin-1 (ATN1), 125 kDa Transcriptional regulator 
Huntington disease (HD) 143100 
chorea, dystonia, 
cognitive deficit, 
psychiatric alterations  
  HD 6-34 36-121   huntingtin (Htt), 350 kDa Unknown 
Spinal and bulbar muscular 
atrophy (SBMA; Kennedy 
disease) 
313200 
motor weakness, 
swallowing, 
gynaecomastia, 
decreased fertility 
  AR 9-36 38-62   androgen receptor, 100 kDa Androgen receptor 
Spinocerebellar ataxia type 1    
(SCA1) 164400 
ataxia, dysarthria, 
spasticity, cognitive 
impairment 
  ATXN1 6-38 39-82   ataxin-1 (ATXN1), 87 kDa Unknown (transcription?) 
Spinocerebellar ataxia type 2    
(SCA2) 183090 
ataxia, polyneuropathy, 
decreased reflexes, 
possible infantile variant 
with retinopathy 
  ATXN2 15-24 35-200   ataxin-2 (ATXN2), 90 kDa Unknown  (RNA metabolism?) 
Machado-Joseph disease  or 
Spinocerebellar ataxia type 3 
(MJD/SCA3) 
109150 
ataxia, dysarthria 
parkinsonism, spasticity, 
myotrophy 
  ATXN3/MJD1 12-41 (51)55-86   ataxin-3 (ATXN3), 42 kDa Deubiquitylating enzyme (?) 
Spinocerebellar ataxia type 6    
(SCA6) 183086 
ataxia, dysarthria, 
nystagmus, tremors   CACNA1A 4-18 19-33   
α1A subunit of the neuronal           
P/Q-type voltage-gated calcium 
channel (CACNα1A), 250 kDa 
Ca2+ channel 
Spinocerebellar ataxia type 7    
(SCA7) 164500 
ataxia, blindness, 
possible infantile variant 
with cardiac failure 
  ATXN7 4-27 37- ≥200   ataxin-7 (ATXN7), 96 kDa Unknown (transcription?) 
Spinocerebellar ataxia type 17  
(SCA17) 607136 
ataxia, cognitive deficit, 
seizures, psychiatric 
alterations 
  TBP 25-42 45-63   TATA-binding protein (TBP),          42 kDa 
Transcription 
factor 
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were centred in determining the biological importance of the polyQ tract in disease.  
Several lines of evidence have been strengthening the hypothesis that the polyQ 
diseases are due to a toxic gain of function attributable to the polyQ expansion: (1) the 
deletion of the endogenous mouse HD homologue gene, lead to embryonic lethality but 
not a HD-like disease (Zeitlin et al., 1995); (2) absence of a functional AR gene causes 
male feminization and not SBMA (Zoppi et al., 1993) while castration of male mice 
exbhiting SBMA reverted dramatically the phenotype, suggesting to be an hormone-
dependent phenotype (Katsuno et al., 2002); (3) nullizygous ATXN1 mice displayed no 
cerebellar ataxia (Matilla et al., 1998); (4) a conditional HD mouse model expressing 
mutated huntingtin (htt) under the regulation of a tet-on/off promoter system showed 
that expression of the mutant Htt led to the appearance of characteristic features of 
the disease and blockage of such expression ameliorated the inclusion formation as well 
as the progressive motor dysfunction (Yamamoto et al., 2000); (5) the existence of 
homozygotes in HD (Squitieri et al., 2003), MJD (Lang et al., 1994) and SCA17 
(Toyoshima et al., 2004) typically exhibiting aggravated phenotype is evidence for a 
partial dominance effect. 
 
The influence of the protein context 
The idea that the expanded polyglutamines are toxic and responsible for pathology, led 
to the early experiments and the development of transgenic mouse models for HD 
(Mangiarini et al., 1996; Mangiarini et al., 1997) and MJD (Ikeda et al., 1996). In both 
cases, mice expressing a truncated fragment of the protein containing an expanded 
polyQ tract could recapitulate most of the disease phenotypes, namely the 
intergenerational instability associated with the expanded alleles. Conversely, no 
disease phenotype was observed in mice expressing normal-sized polyQ tracts. However, 
the most critical biological feature, neuronal degeneration, could only be observed 
when a full-length mutant htt was expressed (Reddy et al., 1998). With an age-
dependent phenotype, the HD mouse model showed selective neuronal degeneration 
and evidence that the protein context, and not solely the polyQ tract, could mediate 
the disease progression and selective vulnerability associated with each different polyQ 
disease (Reddy et al., 1998).  
The importance of the protein context in polyQ proteins was reinforced by the 
identification of key amino acids or segments of the protein that could modulate the 
presentation and severity of disease. In SCA1, Skinner et al. (2002) identified an amino 
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acidic segment, external to polyQ, which could affect the disease progression. Later on, 
in complementary studies, Emamian et al. (2003) observed that a serine at position 776 
in the protein (S776) and its inherent phosphorylation was associated with the formation 
of aggregates and neurodegeneration; Chen et al. (2003) found that, in a fly SCA1 
model, the protein-protein interactions depended on S776 were modulated by its 
phosphorylated-state in a polyQ-dependent manner. More recently, it was demonstrated 
in a cell- and rat-based model, that the toxicity of mutant Htt could be inhibited by the 
AKT-dependent phosphorylation of Htt at S421 (Humbert et al., 2002) or by cyclin-
dependent kinase 5 (Cdk5)-mediated phosphorylation at S434 of Htt (Luo et al., 2005) 
suggesting a neuroprotective role of phosphorylation in HD (Pardo et al., 2006). 
Recently, both normal and mutant ATXN3 were shown to be substrates of glycogen 
synthase kinase 3β (GSK3β); furthermore, phosphorylation was seen to be dependent of 
S256 and to be inversely correlated with polyQ length; moreover, phosphorylation 
inhibited aggregation of mutant ATXN3, implying a critical role of phosphorylation, also 
in MJD (Fei et al., 2007). Together, these observations suggest that post-translational 
modification may be determinant molecular events in the disease initiation and/or 
progression and that the polyQ expansion may be not sufficient to the pathology. 
 The increasing biological relevance of a region external to the polyQ region, may 
suggest that expression of the normal protein is important in the disease process, 
although by a mechanism that remains to be elucidated.  
 
The aggregation phenomenon 
The presence of aggregates containing the mutant protein is a hallmark of all polyQ 
diseases (Orr and Zoghbi, 2007). Analysis of patient’s post-mortem material allowed the 
observation that the expansion of the polyQ segments above a given threshold led to 
neurological disease and to the formation of mutant protein-containing aggregates 
(DiFiglia et al., 1997). This inherent characteristic of expanded polyQ proteins, rapidly 
gathered the interest of the scientific community and several theories emerged trying 
to explain the pathogenesis associated with these aggregation-prone conditions.  
 
Polar zipper 
The “polar zipper” theory presented by Perutz et al. hypothesized that expanded units 
of polyQ proteins could establish strong hydrogen bonds with each other above a 
threshold length leading to insoluble parallel β-sheet structures (Perutz et al., 1994). 
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Later on, it was suggested an alternative model in which β-helices, composed of 20 
residues per turn, could be considered as the precipitating unit underlying the 
aggregation phenomena (Perutz et al., 2002a; Perutz et al., 2002b). 
 
Transglutaminases 
The participation of transglutaminases, and their ability to cross-link the polyQ 
proteins, was also pointed out as a possible mechanism underlying the aggregation 
typical in these diseases (Kahlem et al., 1996; Kahlem et al., 1998).  
 
Aberrant interactions 
The establishment of new aberrant protein-protein interactions dependent of the 
expansion-promoted conformational changes may be important for the formation of 
aggregates. The inhibition and sequestration of cellular proteins as transcription factors 
or activators, which comprise also polyQ tracts, may increase and aggravate the 
aggregative phenomena (Chai et al., 2001). 
 
Toxic fragment 
Based on the intrinsic properties of the polyQ tract, the hypothesis of the existence or 
the production of a toxic fragment, comprising the polyQ domain, also tries to explain 
the neurotoxicity underlying these disorders, attributing secondary importance to the 
protein context. In vitro experiments that showed full-length huntingtin, AR, atrophin-1 
and ATXN3 as substrates of purified caspases (Goldberg et al., 1996; Kobayashi et al., 
1998; Wellington et al., 1998; Berke et al., 2004), consolidated the existence of C-
terminal fragments as putative by-products. The biological relevance of these fragments 
were recently shown both in MJD transgenic mice and MJD patients, where a fragment 
comprising the polyQ domain exerted cytotoxicity when expressed above a critical 
concentration (Goti et al., 2004). Additionally, Haacke et al. (2006) showed that 
expanded ATXN3, upon N-terminal truncation, could initiate aggregation in a neuronal 
cell line; accordingly, they demonstrated that ATXN3 is a substrate of calcium-
dependent calpain proteases (Haacke et al., 2007), reinforcing the biological 
importance of ATXN3 fragmentation mainly at the beginning of the MJD pathology. 
Moreover, work from our group using a worm-based model (Teixeira-Castro et al. 
unpublished work) suggests that a C-terminal fragment of human ATXN3 sustains the 
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nucleation/seeding events that lead, in an aging-dependent manner to visible 
aggregation in the worm. These facts support the notion that proteolytic cleavage of 
polyQ proteins may contribute to onset or progression of the disease process.  
 
Aggregates: a good or a bad solution? 
The role of inclusions in the characteristic neuronal loss remains controversial. Whether 
they are, per se, toxic, neutral or a protective strategy of the cell to restrict the 
abnormal reactivity of misfolded polyQ proteins towards other cellular components still 
needs clarification.  
The fact that inclusions are composed of proteasome subunits, ubiquitin, chaperones 
and even the normal-sized proteins, and not solely by “pure” polyQ proteins, supports 
the inherent toxicity of these structures (Paulson et al., 1997b; Stenoien et al., 1999; 
Chai et al., 2001). In fact, over-expression of chaperones in animal and cell-based 
models of these disorders ameliorated the polyQ toxicity (Warrick et al., 1999; 
Kobayashi et al., 2000; Cummings et al., 2001), further reinforcing that the presence of 
chaperones in the aggregates are failed attempts of the cell to eliminate or solubilize 
such toxic structures.  
Yet, several evidences favour the hypothesis that these structures may be a way that 
cell found to “suppress” the disruptive presence of the mutant proteins by stacking 
them in aggregates. First, inclusions are not restricted to the sites where severe 
neuronal loss is observed (Holmberg et al., 1998). In patients with SCA17, polyQ-positive 
aggregates are present in the neurons of the grey matter that do not die in the disease 
process; whereas, affected, “destined-to-die” Purkinje cells show no aggregation (Rolfs 
et al., 2003). Moreover, experimental conditions that prompted a reduction in the 
formation of inclusions, led to enhanced toxicity of a fragment of mutant huntingtin in 
neuronal cultures (Saudou et al., 1998), and in neurons of a SCA1 mouse model 
(Cummings et al., 1999). Moreover, a SCA1 mouse model expressing the mutant ATXN1 
without its dimerization domain, showed signs of the disease without neuronal inclusion 
(Klement et al., 1998). Another evidence lays on the naturally occurring aggregates 
resulting of the metabolic aging neuron, as the Marinesco bodies found in the substantia 
nigra, which seems to be a strategy adopted by normal-aging neurons, throughout time 
(Fujigasaki et al., 2000). 
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If the inclusions play a protective role, they must be doing so by avoiding inappropriate 
interactions within the cell. Thus, the study of the normal and mutant protein’s 
interactions has also been a theme of great interest, in an attempt to establish the 
pathway(s) in which they participate and, ultimately, the mechanism(s) leading to the 
disease.  
 
The apparently dissonant evidence regarding the importance of the protein context, the 
polyQ tract or the role of aggregates in the cell, may result from the different cell types 
and mouse models explored. The difference in the protein content of the cells used may 
account for some of the differences observed, as can the genetic background of the 
mice used to generate transgenic or KO mice, due to the possible existence of genetic 
modifiers, which are still poorly understood. The differential use of either full–length or 
truncated mutant variants of the polyQ protein may also contribute to some of the 
apparent differences reported. 
 
 
The mechanism of pathogenesis polyQ proteins is intimately linked to at least two major 
cellular events, transcription regulation and the protein quality control. 
 
Transcription (dys)regulation 
The polyQ aggregates are both nuclear and/or cytosolic, but most are predominantly 
intranuclear inclusions, being found in cells affected by the disease, suggesting that the 
nucleus is the major site of the pathology (Orr and Zoghbi, 2007). The exceptions are 
SCA2 and SCA6, characterised mainly by the formation of cytosolic or perinuclear 
inclusions, respectively (Ishikawa et al., 2001).  
The translocation of polyQ proteins to the nucleus has been set as a prerequisite of 
their toxicity. It has been demonstrated that mutation of nuclear localisation signals 
(NLS) aborting the localization of mutant ATXN1 in the nucleus, led to no manifestation 
of the disease in mice (Klement et al., 1998). In a cell-based model, with striatal 
neurons expressing a nuclear export signal (NES) in mutant fragment of huntingtin 
reduced its ability to cause cellular death (Saudou et al., 1998), whereas, the presence 
of a NLS caused the opposite effect (Peters et al., 1999). Recently, Bichelmeier et al. 
(2007), showed the first in vivo evidence that nuclear localization of ataxin-3 is 
required for the manifestation of symptoms, whereas the export of ataxin-3 out of the 
General Introduction 
13 
nucleus prevents the manifestation of phenotype. Thus, the nucleus seems to be critical 
for the pathogenesis of polyQ diseases. Several evidence have supported the notion that 
major alterations in gene expression occur in the cell in polyQ-associated disorders 
(reviewed in Okazawa, 2003), namely HD (Wyttenbach et al., 2001; Zuccato et al., 
2001; Luthi-Carter et al., 2002), DRPLA (Wood et al., 2000), MJD (Evert et al., 2001; 
Evert et al., 2006), SBMA (Lieberman et al., 2002), SCA1 (Lin et al., 2000) and SCA7 (La 
Spada et al., 2001).  
PolyQ-dependent transcription regulation/modulation may be explained by three 
mechanisms.  
 
The entrapment hypothesis suggests that polyQ proteins may “trap” rate-limited 
transcriptional activators or co-activators. The entrapment of rate-limited, essential 
transcriptional modulators, into inclusions, may lead the cell to an unsustainable 
situation, causing cell death. Several reports have directly associated polyQ proteins 
with transcriptional modulators as TBP, TBP-interacting protein TAFII130 and SP1 
transcription activators (Dunah et al., 2002). SP1 is ubiquitously expressed and is 
involved in the regulation of essential genes.  
CBP (CREB-binding protein) is a transcriptional co-activator, typically found in inclusions 
of cell cultures, transgenic models and post-mortem tissues of HD and DRPLA patients 
(Steffan et al., 2000; Nucifora et al., 2001), SCA7 (Strom et al., 2005), SBMA and MJD 
(McCampbell et al., 2000). In vivo proof that the depletion of CBP may lead to 
neurological phenotypes resembling polyQ diseases, came from the KO mice of CREB 
(cAMP response element-binding), which showed neurodegeneration (Mantamadiotis et 
al., 2002).  
Alternatively, polyQ proteins may exert their toxic effect through direct inhibition of 
acetyltransferase activity of transcription modulators, leading to diminished histone 
acetylation and, concomitantly, gene transcription activation. CBP and PCAF 
(p300/CBP-associated factor) are transcription activators that regulate gene expression 
through their intrinsic histone acetylase activity (Ogryzko et al., 1996). A mutant 
truncated fragment of huntingtin has been shown to inhibit transcription, by repressing 
the histone acetylase activity of CBP/p300/PCAF transcriptional co-activator (Steffan et 
al., 2001). An active participation of polyQ proteins in transcription, as dual co-
repressors, has been demonstrated for ATXN3; Li et al. (2002), observed that ATXN3 
could interact through its C-terminal with CBP, p300 and PCAF, inhibiting CREB-
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dependent gene transcription; and through its N-terminal, ATXN3 could inhibit 
transcription by direct binding to histones, masking their acetylation sites. 
 
Besides the analysis of the indirect consequences of the polyQ expression in cells or 
animal models, the involvement of polyQ disorders in the direct repression of the 
transcriptional machinery as cause of neurodegeneration may be ascertained. 
Atrophin-1 (ATN1) is a transcriptional co-repressor; the expansion of its polyQ tract 
leads to DRPLA (Wood et al., 2000). The direct interaction of ATN1 and ETO/MTG8, a 
nuclear protein participating in repressor complexes, unveiled a possible role of another 
polyQ protein in transcription regulation. Zhang et al. (2002) showed that both the 
human and fly homologues of ATN1 had transcription repressive activities in vivo, 
inversely correlating with the length of polyQ tract. As described before, both the 
androgen receptor (AR) involved in SBMA, and the TATA-binding protein (TBP), mutated 
in SCA17 are transcription factors (Nakamura et al., 2001). TBP binds to TATA box of 
several genes, thus having a general effect upon transcription. Moreover, a direct 
interplay between the expression of different polyQ proteins has been reported: 
Schaffar et al. (2004) reported that soluble huntingtin was negatively modulating the 
activity of TBP, in a polyQ–dependent manner.  
None of the hypotheses reviewed is mutually exclusive, and the observed interplay 
between the polyQ proteins suggests exactly the opposite. Either in a more specific 
(e.g. SP1 in HD) or broad manner (CBP has been referenced in a large set of polyQ 
disorders), the evidence gathered are consistent with the polyQ proteins involvement in 
transcription modulation. 
 
Protein quality control 
The proteasome is a large multicatalytic complex found in most prokaryotic and 
eukaryotic cells and is located in both the cytoplasm and the nucleus (Ellis, 2006). 
Working together with the proteasome there are the chaperones. Most chaperones are 
expressed constitutively, though some are heat and stress induced: the heat-shock 
proteins (HSPs). Wickner et al. (1999) showed that HSPs could indeed associate with 
proteasome and facilitate the degradation of unfolded proteins, as an alternative to the 
refolding pathway. For example, the discovery of two additional co-chaperones, CHIP 
and BAG-1, helped to elucidate the link between chaperones and proteasome. CHIP (C-
terminus Hsp70 interacting protein) is a chaperone-dependent E3 ligase that binds to 
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Hsc/Hsp70, inhibits its chaperone activity, and promotes proteasomal degradation of its 
unfolded substrates. Moreover, BAG-1 helps Hsc/Hsp70 to deliver its cargo to the 26S 
proteasome by binding the proteasome through its UBL domain. Conversely if the Hsc-
Hsp70 complex and its bound cargo interact with two other co-chaperones, Hip/Hop, 
the refolding pathway is favoured and the cargo is not destroy in the proteasome. As a 
chaperone-dependent E3 ligase, CHIP establishes a close link between molecular 
chaperones and the ubiquitin/proteasome system in the protein quality control 
(Bregegere et al., 2006). A tight equilibrium underlies the decision for protein refolding 
or degradation.  
 
Protein quality control and neurodegeneration 
Neuronal inclusions in MJD, HD, SCA7, SCA1 and SBMA are known to harbour components 
of the protein surveillance machinery, as ubiquitin, proteasome subunits, chaperones 
and ubiquitin-like proteins (Paulson et al., 1997b; Cummings et al., 1998; Chai et al., 
1999a; Chai et al., 1999b; Stenoien et al., 1999; Takahashi et al., 2002; Chai et al., 
2004; Mori et al., 2005). Such a strong presence of proteins involved in the protein 
quality control mechanisms leaves little doubts about the effort that the cell exposed to 
expanded polyQ endeavors to restore its protein homeostasis. In a fly model of MJD, 
overexpression of chaperones was able to reverse the polyQ aggregation observed 
(Warrick et al., 1998). Moreover, several pieces of evidence demonstrated that 
chaperone overexpression led to increased solubility of polyQ proteins (Chan et al., 
2000; Muchowski et al., 2000; Cummings et al., 2001; Bailey et al., 2002). The shuttling 
of misfolded proteins to the proteasome has been recently addressed by Jana et al. 
(2005) who demonstrated that interaction of CHIP with HSP70 facilitates the 
ubiquitylation of huntingtin and ATXN3.  
The co-existence of proteasome subunits in the polyQ inclusions raised the possibility of 
proteasome impairment in polyQ disease. This was strengthened when Holmberg et al. 
(2004) showed, using live cell imaging, that polyQ aggregates could irreversibly 
sequester the proteasome; additionally, the aggregates could get trapped within the 
proteasome, leading to its inefficient activity. However, conflicting data demonstrated 
that soluble and normal expanded proteins could be efficiently degraded by 26S but the 
aggregates seemed to “overwhelm” the degradation motor of the cell, albeit not 
irreversibly inhibiting it (Yamamoto et al., 2000; Michalik and Van Broeckhoven, 2004). 
Moreover, the pharmacological inhibition of the proteasome in a cell line expressing 
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mutant ATXN3 led to aggregation enhancement, suggesting an active role of the 26S 
complex in aggregate clearance in MJD pathology (Chai et al., 1999b). 
Other ubiquitin-proteasome system (UPS) components are present in polyQ inclusions. 
Typically, neuronal inclusions are ubiquitylated and increasing evidence links the UPS to 
the neurodegeneration. This was demonstrated with a mouse model expressing the 
mutated ATXN1 protein and lacking E3 ubiquitin-ligase E6-AP, which displayed 
accelerated neurodegeneration (Cummings et al., 1999). The presence of frameshifted 
ubiquitin, Ub+1, in inclusions found in several neurodegenerative diseases, namely MJD, 
reinforced the idea that altered UPS may contribute to the pathology (van Leeuwen et 
al., 1998; de Pril et al., 2004). Mutated Ub+1 is incorporated in polyUb chains, but is 
resistant to deubiquitylation, and competes with normal ubiquitin inhibiting the 
proteasome (Lam et al., 2000 1579), when present at a high concentration in vivo (van 
Tijn et al., 2007). The authors suggested that this frameshifted Ub+1 molecule may, 
over time, be an aggravating factor/modifier in polyQ disease progression. 
 
Ubiquitin-proteasome system 
For a protein to be degraded by the UPS it is mandatory that it follows two steps: suffer 
conjugation with polyUb chain(s) and be efficiently translocated for the 20S catalytic 
chamber of the proteasome for degradation, with the concomitant release of reusable 
ubiquitin, a crucial step promoted by deubiquitylating enzymes (DUB) (reviewed in 
Glickman and Ciechanover, 2002). Several positive and negative modulators regulate 
protein ubiquitylation and, subsequently, the UPS, by balancing the refolding of the 
misfolded proteins with a close interplay of 19S proteasome cap, chaperones and co-
chaperones and their actual degradation by the 20S catalytic core, with the necessary 
ubiquitin and amino acidic recycling.  
 
Positive regulators 
E4 multiubiquitin elongation factors are examples of positive regulators of UPS. These 
catalyse the elongation of the ubiquitin chains of substrates linked to E2-E3 complexes. 
CHIP, as mentioned before, is one of such factors and acts with HSP70 as shuttling 
substrate cargo to the 26S proteasome (Esser et al., 2004); for instance, its association 
with parkin (an E3 ligase whose mutation causes autosomal recessive juvenile 
Parkinsonism) enhances Pael-R ubiquitylation, leading to its degradation (Imai et al., 
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2002). Moreover, CHIP has been also implicated in the ubiquitylation of ATXN3 (polyQ 
length-dependent); CHIP overexpression reduces ATXN3 aggregation rate and cell death 
ensued by polyQ truncated or full-length protein (Jana et al., 2005). Interestingly, 
mammalian E4B (UFD2a, ubiquitin fusion degradation protein-2) has also been 
implicated in mutant ATXN3 clearance, through enhancement of its ubiquitylation rate 
and degradation by the proteasome (Matsumoto et al., 2004).  
 
Negative regulators 
Negative modulators of UPS include two classes of deubiquitylating enzymes (DUB): 
ubiquitin C-terminal hydrolase (UCHL) and ubiquitin-specific protease (USP); both have 
been implicated in neurodegenerative disorders. It is known that ATXN1 interacts with 
USP7, in a polyQ dependent manner (Hong et al., 2002); mutations in UCH-L1 are linked 
to Parkinson's disease (PD); they cause a reduction in the enzyme’s proteolytic activity 
and enhance aggregation (Ardley et al., 2004), and to gracile axonal dystrophy (gad) in 
mice, an autosomal recessive disorder characterised by altered UPS. Moreover, the AR is 
able to establish an interaction with ARNIP (androgen receptor N-terminal interacting 
protein), an E3 ubiquitin ligase (Beitel et al., 2002). The 19S regulatory base itself 
showed chaperone-like activity, refolding to their native conformation substrates that 
had been ubiquitin-targeted, preventing their translocation and degradation in the 20S 
chamber (Braun et al., 1999), suggesting that unfolded proteins “kissed for death” and 
delivered at the proteasome, do not necessarily undergo 26S-dependent degradation 
(reviewed in Glickman and Ciechanover, 2002). Furthermore, several reports showed 
that normal ATXN3 binds polyUb chains with at least four molecules of Ub (Burnett et 
al., 2003; Donaldson et al., 2003; Doss-Pepe et al., 2003) and shows deubiquitylating 
activity in vitro (Burnett et al., 2003; Burnett and Pittman, 2005).  
The UPS system is highly regulated, and a perturbation at any point of it may lead to 
deregulation of the cell’s protein homeostasis, which, in time, may eventually lead to 
neurodegeneration. 
 
Ubiquitylation 
Two aspects increase the complexity of ubiquitylation in the cell: the number of Ub 
molecules conjugated to the substrate and the position of the lysine residue in Ub used 
for the attachment and the formation of the chain. Substrates can be mono-, oligo- or 
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polyubiquitylated. Moreover, some proteins can also be N-terminal ubiquitylated; in 
these cases, the first ubiquitin is attached to the free -NH2 terminus of the protein, 
rather than to an internal lysine (Glickman and Ciechanover, 2002). 
In monoubiquitylation, the post-translational modification consists in the conjugation of 
a single ubiquitin to the substrate. Polyubiquitylation requires the attachment of a 
ubiquitin chain comprising four or more molecules of Ub. In oligoubiquitylation, the 
substrate may be monoubiquitylated in several different lysine (K) residues or modified 
by the covalent attachment to a single lysine of Ub chains containing less than four Ub 
molecules (Glickman and Ciechanover, 2002).  
In oligo- and polyubiquitylation chains can be extended using one of the seven possible 
residues in Ub (K6, K11, K27, K29, K33, K48 and K63). Although the biological relevance 
of some polyUb conjugations is unknown, all seven lysine residues can be used for 
polyUb chain formation in vivo (reviewed in Woelk et al., 2007).  
Proteins conjugated with a K48-linked polyUb chain are typically sent for degradation at 
the proteasome, whereas monoubiquitylated or polyubiquitylated proteins using lysine 
other than K48 are involved in mediating the protein’s subcellular localisation or its 
function, as in DNA repair, translation, endocytosis and vesicle transport (Glickman and 
Ciechanover, 2002; Welchman et al., 2005).  
A substantial intricacy appears to exist within the ubiquitylation pathway, as recently it 
was postulated that NEMO, an essential regulator of NF-kB activation, protects it’s poly-
Ub(K63)-conjugated substrate from degradation, by preventing the conversion of the 
conjugated ubiquitin chain into a K48-branched polyUb chain (Heyninck and Beyaert, 
2005). Moreover, Saeki et al. (2004), reported that UFD2 is able to catalyse the linkage 
switch from K29, typically used in monoubiquitylation, to elongated K48-linked polyUb 
chains. This interchangeability of polyUb chains intensifies the complexity of post-
translational modifications (Woelk et al., 2007). In addition to this, several ubiquitin-
like proteins (UBL) have been identified. The attachment of UBL proteins UBL is known 
to be involved in the regulation of several cellular functions and in target specificity.   
 
Ubiquitin-like proteins 
Like ubiquitin, and using a similar conjugation cascade, UBLs can be covalently attached 
through their C-terminal glicine to the ε-NH2 group of lysine in the substrate. Ubiquitin 
like-proteins are sub-divided in two classes, depending on their primary sequence 
(Table 3) (Walters et al., 2004). Type I proteins are similar to ubiquitin and exist as 
General Introduction 
19 
free molecules, conjugatable to substrates upon processing; besides Ub, only SUMO-2 
and SUMO-3 are able to constitute poly-UBL chains, but no function has been attributed 
to these yet (Welchman et al., 2005). Type II proteins have at least one conjugatable, 
built-in ubiquitin-like domain (UBL), highly similar to Ub, and other ubiquitin-associated 
domains (UBA).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 3. Ubiquitin-like proteins: description of several ubiquitin family members. Type I group includes 
NEDD8, neural precursor cell expressed developmentally downregulated-8; SUMO1,-2, -3, small ubiquitin-
related modifier-1, -2, -3 ; ISG15, interferon-stimulated gene-15; FUBI, fau ubiquitin-like protein; FAT10, F-
adjacent transcript-10; Apg8 and 12, autophagy 8 and 12; Urm1, ubiquitin-related modifier-1; UBL5, 
ubiquitin-like protein-5; Ufm1, ubiquitin-fold modifier-1. Type II classe comprises HHR23a and -b, human 
homolog of RAD23-A and -B; hPLIC-1 and -2, human proteasome ligase interaction component-1 and -2; 
ubiquilin-3; A1Up, ataxin-1 ubiquitin-like interacting protein; NUB1, NEDD8 ultimate buster-1; BAG1, BCL-2 
binding athanogene-1 protein; Parkin; Elongin-B; U7I3, ubiquitin conjugating enzyme 7 interacting protein 
3; S3A1, splicing factor 3 subunit 1; BAT3, HLA-B-associated transcript; Uch14, ubiquitin carboxyl-terminal 
hydrolase 14.  
 
Due to the presence of these domains, type II UBL proteins are able to bind directly to 
subunits of the proteasome, through the UBL domain, and to ubiquitin or polyUb chains, 
through their UBA domain (reviewed in Jentsch and Pyrowolakis, 2000; Glickman and 
Ciechanover, 2002; Welchman et al., 2005). Of note is that, ATXN3 has been related to 
some of type I and type II proteins, as SUMO-1 (Shen et al., 2006), HHR23 proteins 
(Wang et al., 2000), parkin (Tsai et al., 2003) and hPLIC-1 (Heir et al., 2006). The 
interaction of ATXN3 and NEDD8 will be discussed later in this work (Chapter 2). Both 
Ubiquitin-like protein 
Type I Type II 
NEDD8 HHR23A 
ISG15 HHR23B 
FUB1 NUB1 
FAT10 parkin 
SUMO-1 hPLIC-1 
SUMO-2 hPLIC-2 
SUMO-3 A1Up 
Apg 8 BAG1 
Apg 12 ubiquilin3 
Urm1 elongin-B 
UBL5 U7I3 
Ufm1 S3A1 
 BAT3 
  Uch14 
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NEDD8 and SUMO have been implicated in neurodegenerative diseases (Kuazi et al., 
2003; Mori et al., 2005).  
 
NEDD8 
NEDD8 (neural precursor cell expressed developmentally downregulated-8) is the UBL 
with the highest structural homology with Ub (Whitby et al., 1998) and conjugates to 
target proteins in a cascade of events similar to ubiquitylation (Hochstrasser, 2000). The 
E1-activating enzyme APPB1-UBA3 determines the specificity for NEDD8 and E2-
conjugating enzyme, UBC12 catalyzes the conjugation of NEDD8 to the target through 
an isopeptide bond (Osaka et al., 1998). So far, NEDD8 has been reported to conjugate 
with a limited number of target proteins, including the cullin family members (Pan et 
al., 2004), p53 and mdm2 (Xirodimas et al., 2004) and more recently, synphilin-1, a 
major component of inclusion bodies found in the brains of patients with 
neurodegenerative α-synucleinopathies, including Parkinson’s disease (Tanji et al., 
2006). Cullins are the molecular scaffolds for the assembly of several E3 ubiquitin 
ligases, and the best-known substrates for NEDD8 conjugation (Pan et al., 2004). 
Neddylation upregulates the activities of cullin-organized E3 ubiquitin-ligases while 
conferring intrinsic instability onto cullins (Wu et al., 2005), thereby outlining the close 
link that exists between the ubiquitin and the NEDD8 pathways. NEDD8 deconjugation is 
equally important for the cell and can be carried out by members of most of the 
deubiquitylating enzyme (DUB) families USP (USP21), JAMM group (CNS/COP9 
signalosome) and the ULP family (NEDP1/SENP8/DEN1) (Parry and Estelle, 2004). NEDD8 
has an essential role in cell cycle control and embryogenesis evidenced by gene 
knockout studies (Tateishi et al., 2001; Kurz et al., 2002). Recently, Oved et al. (2006) 
showed that NEDD8 is implicated also in the metabolism of membrane growth factor 
receptors. Conjugation of NEDD8 can also lead to direct target degradation in the 
proteasome. This is mediated by NEDD8 ultimate buster-1 (NUB1) (Tanji et al., 2005) 
and NUB1 ligand (NUBL1) (Tanaka et al., 2003), which bind the S5a subunit of the 19S 
regulatory particle. Hence, NEDD8 is primarily a regulator of ubiquitin E3 ligase activity 
but is also involved in proteasome degradation. This has been strengthened with the 
reported accumulation of NEDD8, in ubiquitylated inclusions in brain tissue from 
patients with various neurodegenerative disorders, namely MJD, which suggest the 
involvement of NEDD8 in the formation of inclusions via the UPS (Mori et al., 2005). 
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DNA repair 
The diversity of ubiquitylation possibilities mentioned before sets this post-
transcriptional modification as an important mechanism involved in virtually all cellular 
processes. Genomic integrity enables the correct transmission of DNA information to the 
next generations. Through time, cells are exposed to several exogenous (e.g., ionizing 
radiation, ultraviolet light and natural/synthetic chemicals) and endogenous (e.g. 
oxidative generated species) genotoxic conditions. DNA lesions may range from single-
stranded breaks (SSB), double stranded breaks (DSB) or formation of DNA adducts 
normally inducing large DNA–helix distorting (Huang and D'Andrea, 2006). These 
alterations may interfere with DNA replication, induce cell cycle arrest, or block 
transcription (reviewed in Hoeijmakers, 2001).  
There are five main DNA repair pathways that cell may engage to cope with the DNA 
lesions, with overlapping features: nucleotide excision repair (NER), base excision repair 
(BER), mismatch repair (MMR) all involved in SSB repair; homologous recombination (HR) 
or non-homologous end joining (NHEJ) repair leads to the excision of DSB lesions (Huang 
and D'Andrea, 2006). 
 
Nucleotide excision repair 
The most versatile DNA damage repair mechanism is nucleotide excision repair (NER), as 
it comprises two sub-pathways: transcription-coupled repair (TCR) and genome global 
repair (GGR). NER is responsible for the removal of single-stranded alterations and large 
DNA helix-distorting lesions induced by UV-light, as cyclobutane pyrimidine dimmers 
(CPD) and pyrimidine(6-4)pyrimidone dimers (6-4PP) as well as intrastrand crosslinks 
and bulky adducts provoked by several chemical agents, and to some extent, reactive 
oxygen species (ROS) (de Laat et al., 1999). TCR is specifically engaged in removing 
lesion from the coding strands of genes that are actively transcribed by RNA polymerase 
II; whereas GGR is responsible for the subtracting NER-inducible DNA lesions occurring 
throughout the entire genome (Hoeijmakers, 2001; Huang and D'Andrea, 2006). 
 
NER associated diseases  
Defective NER activity has been associated with several human genetic disorders 
showing severe sun-sensitivity, with high cancer-propensity, and severe neurological 
abnormalities as is the case of Xeroderma pigmentosum (XP) and Cockayne’s syndrome 
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(CS). Seven NER-deficient genetic complementation groups of XP (XP-A to XP-G) and two 
groups of CS (CS-A and -B) have been identified. In Xeroderma pigmentosum 
complementation group C (XP-C) patients, only the GGR sub-pathway appears impaired, 
whereas TCR rate is normal (Bootsma et al., 1997). The gene involved in XP-C encodes 
for the XPC protein, a 125 kDa protein, which forms in vivo a trimeric complex with 
HHR23B and centrin-2 (Masutani et al., 1994; Araki et al., 2001).  
 
The mechanism 
The NER pathway requires the formation of multiprotein complexes at the lesion sites 
and ~20 proteins acting cooperatively to achieve proficient nucleotide excision repair 
(Sancar et al., 2004) (Fig.1). In the GGR sub-pathway, the XPC/HHR23B/CETN2 complex 
functions as a recognition complex with binding properties to the lesion site. Given the 
versatility of NER and the wide range of damaged substrates recognized by NER-specific 
proteins, the excision repair complex appears not to recognize specifically the chemical 
group involved in the lesion, but instead the major structural conformations induced by 
the lesions (Sancar et al., 2004). The recognition and subsequent binding of the 
XPC/HHR23B/CETN2 recognition complex is thought to favour the sequential binding of 
other repair factors as TFIIH, XPA, RPA and two NER-specific endonucleases XPG and 
XPF (complexed with ERCC1), essential for an efficient NER reaction.  
The XPC/HHR23B/CETN recognition complex shows low affinity to subtle-distortion 
lesions (e.g. CPD) (Kusumoto et al., 2001). This raised the possibility that the DDB 
protein (Damaged DNA binding, aka XPE) could cooperate with the recognition complex 
in the identification of low-distorting DNA damages (Fitch et al., 2003b). The DDB is a 
heterodimeric protein comprising 127 kDa (DDB1/p127) and 48 kDa (DDB2/p48) subunits 
(Costa et al., 2003). Recently, Sugasawa et al. (2005) showed that XPC and UV-DDB 
interact physically and that XPC is ubiquitylated upon UV irradiation, in a DDB-
dependent manner. Interestingly, it was shown that p53 controls the expression of DDB2 
(Hwang et al., 1999) and XPC (Fitch et al., 2003a; Wang et al., 2003). The DDB2 subunit 
is also a substrate of CUL4A, which was shown to stimulate its ubiquitylation and 
proteasome degradation, establishing a direct link between the CUL4A expression, the 
down-regulation of DDB2 expression and therefore the GGR rate (Chen et al., 2001). 
Both p53 and CUL4A are substrates of NEDD8 raising the possibility that deneddylases 
may participate in the regulation of the NER pathway.  
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Figure 1. Schematic representation of global genome repair (GGR) sub-pathway. The association and 
dissociation steps of the different proteins involved in GGR-NER are represented by oriented arrows. The 
TFIIH complex denotes the strong interplay existing between DNA repair and transcription. Adapted from 
(Park and Choi, 2006).  
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Upon binding of XPC/HHR23B/CETN2, TFIIH recruitment is essential, as is the helicase 
activity of its XPB and XPD subunits which unwinds the DNA helix around the inflicted 
DNA damage site. Positioning of TFIIH at the damage site triggers the formation of the 
incision complex formed by RPA and XPA, plus the two endonucleases, XPG and 
XPF/ERCC1. Binding of the endonucleases occurs independently of each other, but the 
association of XPG to the complex is thought to be mediated by its interaction with 
TFIIH (Iyer et al., 1996). The release of XPC/HHR23B/CETN2 complex is triggered by 
XPG association and binding of XPF/ERCC1 and XPA completes the incision complex; 
both binding of the endonuclease XPF/ERCC1 to the lesion site and the activation of 
bound XPG to perform 3’ cleavage are XPA-oriented with the cooperation of RPA; the 
XPF/ERCC1 is responsible for the 5’ DNA cleavage. Finally, the DNA portion containing 
the lesion is removed by dual excision (reviewed Volker et al., 2001). The synthesis and 
ligation of new undamaged DNA may be carried out by either polymerase δ or 
polymerase ε, in the presence of the processivity factor PCNA (proliferating cell nuclear 
antigen) and its cofactor RCF (replication factor C). Ligation of newly synthesised DNA 
to the initial sequence is dependent of DNA ligase I (Costa et al., 2003).  
In TCR-NER, the DNA lesions are detected directly by RNA polymerase II that stops 
transcription at the lesion site; the CSA and CSB proteins and subsequent TFIIH binding 
at the lesion site displace the stalled polymerase II allowing further binding of other 
repair factors, as described above. Upon lesion detection and recruitment of TFIIH, both 
the TCR- and GGR-NER follow a common mechanism (reviewed in de Laat et al., 1999; 
Park and Choi, 2006). 
The DNA repair mechanisms must be tightly regulated, as at least three of the NER 
factors play crucial roles in other cellular processes as transcription (TFIIH), 
recombination (RPA) and replication (XPF/ERCC1).  
Recently, Wang et al. (2005) showed that SUMO-1 may also modify XPC, upon UV 
irradiation. It is a modification dependent of DDB2 and XPA proteins and seems to be 
related with the stabilization and availability of XPC in cells.  
 
DNA repair and neurodegeneration  
Evidence showing DNA repair and neurodegeneration overlapping is growing. Many 
human disorders characterised with neurological deficits are associated with mutations 
affecting the cellular machinery participating in DNA repair. Two distinct groups of 
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defective DNA repair disorders associated with ataxia can be appointed: the first is 
characterised by diseases with defects in the double strand breaks (DSB) repair and 
maintenance mechanisms and includes ataxia telangiectasia (AT), AT-like disease and 
Nijmegen breakage syndrome (NBS), characterised also by a high susceptibility to 
cancer. The second group is that of purely neurological disorders, associated with an 
abnormal cellular response to single-strand breaks (SSB) and includes ataxia oculomotor 
apraxia type 1 (AOA1), AOA2 and spinocerebellar ataxia with axonal neuropathy-1 
(SCAN1) (reviewed in Paulson and Miller, 2005). All AT, AT-like, AOA1 and AOA2 are 
autosomal recessive spinocerebellar ataxias with oculomotor apraxia. Mutations in ATM 
gene causes ataxia telangiectasia; ATM protein is the ultimate controller of the cellular 
responses to DBS repair and is closely related to the MRN complex that comprises 
MRE11/RAD50/NBS1(nibrin) proteins. Mutations in the MRE11 gene are responsible for 
AT-like disease, whereas defective NBS1 protein is associated with the Nijmegen 
breakage syndrome.  
Ataxia due to defects in SSB can be caused by mutations in gene encoding tyrosyl 
phospohodiesterase (TDP1) leading to SCAN1, in aprataxin (APXT) causing AOA1 (Moreira 
et al., 2001), and an inactivating mutation in senataxin (SETX) leads to AOA2; senataxin 
has also been implicated in an autosomal dominant form of juvenile amyotrophic lateral 
sclerosis (ALS). Interestingly, oxidative stress (a known cause of DNA damage) was 
shown to be associated with the recessive forms of ALS (Ferrante et al., 1997; Manfredi 
and Xu, 2005). Both DSB and SSB cellular responses can be triggered by ROS or ionizing 
radiation (Taroni and DiDonato, 2004).  
 
Terminally differentiated cells are naturally more sensitive to any kind of stress. But 
why can neurons be particularly susceptible? Due to the metabolic and energy demands, 
neurons may be exposed to continued, high levels of ROS species produced from 
neuronal metabolism. Thus, oxidative stress may be, throughout time, responsible for 
the accumulated DNA damage. In fact, direct involvement of oxidative stress has been 
reported in several neurodegenerative diseases, apart from the mentioned above: PD 
(Moore et al., 2005), AD (Smith et al., 2000), HD (Firdaus et al., 2006), SCA2 (Giuliano 
et al., 2003). Thus, neurons that are more prone to the formation of ROS due to their 
O2 and energy requirements, may be more susceptible to DNA damage, for example, 
oxidation, than other cells with less energy requirements and that are capable to 
“dilute” and repair upon cell division, accumulated toxic species. In fact, mutant ATXN3 
was shown to confer a higher susceptibility to post-mitotic cell death, as its N-terminal 
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truncated expanded enhanced cytotoxicity in G0/G1 phase-arrested cells subjected to 
starvation (Yoshizawa et al., 2000), evidencing that differentiated neurons may be 
potentially more susceptible to the stress induced by polyQ and aggravated by their 
expansion. 
Neurons might either be more susceptible to accumulated DNA damage than other cell 
or have a lower threshold for DNA damage-prone conditions leading more easily to 
neuronal death (Paulson and Miller, 2005).  
 
 
 
Machado-Joseph disease 
This disease was first described in North-American families of Azorean ancestry, later in 
the mainland and then in non-Portuguese families from all continents (Sequeiros and 
Coutinho, 1981; Sequeiros and Coutinho, 1993). Nakano et al. (1972) reported the first 
cases, in the Machado family from S. Miguel, in 1972; the disease presented as an 
autosomal dominant ataxia, and was named by the authors, Machado disease. Woods et 
al. (1972) observed the Thomas family, also with Portuguese-Azorean ancestry; although 
resembling that reported by Nakano et al. (1972), some clinical particularities led the 
authors to define it as a new clinical entity, they named nigro-spino-dentatal 
degeneration. A few years later, Rosenberg et al. (1976) defined a new hereditary 
ataxia by observation of the Joseph family, originated from Flores Island, which they 
named as Joseph disease. In 1978, Coutinho and Andrade reached a milestone in the 
disease history, with the re-definition of Machado-Joseph disease as a unique, well-
defined single pathology. With families described all over the world, Machado-Joseph 
disease (MIM #109150), also known as spinocerebellar ataxia type 3, is the most common 
form of dominantly inherited ataxia (Schols et al., 2004; Sequeiros et al., 2007).  
 
Clinico-pathology 
MJD is a progressive neurodegenerative disease, affecting mainly the motor function. 
Patients usually present with ataxia, pyramidal and extrapyramidal signs, peripheral 
amyotrophies, external progressive ophthalmoplegia, intention fasciculation-like 
movements of facial and lingual muscles, rigidy, and bulging eyes (Coutinho and 
Andrade, 1978; Lima and Coutinho, 1980; Barbeau et al., 1984; Coutinho, 1992). 
Importantly, no cognitive impairment is observed in MJD patients; this may be a key 
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criterium in the differential diagnosis with other spinocerebellar ataxias including 
alterations of the intellect (Coutinho, 1992).  
The high phenotypic variability associated with MJD, led to the organization of the 
disease into four sub-types, sorted by the age of clinical onset and major symptoms of 
the disorder (Lima and Coutinho, 1980). In sub-type 1 are classified the MJD forms with 
early age of onset, a faster progression, and more intense pyramidal and extra-
pyramidal signs. Sub-type 2 is the most frequent, and is characterised by intermediate 
age-of-onset and progression, with patients exhibiting the usual ataxia and 
ophthalmoplegia and the possible evolution to either sub-type 1. In sub-type 3, MJD 
patients show the latest age at onset, slowed disease progression and more peripheral 
signs. A fourth sub-type was added by Rosenberg (1983); it is the rarest and 
comprehends MJD patients exhibiting Parkinsonic symptoms associated with the more 
typical MJD symptoms (Rosenberg, 1983; Margolis, 2002). 
 
Anatomopathology 
The neuropathological features show also a large variability, but most frequently MJD 
patients exhibited spinocerebellar degeneration and neuronal loss of the dentate 
nucleus. A progressive neuronal loss and gliosis of the striatum, substantia nigra 
(compacta and reticulate), pons and of the medulla anterior horn and motor cranial 
nuclei is also reported (Coutinho et al., 1982; Coutinho, 1992; Ross, 1995).  
 
Inheritance 
Machado-Joseph disease is transmitted in an autosomal dominant manner, implying that 
one copy of the mutated gene is sufficient for the disease to be transmitted to the 
offspring; some rare cases of skipped generations are known (Sequeiros and Coutinho, 
1981). In MJD, intergenerational instability in the transmission of the mutated allele is 
very common. Often, the expanded alleles in paternal transmission are less stable than 
in maternal transmission, originating larger repeat expansions in the offspring (Maciel et 
al., 1995; Maruyama et al., 1995; Igarashi et al., 1996). The affected offspring often 
manifest the disease earlier in life, with faster progression and aggravated 
symptomatology. This phenomenon of anticipation is common in MJD families (Sequeiros 
and Coutinho, 1981; Sequeiros and Coutinho, 1993) and there is an inverse correlation 
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between the CAG size and the beginning or course of the disease (Maciel et al., 1995; 
Takiyama et al., 1998; Maciel et al., 1999), though with no clinical predictive value. 
 
The MJD1/ATXN3 gene 
In 1994, the mapping of the MJD locus to chromosome 14q was confirmed in Azorean 
families (Sequeiros et al., 1994). Based on the novel characteristics of the genes 
identified for SBMA, HD, SCA1, SCA2 and DRPLA, Kawaguchi et al. (1994) soon identified 
and mapped MJD1 to the long arm of chromosome 14 (14q24.3-32.1). MJD1 was then 
confirmed as the mutated gene in MJD, since an expanded CAG tract was present only in 
clinically confirmed patients. The molecular diagnosis of MJD then became possible, and 
the mutation was then confirmed in families of diverse origins (Maciel et al., 1995; 
Higgins et al., 1996; Lopes-Cendes et al., 1996; Gaspar et al., 2001). 
MJD is caused by the expansion of a CAG repeat in the 3’ coding portion of the gene 
ATXN3 (formerly MJD1). The repeat is highly polymorphic, ranging from 12-41 repeats in 
normal-sized alleles, and 55-86 in the expanded allele of MJD patients (Maciel et al., 
2001).  
ATXN3 is evolutionary conserved and found in genomes from fungi to humans. The 
human ATXN3 gene spans for 48240 bp and comprises 11 exons; the CAG repeat is 
located in exon 10. 
Northern blot analysis revealed ubiquitous ATXN3 expression and the existence of four 
different transcripts (1.4, 1.8, 4.5 and 7.5 Kb), thought to result from alternative 
splicing and polyadenylation events, occurring in exon 10 or exon 11 (Ichikawa et al., 
2001). So far, five ATXN3 cDNA variants were described: MJD1a, MJD1-1 and MJD5-1, 
MJD2-1 and H2 (Kawaguchi et al., 1994; Goto et al., 1997); the latter lacks exon 2, but 
preserves the open reading frame, identical to variant MJD1-1 (Ichikawa et al., 2001). 
 
The ATXN3 protein(s) 
The human ATXN3 gene product, ataxin-3, is a 42 KDa ubiquitiously expressed protein, 
with a polyglutamine (polyQ) tract located in the C-terminal region (Kawaguchi et al., 
1994; Schmitt et al., 1997). Ataxin-3 is the smallest of the known polyglutamine-
containing proteins. It comprises an N-terminal domain, the Josephin domain (JD), two 
to three ubiquitin interacting domains (UIM), depending on the isoform, and the polyQ 
region (Fig.2). Ataxin-3 has at least three protein isoforms reported. ATXN3 isoform 1 
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(ATXN3 var2.1, SwissProt no P54252) is encoded by the MJD2.1 cDNA variant and is the 
longest ATXN3 variant, spanning 364 aa, contains only two UIMs located before the 
polyQ region, and has an hydrophobic C-terminal (Goto et al., 1997). Isoform 2 (ATXN3 
var1.1, SwissProt no P54252-2 VSP_ 002784) is a splicing variant encoded by the cDNA 
variants MJD1.1 and MJD5.1, has 361 amino acids, possesses three UIMs and has a 
hydrophilic C-terminal; the MJD1a encodes a truncated variant of isoform 1 (16 aa 
shorter, 348 aa), due to premature stop codon (ATXN3 var1a, SwissProt no P54252 
VAR_013690) (Kawaguchi et al., 1994). Isoform 3 (SwissProt no P54252-3 VSP_002783, 
VSP_002784) is 55 aa shorter than isoform 2 due to the absence of exon 2 in the 
encoding cDNA variant H2, what makes it the only ATXN3 variant lacking the C14 
residue in the JD (Ichikawa et al., 2001). 
 
The JD domain (Pfam02099) comprises the first 198 aa and is the most highly conserved 
domain of the protein (Fig.3). Using a bioinformatic-integrated approach Scheel et al. 
(2003) predicted that ATXN3 could be an ubiquitin-specific cysteinic-protease (USP), 
based on the conservation of the predictive catalytic triad (C14-H119-N134), typically 
found in these proteins as well as ubiquitin C-terminal hydrolase (UCH). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Schematic representation of the protein domains in ataxin-3 isoforms. ATXN3 is a 42-kDa 
protein comprising three splice variants. ATXN3 isoforms may comprise two-to-three ubiquitin-interacting 
motifs (UIM). The repetitive polyQ segment is located at the C-terminal region of the protein. Of note is 
absence of the C14 residue in the ATXN3 varH2. 
 
 
Moreover, further evidence from the work of Donaldson et al. (2003) who, using a 
bioinformatic analysis, suggested also ATXN3 to be an ubiquitin-binding protein, 
localizing to polyQ aggregates in a UIM-dependent manner, with partial modulation of 
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the JD. Soon, in vitro assays validated these observations and a binding preference of 
ATXN3 for K48-linked polyubiquitylated proteins containing chains of at least four 
ubiquitin molecules was shown, a property dependent on the integrity of ATXN3’s UIMs 
(Burnett et al., 2003; Chai et al., 2004). Moreover, in independent studies ATXN3 
showed a C14-dependent deubiquitylating (DUB) activity in vitro (Burnett et al., 2003; 
Chow et al., 2004). Over-expression of inactive C14A-mutated protein in neural cell 
lines led to an evident accumulation of ubiquitylated proteins, comparable only to 
proteasome-inhibited conditions. The authors also suggested that ATXN3 is able of self-
ubiquitylation (dependent of the UIMs) and self-deubiquitylating processing, unveiling a 
possible auto-regulation of its participation in the protein quality control pathways 
(Berke and Paulson, 2003).  
Little information has been reported on the structure of full-length ATXN3. A first 
“draft” of the structure was obtained using limited proteolysis and NMR assays that 
revealed the existence of a compact 20 kDa region resistant to proteolysis, comprising a 
region later defined as the JD, and a flexible C-terminal that includes the polyQ domain 
(Masino et al., 2003).  
More recent structural studies, using NMR on JD alone, confirmed that this is the only 
constitutively folded region in ATXN3, rich in  α-helices and adopting an open semi-
elongated L-structure, compatible with its cysteinic protease activity (Nicastro et al., 
2005; Nicastro et al., 2006). 
The ubiquitin interacting motif (UIM) is a highly conserved amino acidic sequence first 
assigned to proteasome S5a subunit, but then extended to proteins participating in 
pathways as diverse as ubiquitylation, ubiquitin metabolism and endocytosis (Young et 
al., 1998; Hofmann and Falquet, 2001; Miller et al., 2007). A dual function has been 
ascertained to UIMs: binding of ubiquitin or ubiquitylated proteins and promotion of 
ubiquitylation (mono-, oligo- and polyubiquitylation) (Miller et al., 2004; Regan-Klapisz 
et al., 2005).  
ATXN3 has also been found to bind ubiquitylated proteins in a way modulated by its UIM 
domains. Recently, Miller et al., showed that the UIMs of ATXN3, on their own can 
inhibit the aggregation of mutant Htt (Miller et al., 2007). 
 
ATXN3 homologues 
In the human genome, there are two loci for ATXN3 on chromosomes 14q32 and Xp22.2. 
The latter is known as ATXN3L (like) gene (NR_003585) and it encodes a putative 
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ATXN3-like protein (SwissProt no Q9H3M9) though no biological proof for this protein has 
been reported. ATXN3L has 355 aa and comprises a JD, two UIM and the polyQ domain; 
ATXN3L is similar to isoform 1 of ATXN3 (Fig.2) and shows 80% identity at the amino 
acid level, with this isoform. The lack of introns, known functionality and the high 
homology displayed by ATXN3L sets it as a pseudogene of ATXN3. 
ATXN3 is evolutionarily conserved and homologous proteins are found in several animal 
and plant species. Namely, ATXN3 was found in rodents, Rattus norvegicus (NP_067734, 
88% identity (Id)) (Schmitt et al., 1997), Mus musculus (NP_083981, 88% Id) (do Carmo 
Costa et al., 2004), chicken (Gallus gallus, NP_989688, 82% Id) (Linhartova et al., 1999), 
Caenorhabditis elegans (NP_506873, 38% Id) (Rodrigues et al., 2007) and plants, 
Arabidopsis thaliana (NP_190981, 36% Id) (Fig.3).  
Studies of the ATXN3 rat homologue were restricted to gene sequence and transcription 
analysis. The rat sequence was found to be identical to the human sequence. Expression 
analysis revealed an ubiquitous expression of a larger transcript (6 Kb), whereas a 
smaller variant (1.3 Kb) was exclusively found in the testis (Schmitt et al., 1997), as 
proposed for the human gene (Ichikawa et al., 2001). 
An exhaustive study of the mouse homologue gene carried out by Costa et al. (2004), 
led to the determination of a genomic structure similar to that of the human gene 
(Schmitt et al., 2003); characterisation of the promoter also revealed a TATA-less 
structure, with several conserved putative transcription factor binding regions, namely 
SP1 and MyoD. The murine protein is ubiquitously expressed throughout development as 
in adult tissues, showing a particularly elevated expression in muscle, ciliated epithelial 
cells and brain regions affected in MJD; as in the rat, differentially expressed protein 
isoforms were found in the mouse heart, skeletal muscle and testis, denoting a tissue-
specificity of ATXN3 expression that warrants further investigation.  
More recently, the gene structure, mRNA and protein expression of the C. elegans 
homologue were also reported (Rodrigues et al., 2007). The atx-3 gene is expressed 
throughout the C. elegans development and mainly in adulthood. Sub-cellular 
expression analysis showed a cytoplasmatic but also nuclear localization; in vitro assays 
showed that the worm homologue is, like the human protein, a cysteinic-
deubiquitylating enzyme. This work suggests that atx-3 is the true ortholog of ATXN3 in 
the worm. Moreover, using a genome-wide expression approach, the authors showed 
that the absence of atx-3 gene in KO animals leads to a major deregulation of genes 
involved in UPS, structure/motility and signal transduction (Rodrigues et al., 2007).  
General Introduction 
32 
It is interesting to observe in Fig.3 that there is no conservation of the polyQ region in 
the homologous proteins, indicating that the polyQ domain may not have a major 
functional relevance in normal ataxin-3.  
 
ATXN3 expression  
The first evidence regarding human ATXN3’s expression was obtained from brain tissue 
and lymphoblastoid cells lines of MJD patients and healthy individuals (Paulson et al., 
1997a; Wang et al., 1997). Expression of both normal and expanded ATXN3 was 
observed in the CNS, including in areas usually spared by the disease, and the PNS; 
moreover, ATXN3 showed mainly cytoplasmatic staining. A restricted expression pattern 
was reported for some brain regions, namely the striatum, where only a subset of 
neurons showed ATXN3 expression (Paulson et al., 1997a). Later, Paulson et al. (1997b), 
reported that the mutant protein accumulates in the nucleus as ubiquitylated inclusions 
solely in the neurons of affected MJD regions. However, conflicting evidence regarding 
ATXN3 localization started to emerge. Wang et al. (1997), showed both cytoplasmatic 
and nuclear staining of ATXN3 in MJD brains. Trottier et al. (1998) reported a cytosolic 
expression of ATXN3 in HeLa; although in subcellular fractionation, ATXN3 co-fractioned 
in both the nuclear and mitochondrial fractions; conversely, in brains of MJD patients, 
most neurons of the areas analysed showed cytosolic expression. Mammalian cell line 
assays revealed that ATXN3 was found mainly, though not exclusively, in the nucleus, 
where it was associated with the inner nuclear membrane (Tait et al., 1998). The 
growing evidence of the nuclear localization of normal ATXN3, and the finding of a 
nuclear localisation signal (NLS) led to the conclusion that normal ATXN3 may 
translocate into the nucleus, independently of an expanded polyQ domain (Tait et al., 
1998). 
It is possible that the conflicting results regarding sub-cellular localization are 
consequence of the use of different antibodies and tissue processing methods, which in 
our experience may alter the results. 
 
ATXN3 known interactome 
Although much has been learned about ATXN3 in the last decade, its physiological 
function remains elusive.  
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Figure 3. Multiple alignment of human (Hs_var2.1, Hs_var1.1 and Hs_ATXN3L), rodent (M.musculus and R.norvegicus), chicken (G.gallus), frog (Xenopus), worm 
(C.elegans) and plant (A.thaliana) ataxin-3 homologous proteins. Columns frames show a global similarity score over 60 %, calculated from all group, completely 
conserved amino acids are black-countershaded and similar amino acid are in bold. In the picture, the black lines depict the Josephin domain, the dark grey and light grey 
lines represent UIM1 and UIM2, respectively; the horizontal light grey square highlights the UIM3 in ATXN3 var1.1; the black dots mark the predicted catalytic triad C14-
H119-N134. Sequence alignments and colouring were performed with the T-Coffee (Notredame et al., 2000) and ESPrit (Gouet et al., 1999) programs, respectively. 
Numbers represent the amino acid scale bar. 
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The absence of atx-3 expression produced no obvious phenotype in atx-3-/- KO worm 
animals (Rodrigues et al., 2007). Moreover, Costa, MC (unpublished results) showed that 
the knockdown expression of the murine homologue of ATXN3 did not affect the 
viability of mouse cell lines, further supporting the notion that the ATXN3 expression is 
not essential for cells or, perhaps, the existence of genetic redundancy. Without an 
obvious pathway affected by the abrogation of ATXN3 expression in these genetic 
approaches, the discovery of novel interactors may help to gain insight into the 
molecular mechanisms in which ATXN3 is participating. The first direct interaction of 
ATXN3 was reported by Wang et al. (2000), who demonstrated that ataxin-3 binds the 
two human homologues of the yeast DNA repair protein RAD23, HHR23A and HHR23B; 
the interaction described was mediated by the JD domain of ATXN3 and the N-terminal 
domain ubiquitin-like (UBL) domain of HHR23 proteins. Both HHR23A and HHR23B 
proteins have been defined as two important participants of the global genome NER 
sub-pathway (Li et al., 1997; Sugasawa et al., 1997; Hsieh et al., 2005). In addition to 
its function in DNA repair, HHR23B was shown to be a modulator of UPS, as it 
participates in the translocation of substrates targeted for degradation at the 
proteasome (Hiyama et al., 1999; Doss-Pepe et al., 2003). 
In vitro and in vivo assays demonstrated that both normal and expanded ATXN3 also 
interact with the cAMP-response element (CREB)-binding protein (CBP), p300 and 
p300/CBP associated factor (PCAF), inhibiting the transcription of CREB-dependent 
genes; moreover, it was showed that ATXN3 is able to bind directly the acetylation site 
in the histones, acting as a dual transcriptional repressor (Li et al., 2002). More 
recently, the involvement of ATXN3 in the regulation of transcription has been 
strengthened, as normal ATXN3 binds to target DNA sequences in specific chromatin 
regions of the matrix metalloproteinase-2 (MMP-2) gene promoter. The recruitment of 
histone deacetylase 3 (HDAC3), nuclear receptor corepressor (NCoR) and the 
deacetylation of histones bound to the promoter underlies the mechanism of the 
transcription repression (Evert et al., 2006). 
ATXN3 is also known to interact with VCP (valosin-containing protein, and yeast cdc48), 
in a polyQ dependent manner; VCP is a molecular chaperone involved in the 
translocation of polyubiquitylated substrates to 26S proteasome, together with ATXN3 
and HHR23B (Dai and Li, 2000; Kobayashi et al., 2002; Doss-Pepe et al., 2003). 
Moreover, this interaction is able to modulate the fribrillogenesis of mutant ATXN3 in 
vitro, in a concentration-dependent manner (Boeddrich et al., 2006).  
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A binding preference of ataxin-3 for K48-linked polyubiquitylated proteins containing 
chains of at least four ubiquitin molecules has been also demonstrated in vivo and in 
vitro (Burnett et al., 2003; Donaldson et al., 2003). The interaction between ATXN3 and 
polyubiquitylated proteins is evolutionarily conserved, as both the C. elegans and mouse 
ataxin-3 homologues also exhibit deubiquitylating activity in vitro, also dependent of 
the cysteine residue (Costa MC et al. unpublished data and Rodrigues et al., 2007). 
Interestingly, ATXN3 also showed self-interaction, mediated by its JD (Gales et al., 
2005), reinforcing the results of Berke et al. (2005) that pointed out ATXN3 as a 
substrate of itself. 
Recently, in a genetic screening, five new interactions of ATXN3 were identified using 
mutant ATXN3, in an yeast two-hybrid human brain cDNA library and colocalisation 
studies; of note are the SUMO-1 (small ubiquitin-like modifier-1), human rhodopsin 
guanosine diphosphate dissociation inhibitor alpha and human neuronal amiloride-
sensitive cation channel 2 (Shen et al., 2006). The interaction between ATXN3 and 
SUMO-1 was reported as being mediated through the N-terminal region of ATXN3, 
suggesting some independency of the polyQ domain. Conversely, Miller et al. (2007), 
reported that the new interaction between SUMO-1 and ATXN3 was established through 
its UIM regions, at C-terminal portion of ATXN3. Further clarification on this interaction 
is need, as SUMO-1 may play an important role in the post-transcriptional modification 
of ATXN3, namely affecting its cellular localisation. 
ATXN3 has been also reported to interact with UFD2a (ubiquitin fusion degradation 
protein-2) (Matsumoto et al., 2004) and with CHIP (Jana et al., 2005), two ubiquitin 
ligases, strengthening the hypothesis of ATXN3 participation in UPS. 
 
 
ATXN3 is involved is several pathways 
The evidence gathered about ATXN3 subcellular localisation and interactions support 
several possibilities for the biological function of ATXN3 in cells: 
  
(1) ATXN3 may be a transcriptional repressor by interacting directly with transcription 
factors and histone deacetylases, enhancing its activity (Li et al., 2002) (Evert et 
al., 2006). 
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(2) ATXN3 may participate in cellular DNA damage response, specifically in GGR-NER 
due to the interaction of ATXN3 with the HHR23 proteins (Wang et al., 2000), 
though no biological proof of this has been reported.  
(3) ATXN3 may also be participant of the protein surveillance mechanisms since it: 
(i) interacts specifically with the HHR23 proteins, two known proteasome-binding 
factors;  
(ii) interacts with VCP, a chaperone involved in the retro-translocation of 
misfolded protein from the endoplasmic reticulum to the 26S proteasome, 
broadening its participation in the cell quality control systems (Hirabayashi et 
al., 2001; Kobayashi et al., 2002; Doss-Pepe et al., 2003; Nakayama, 2003; 
Boeddrich et al., 2006; Zhong and Pittman, 2006); 
(iii) it is associated with several E3-ligases such as parkin (Tsai et al., 2003), CHIP 
(Jana et al., 2005), p300 and PCAF, the p300–CBP-associated factor (Li et al., 
2002; Linares et al., 2007).  
(iv) shows deubiquitylating activity towards polyUb chains in vitro (Burnett et al., 
2003; Chai et al., 2004; Berke et al., 2005; Mao et al., 2005; Rodrigues et al., 
2007);  
(v) was shown to suppress the polyQ toxicity in a Drosophila model of MJD, and 
such neuroprotective role was dependent of the deubiquitylating activity of 
normal ATXN3 and of the proteasome (Warrick et al., 2005). 
 
However, a definite conclusion about the ATXN3 function remains elusive. 
 
 
 
Objectives 
 
Little was known about the ATXN3 protein itself or its physiological function(s), when 
this experimental work was started. Given this unexplored area, our objective was set 
in the identification and further characterisation of the molecular partners of ATXN3, 
gathering insight about the normal function(s) of ATXN3.  
We initiated our work by performing a functional screening of a human brain cDNA 
library, using the yeast two-hybrid system, in order to identify novel ATXN3 interactors. 
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However, the results obtained with this strategy, for technical reasons, were not 
sufficient (Appendix 1). For this, we aimed at: 
 
1. studying potential direct atxn3 protein-protein interactions, assessing strong 
candidates for the ATXN3 interactome (Chapter 1 and Chapter 2); 
2. evaluating the potential evolutionary conservation of the interactions identified, 
verifying if the interaction pairs identified in human were maintained for the 
ATXN3 C. elegans homologue, atx-3 (Chapter 1 and Chapter 2). 
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DNA techniques 
DNA quantification was determined on a spectrophotometer and stock concentrations 
was calculated accordingly to the formula: Cstock= A260 x dilution x 50 μg/mL. Restriction 
digestions and ligation reactions were performed by standard cloning techniques 
(Sambrook and Russel, 2001). Polymerase chain reactions (PCR), in this work, were 
carried out using regular Taq (Fermentas), or with proofreading properties as Expand 
High Fidelity and Expand Long Template (Roche), following the manufacturer’s 
instructions; Pfu polymerase (Stratagene) was used for the site-directed mutagenesis 
reactions. 
 
Plasmid DNA isolation from E. coli 
In general, plasmid DNA was extracted from bacteria, using procedures from 
commercial available kits (Qiagen), or using the standard alkaline method. Briefly, 
overnight cultures were harvested by centrifugation, at 3250 rpm, for 5 min. Pellet was 
resuspended in maxiprep solution (10 mM EDTA, 25 mM Tris-Cl pH 8, 1% glucose); fresh 
made lysis NAHO/SDS buffer (0.2 M NaHO/1% SDS) was added and the mixture was 
incubated on ice for 15 min. Proteins were precipitated with 3 M NaCH3COO pH 5.5, and 
separated, at 16400 rpm, for 10 min. The supernatant was transferred to new 
microtubes; DNA was precipitated with ethanol absolute, mixed, and then centrifuged 
at 16400 rpm, for 20 min. The pellet was washed with 70% ethanol, air-dried and 
resuspended in H2O or TE (100 mM Tris-HCl pH 8.0, 10 mM EDTA). Mix 1 μL RNase 
(DNase-free, 0.5 μg/μL) per 50 μL DNA and incubated one hour, at 37 ºC. 
 
Protein techniques 
Quantification of proteins was performed by Bradford’s method (Bradford, 1976), 
according to the manufacturer’s instructions (Sigma). Absorbance was measured at 595 
nm, on a spectrophotometer, using 1:1000 dilutions; protein concentrations were 
extrapolated from a standard curve obtained with a bovine serum albumin (BSA) 
dilutions set. Proteins were separated in SDS-PAGE gels, according to the expected size 
of the protein. Proteins were either stained with blue coomassie or electro-transferred 
into PVDF or nitrocellulose membranes, according to standard methods. Proteins were 
visualized with Ponceau S staining and/or immunoblotted. 
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SDS-PAGE electrophoresis 
SDS-PAGE separation was performed as described (Laemmli, 1970), using a 40% 
acrylamide solution (37.5:1 acrylamide/bis-acrylamide), or 30% acrylamide solution 
(29:1 acrylamide/bis-acrylamide). The protein samples were diluted sample buffer 1X 
(62.5 mM Tris-HCl pH 6.8, 20% glycerol, 2% SDS, 200 mM DTT, 0.02% bromophenol blue), 
denatured at 95 ºC, for 5 min, and loaded onto the SDS-PAGE with a prestained protein 
marker. Gels were run at 130 V (constante voltage), using SDS-PAGE running buffer 1X 
(25 mM Tris-base pH 8.3, 192 mM glycine, 1% SDS). 
 
C. elegans strains 
The nematode N2 Bristol (wild-type) and atx-3 (knockout for the atx-3 gene) strains 
were obtained from Caenorhabditis Genetic Consortium (CGC). The atx-3 KO strain 
contains a 366 bp delection, comprising 287 bp of the promoter and 79 bp of atx-3 exon 
1. The strain was back-crossed twice in our lab, in order to eliminate random mutations 
due to the original trimethyl psolaren/UV mutagenesis. The strains were maintained at 
20-21 ºC, in NGM plates [3 g/L NaCl, 2,5 g/L bacto-peptona, 20 g/L agar, 1 mM CaCl2, 1 
mM MgSO4, 5 μg/ml cholesterol, 19 mM potassium phosphate (pH6.0)], seeded with the 
E. coli NA22 strain. 
 
Worm synchronized cultures 
Synchronously growing plates for total RNA extraction were prepared by the alkaline 
hypochlorite method. For large quantities of worms, 9-cm enriched peptone plates [3 
g/L NaCl, 20 g/L bacto-peptona, 20 g/L agar, 1 mM MgSO4, 5 μg/ml cholesterol, 19 mM 
potassium phosphate (pH 6.0)], seeded with NA22, were chunked from growth plates. 
Plates were grown for two days, until gravid adult worms were the majority of the 
population. The worms from two to three grown plates were collected to a conical 
screw-cap tube, washed twice with 10 mL sterile M9 buffer (6 g/L Na2HPO4, 3 g/L 
KH2PO4, 5 g/L NaCl, 1 mM MgSO4) with brief spun (1000 rpm, 1 min) in-between. The 
bleaching of the worm pellet was performed with 7-10 mL of alkaline hypochlorite 
solution (2 mL fresh bleach, 5 mL 1 M NaHO), for 10 min, with careful vortexing every 2 
min. After bleaching, the released eggs were spun (1000 rpm, 1 min), washed twice 
with 10 mL of sterile M9 buffer and collected by centrifugation. The pellets were then 
resuspended in 500 μL of sterile M9 buffer, transferred to the necessary fresh enriched 
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peptone plates with a glass Pasteur pipette, and grown to the desired larval stage at   
20 ºC. 
 
ENU mutagenesis 
For the N-ethyl-N-nitrosourea (ENU) mutagenesis experiments, the working solutions of 
ENU were always prepared in sterile M9 buffer, from a stock solution of 100 mM of ENU 
(in 100% ethanol) with no more then one week old at -20 ºC as described (De Stasio and 
Dorman, 2001). The stock solutions were prepared from the same ENU powder stock 
(Sigma). Five or six synchronized 9-cm enriched peptone plates of N2 or atx-3 L4 larval-
stage worms were collected in a conical screw-cap tube. The animals were washed 
twice, with 20 mL of sterile M9 buffer. For the mutagenesis experiments, the control 
worm pellet was resuspended with 4 mL of M9 buffer, whereas the mutagenized worms 
were resuspended in 4 mL of ENU working solutions. The worms were incubated in the 
dark, in a rotary shaker (40 rpm) for four hours, at 20 ºC. The worms were then spun 
(1000 rpm, 1 min) and washed two to three times with sterile M9 buffer. The worm 
pellet was then processed as necessary (see below). 
 
Protein extraction from C. elegans 
Protein extracts of C. elegans were prepared, generally from five L4 larval-stage 
synchronized 9-cm enriched peptone plates. Worms were collected with 10 mL of M9 to 
a tube, briefly centrifuged, and washed two to three times with M9 to wash-off 
bacteria. To obtain protein extracts from ENU-treated worms, the animals were first 
treated as described in “ENU mutagenesis” protocol or processed as follows. Proteins 
were extracted from the worm pellets by adding 1V of worm lysis buffer [WLB, 100 mM 
Tris pH6.8, 2% SDS, 15% glycerol plus 1X complete protease cocktail inhibitors (Roche)]. 
Samples were then boiled for 5-10 min in a water bath, with occasional shaking. 
Proteins were spinned at 3200 rpm, for 20 min at 4 ºC. The supernatants were collected 
and protein concentration measured by Bradford method. Protein stocks were stored at 
-80 ºC. 
 
Total RNA extraction 
Extraction of total RNA from C. elegans was carried out from synchronized 9-cm 
enriched peptone plates of larval-stage worm cultures. Mutagenised (previous section) 
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or control C. elegans were colleted, and total RNA was extracted using Trizol 
(Invitrogen), as described (http://cmgm.stanford.edu/~kimlab/germline). Briefly, 1 mL 
Trizol/500 μL worm pellet was added, mixtures vortexed, and immediately frozen at -80 
ºC; then, 6-8 to eight cycles of -80 ºC/37 ºC incubations were carried out to burst the 
worms. Total RNA extraction was carried out according the manufacturer’s instructions. 
 
Brood size test 
Synchronized cultures of worms were obtained by picking 20 gravid adults to a single 6-
cm seeded NGM plate, which were left to lay eggs for four hours. The gravid adults 
were then removed, and the eggs were grown synchronously until L4-larval stage. These 
synchronized cultures were collected and washed twice with 10 mL of sterile M9 buffer. 
For the mutagenesis assays, the pellet of each 5-cm plate were incubated with 4 mL of 
ENU working solution at the desired concentration for four hours, in the dark, at 20 ºC, 
while the control animals (one plate per each ENU concentration tested) were 
incubated with 4 mL of sterile modified M9. Afterwards, the animals were washed two 
to three times with sterile M9 buffer, transferred to a fresh 9-cm seeded NGM plate, 
and left to recover overnight, at 20 ºC. The next day, 15 alive and moving animals (P0) 
of each condition were individually plated in a 6-cm seeded NGM plate, and its progeny 
scored in the following six days. The P0 animals were transferred to a new seeded plate 
every day, and the progeny in each plate was scored at L4-young adult stage. 
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Abstract 
 
Machado-Joseph Disease (MJD/SCA3) is an autosomal dominant neurodegenerative 
disorder caused by the expansion of a CAG segment in the coding portion of the gene. In 
humans, the ATXN3 gene encodes for ataxin-3 (ATXN3), a 42-KDa intracellular protein 
with deubiquitylating properties. The establishment of differential interactions by 
ATXN3 may be the basis of the selective neuronal loss characteristic of MJD albeit the 
ubiquitous expression of ATXN3. The first molecular interactors of human ATXN3 
identified were the human homologues of RAD23, HHR23A, and HHR23B. These proteins 
have been characterised as modulators of the ubiquitin/proteasome system (UPS) and as 
participants of the DNA damage recognition mechanism in nucleotide excision repair 
(NER), through interaction with Xeroderma pigmentosum group C (XP-C) protein. Here, 
we show by immunofluorescence analysis in HEK293 cells that ATXN3 and XPC proteins 
are co-localized and that UV radiation enhances this co-localization in the exposed 
cells. In addition, we report, for the first time, the cloning and expression of the C. 
elegans RAD23 protein homologue 2-like, ZK20.3, and we show that atx-3 interacts with 
ZK20.3 suggesting evolutionary conservation of the structural determinants relevant for 
this novel interaction. ZK20.3 is highly expressed in worm adults, as previously observed 
for atx-3. Using semi-quantitative RT-PCR, we analysed the effect of N-ethyl-N-
nitrosourea (ENU) upon the expression of atx-3, ZK20.3 and xpc-1 in C. elegans. We then 
demonstrated that atx-3 is upregulated in ENU-mutagenized worms, suggesting a 
potential role of atx-3 in C. elegans’ response to mutagenesis. Behavioural assays 
showed no effect of ENU upon N2 or KO’s progeny when compared to controls, thought 
a significant difference was observed between the two genotypes. 
 
 
 
Introduction 
 
There are nine polyglutamine diseases reported to date. Machado-Joseph disease 
(MJD/SCA3) is the most common form of these dominantly-inherited ataxia worldwide 
(Schols et al., 2004). Affected individuals present an abnormal form of the ATX3 gene 
product comprising 55 to 87 glutamines in the C-terminal region instead of the usual 12 
to 41 glutamines found in normal individuals (Maciel et al., 2001). This is due to a 
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dynamic mutation caused by the expansion of a trinucleotide repeat (CAG) in the 3’-
coding region of ATXN3 (Kawaguchi et al., 1994). Despite, the ubiquitous expression of 
ATXN3 (Paulson et al., 1997a), only specific brain regions are affected in MJD. Expanded 
ATXN3 accumulates in the MJD affected regions as ubiquitylated neuronal inclusions 
containing, also, proteasomal subunits and molecular chaperones (Paulson et al., 1997b; 
Schmidt et al., 2002; Berke and Paulson, 2003; Chai et al., 2004). Intraneuronal 
aggregation is a common feature of all polyglutamine diseases, but whether these 
proteinaceous structures are a cell’s attempt to suppress toxicity, or if they are per se, 
the cause of neuronal dysfunction leading to disease, remains controversial. 
 
Recent reports have described ATXN3 as a polyubiquitin binding protein, with a 
preference for chains with at least four ubiquitin-moieties (Donaldson et al., 2003; 
Doss-Pepe et al., 2003; Chai et al., 2004), and to possess deubiquitylating (DUB) activity 
in vitro (Burnett et al., 2003), dependent on its catalytic centre cysteine residue (C14) 
(Berke et al., 2005; Burnett and Pittman, 2005). 
As described in the “General Introduction” the normal function of ATXN3 is not fully 
understood and the study of its interacting partners is therefore expected to help in this 
elucidation. Wang et al. (2000) reported the interaction of ATXN3 and HHR23A/B 
proteins, the human homologues of RAD23 protein. In addiction to their role in DNA 
repair (van der Spek et al., 1996; Li et al., 1997; Sugasawa et al., 1997; Hsieh et al., 
2005; Chen and Madura, 2006), these proteins were shown to act as shuttling factors, 
acting in conjugation with ATXN3, p97/VCP (valosin-containing protein) and 
proteasomal subunits (Walters et al., 2003) for the delivery of polyubiquitylated 
proteins to the proteasome (Dai and Li, 2000; Doss-Pepe et al., 2003; Boeddrich et al., 
2006). However, the importance of ATXN3 and HHR23A/B interactions for DNA 
nucleotide excision repair (NER) mechanism has remained unexplored.  
 
NER eliminates bulky helix-distorting DNA adducts caused by genotoxic lesions, such as 
UV-induced cyclobutane pyrimidine dimmers (CPD), pyrimidine-pyrimidone (6-4) 
photoproducts (6-4 PP), caused by several chemical agents, including oxidative DNA 
damage (Reardon et al., 1997; Costa et al., 2003). Efficient repair is vital for the 
maintenance of genomic integrity (Friedberg, 2001). XPC-HHR23B is one of the 
complexes known to be involved in the recognition of the DNA lesion, the earliest step 
of GGR-NER (Huang and D'Andrea, 2006). XPC is responsible for the physical binding of 
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the complex to damaged DNA, but HHR23B stimulates XPC action at early stages of 
damage recognition and modulates the complex displacement afterwards (You et al., 
2003). It was shown that XPC also interacts with centrin-2 (CETN2), forming a trimeric 
complex in vivo, XPC/HHR23B/CETN2. Centrin-2, together with HHR23B, stabilizes XPC, 
hence stimulating the repair activity of the complex (Araki et al., 2001). 
 
How does this correlate with polyglutamine diseases? Neurons are particularly 
susceptible to many kinds of stress, and polyglutamine protein accumulation imposes a 
great deal of cellular stress. Either by depletion of important factors, impairment of the 
proteasome by misfolded protein overloading, or other mechanisms not yet fully 
understood, it might lead neuronal cells to significant dysfunction and death. 
Evidence shows that, cellular models of HD expressing expanded full-length huntingtin 
(Wyttenbach et al., 2002) or its pathogenic N-terminal portion (encoded by exon 1 of 
HD), produced increased levels of ROS, in a CAG length-dependent manner (Firdaus et 
al., 2006). It has been reported that mitochondrial dysfunction and excitotoxic 
mechanisms promote oxidative damage in the brain of HD patients (Tabrizi et al., 
1999). Moreover, experiments with lymphoblastoid cell culture of patients homozygous 
for HD mutation revealed severe ultra-structural and functional mitochondrial 
alterations (Squitieri et al., 2006). Accumulation of oxidative damage products, such as 
8-hydroxydeoxyguanosine (OH8dG) in areas degenerated in HD (Browne et al., 1999), 
and in a HD mouse model overexpressing huntingtin (Bogdanov et al., 2001), provided 
further evidence that oxidative stress may be involved in HD pathogenesis. Moreover, 
Giuliano et al., reported accumulation of ROS in HD and SCA2 patients, due to 
polyglutamine activation of ATM/ATR-dependent DNA damage response (Giuliano et al., 
2003). ROS/oxidative DNA damage may cause neurodegeneration by, e.g., impairing the 
transcription of neural genes, due to progressive impairment of DNA repair.  
 
NER repairs DNA damage induced by UV and chemical agents, and, to some extent, DNA 
oxidative lesions produced by ROS (Reardon et al., 1997; Brooks et al., 2000).  
Recently, a study conducted in cultured CNS neurons showed that expanded ATXN3 
induces neurodegeneration in specific neuronal subpopulations, normally affected in the 
disease, by activating a mitochondria-dependent apoptotic cascade and by promoting 
the release of apoptogenic proteins (Chou et al., 2006). The mitochondrial damage seen 
in cultured neurons normally affected in the disease may be only the tip of the iceberg. 
In vivo, this type of damage may go on for decades, with progressive mitochondrial 
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impairment leading to cellular energy imbalance and marked production of ROS. The 
depletion of the ATP supply in the neuron will interfere with removal of proteins by the 
ubiquitin-proteasome system, due to the 26S absolute energy requirement. As shown 
before, proteasome impairment causes accumulation of polyubiquitylated proteins, and 
its diminished catalytic activity may influence NER negatively (Wang et al., 2005). DNA 
damage, mitochondria shutdown, ROS production, transcription deregulation or protein 
quality control impairments are phenomena affecting all kinds of cells. Neurons, 
however, as non-replaceable, highly metabolic cells, with large energy requirements 
will, overtime, suffer any disturbance more dramatically, and this may be translated in 
irreversible cellular damage.  
 
Apart from its role in the protein quality control system, ATXN3 was shown to be also a 
transcription regulator (Li et al., 2002). ATXN3 has been reported as a dual factor, 
either binding histones directly, inhibiting their acetylation and transcription, or as a 
transcription co-repressor of CREB-dependent genes, by interacting with 
acetyltransferases like CBP, p300 and P/CAF, inhibiting their histone acetyltransferase 
activity.  
 
This link of ATXN3 to chromatin remodelling, may well be linked to a putative role in 
DNA repair. Histones may be modified by methylation, acetylation, ubiquitylation or 
sumoylation, modifications, which generally favour, through specific mechanisms, 
chromatin relaxation and nucleosome unwinding, allowing replication, transcription, 
and/or DNA repair (Peterson and Laniel, 2004). Recently, it was reported that UV 
radiation-stimulated histone acetylation, in yeast, is independent of Rad4 or Rad14 (XPC 
and XPA human homologues, respectively) (Yu et al., 2005). ATXN3 interacts with NER 
components known to be involved in the initial/recognition events, participating in 
GGR-NER on naked chromatin (de Laat et al., 1999), namely HHR23 proteins (Wang et 
al., 2000). Hence, the transcriptional co-repressor capacity of ATXN3 (Li et al., 2002) 
does not exclude the possibility of ATXN3 participation in NER or recruitment of DNA 
damage recognition factors to lesion sites, but may potentially reflect different 
functions of ATXN3 upon hetero- or euchromatin.  
The HHR23 proteins have been characterized both as modulators of the 
ubiquitin/proteasome system (UPS) and as participants of the DNA damage recognition 
mechanism in nucleotide excision repair (NER), through interaction with xeroderma 
pigmentosum group C (XPC, NP_004619) and centrin-2 (CETN2, NP_004335) proteins. 
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These proteins form a trimeric complex and the direct interaction of HHR23B and CETN2 
with XPC stabilizes it (Araki et al., 2001; Popescu et al., 2003; Nishi et al., 2005).  
The interaction of ATXN3 with HHR23 proteins led us to raise the hypothesis that ATXN3 
could also interact with the other proteins of the trimeric complex, XPC and CETN2, and 
be modulating the damage recognition complex activity.  
These hypotheses were studied in both human cell and C. elegans systems. In human 
cell system (see section 1A), we focused on the interactions between the human 
proteins and how they might be modified by DNA damage-inducing conditions. Due to its 
easy manipulation, the possibility to perform functional assays and the availability of a 
knockout strain for atx-3, we also used C. elegans in our studies (see section 1B). We 
analysed the conservation of the interactions, determined the effect of genotoxic stress 
in the homologue genes of C. elegans, and assessed the importance of ataxin-3 in 
worm’s response to genotoxic insult. 
 
 
  
 
ATXN3 and DNA repair 
55 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 1: Section 1A 
 
 
 
Human ATXN3 and the NER pathway 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
ATXN3 and DNA repair 
57 
Introduction 
 
The reported interaction between ATXN3 and the two proteins HHR23A and HHR23B 
(Wang et al., 2000), known to be involved in DNA repair, namely in the global genome 
repair branch of the nucleotide excision repair system (GGR-NER), instigated us to study 
the consequences of this interaction, and explore the possible interaction of ATXN3 with 
other proteins, involved in GGR-NER, as XPC and centrin-2 (CETN2).   
For this we analysed these putative interactions using in vitro and in vivo approaches, 
as the yeast two-hybrid system (Fields and Song, 1989), GST pull-down and 
immunofluorescence assays. Moreover, we assessed the effect of DNA damage-inducing 
condition upon these interactions, in a cell-based system. 
 
 
 
Material and Methods 
 
Antibodies  
A novel primary antibody against the ATXN3 variant MJD2.1, anti-MJD2.1 antibody, was 
synthesized externally in Davids Biotechnologie by immunization of rabbits. The 
antibody anti-MJD2.1 was raised against the recombinant full-length ATXN3 var2.1. 
Competition assays were performed to assess the specificity of the antibody (Fig.A5 of 
Appendix 2).  
The anti-MJD1.1 antibody against the human ATXN3 var1.1 in described in chapter 2, 
whereas the anti-303JSP antibody specific for the atx-3 protein was described before 
(Rodrigues et al., 2007); the anti-mjd antibody was kindly provided by Dr Henry Paulson 
(Paulson et al., 1997a).  
 
Yeast expression plasmids  
The pAS1/MJD2.1(17Q), pAS1/2.1N, pAS1G/MJD1.1(14Q) and pAS1G/JD plasmids and the 
empty vectors pAS1G and pACT2G were previously described (chapter 2). To obtain the 
pACT2G/HHR23A and pACT2G/HHR23B plasmids, the cDNA sequence encoding HHR23A 
and HHR23B were reverse transcribed from total RNA of HeLa cells, and then amplified 
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using attB1-HHR23A, attB2-HHR23A and attB1-HHR23B, attB2-HHR23B primers, 
respectively. To obtain the pACT2G/XPC-D1 encoding the N-terminal fragment of XPC 
protein, and pACT2G/XPC-D2 construct for its C-terminal, the cDNA sequence encoding 
XPC-D1 and XPC-D2 were reverse transcribed from total RNA of HeLa cells, and then 
amplified using attB1-XPC-D1, attB2.1-XPC-D1 and attB1.2-XPC-D2, attB2-XPC-D2 
primers, respectively. The cDNA encoding human centrin-2 (CETN2) was obtained from 
total RNA of HeLa cells as described (Araki et al., 2001) but the second amplification 
was carried out using attB1-CETN2 and attB2-CETN2, in order to clone the cDNA 
fragment into pACT2G using the Gateway system (Hartley et al., 2000). All 
aforementioned PCR products were first cloned into pDONR201 or pDONR207 Gateway 
vectors, and then transferred to pACT2G or pAS1G; the HHR23A and HHR23B attB-PCR 
products were first cloned into pGEM-T-Easy vector (Promega), and then sub-cloned to 
yeast expression vectors using classical cloning techniques (Sambrook and Russel, 2001). 
All clones were verified by automated sequencing. For primers sequence, refer to Table 
A3 of Appendix 2. 
 
Bacterial expression plasmids 
To obtain the plasmids expressing the GST-HHR23A, GST-HHR23B and GST-CETN2, the 
attB-PCR products were transferred from the specific pDONRs vectors to pDEST15, using 
the Gateway technology (Hartley et al., 2000). All clones were verified by automated 
sequencing. The plasmids expressing 6His-ATXN3 var1.1, 6His-JD (6His tagged-Josephin 
domain) and 6His-D1 (comprising the JD plus ubiquitin interacting motifs UIM1 and UIM2) 
were described before (Gales et al., 2005).  
 
Yeast two-hybrid assay 
The yeast strains Y190 (ATCC, 96400) and Y187 (ATCC, 96399) were transformed using 
the lithium acetate method, as described (Gietz et al., 1995). All transformations with 
pAS1G-JD, pAS1G-ATXN3 var1.1 and pAS1-2.1N were grown on SC-WLH supplemented 
with 130, 140 or 170 mM of AT (amino-1,2,3 triazole), respectively; the remaining were 
grown on SC-WLH with 20 mM AT. The interactions between TSCII (hamartin) and TSCI 
(tuberin) (van Slegtenhorst et al., 1998), or SNF4 and SNF1 (Fields and Song, 1989), 
were used as positive controls in the assays. Incubations were performed at 30 ºC,for 
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five to ten days. Colony-lift β-galactosidase filter assay was performed according the 
manufacturer’s instructions (Clontech). 
 
Expression of recombinant proteins  
Expression and purification of 6His-tagged ATXN3 var1.1 and 6His-JD was described 
before (Gales et al., 2005). Expression of GST-HHR23A, GST-HHR23B and GST-CETN2 
were carried out in BL21-SI E.coli strain (Invitrogen) with 300 mM NaCl. Generally, 
protein expression was induced for three hours. Harvested cells were ressuspended in 
1/10 volume of ressuspention buffer (TBS 1X, 10 μg/mL lisozyme, 10 mM EDTA pH8, 
PMSF 0.5 mM), supplemented with EDTA-free protease inhibitors cocktail (Roche). After 
lysis, the supernatant was cleared by centrifugation, and the GST-tagged proteins were 
purified with glutathione-sepharose™ 4B beads (Amersham Biosciences); elution was 
carried out with 10 mM reduced glutathione in 50 mM Tris-Cl pH 8.  
 
GST pull-down assay 
The purified GST or GST-tagged proteins were incubated for one hour, at 4 ºC, with 50 
μl of glutathione-sepharose™ 4B beads, in 500 μl of in vitro binding buffer (IBB, 50 mM 
Tris-Cl pH 7.5, 150 mM NaCl, 10% glycerol, 1% Triton X-100, 1 mM EDTA, 1 mM DTT, 1 
mM PMSF) (Otera et al., 2000). The 6His-JD or 6His-ATXN3-var1.1 were added and 
incubated for 1-2 hours, at 4 ºC, on a rotator; 1% bovine serum albumin (BSA)was used 
for blocking in 6His-ATXN3-var1.1 reactions. Bound fractions were washed with IBB 
without glycerol and BSA, eluted by boiling in 50 μl of 2X SDS sample buffer, and then 
analyzed by SDS-PAGE (12%). Immunoblottings were performed using goat anti-GST 
(1:7500, GE Healthcare) or rabbit anti-MJD1.1 (1:2000) with overnight incubation. 
Secondary HRP-coupled anti-goat antibody (Sc-2020, Santa Cruz Biotechnology) was 
diluted at 1:20000, and anti-rabbit (401393, Calbiochem) at 1:20000. All antibodies 
were diluted in 3% SM/TBST (3% skimmed milk, Tris-buffered saline (TBS) 1X, 0.05% 
Tween 20). Detection was carried out with ECL (GE Healthcare). 
 
Immunofluorescence analysis 
For immunolocalization of endogenous ATXN3 and XPC, HEK293 cells were grown on 
glass coverslips, for 48h, on DMEM (D5648, Sigma). Cells were fixed and permeabilized, 
as described before (Correia et al., 2003). Briefly, cells were fixed with 4% 
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paraformaldehyde/4% sacarose. After washing twice with PBS, permeabilisation was 
carried out using PBS/0.3% Triton X-100, and blocking was performed, for one hour, 
with PBS/0.1% Tween 20/0.2% gelatin (Sigma) (PBST-0.2%G). The endogenous XPC and 
ATXN3 proteins were detected with anti-XPC monoclonal antibody (ab-6264, Abcam) at 
1:50, and with polyclonal anti-mjd antibody (Paulson et al., 1997a) at 1:10000, 
respectively, both in PBST-0.1%G. AlexaFluor 488-coupled goat anti-rabbit and 
AlexaFluor 568-coupled goat anti-mouse (Molecular probes) secondary antibodies were 
used simultaneously at 1:1000 in PBST-G. Coverslips were mounted in VectorShield with 
DAPI, and analyzed using a x63/1.40 NA oil objective (Leica) in a laser scanning confocal 
microscope (SP2 AOBS SE; Leica Microsystems), at room temperature, using LCS 
software (Leica Microsystems).  
 
UV radiation  
To perform UV radiation assays, the HEK293 cells were grown on glass coverslips, for 
48h. Immediately before irradiation, cells were washed in pre-warmed PBS and then UV 
irradiated (254 nM) from above, with 20 J/m2, using a UV crosslinker device (GE 
Healthcare). Afterwards, cells were either processed for immunocytochemistry, or 
maintained in the initial medium (preserved during the assay), to allow repair before 
the immunofluorescent staining (described above). 
 
 
 
Results 
 
Human ATXN3 binds more than one component of the XPC DNA damage 
recognition complex 
ATXN3 interacts with XPC 
We prepared for the yeast two-hybrid assays the following constructs: bait encoding 
normal full-length ATXN3 var1.1 (Gal4BD-ATXN3(14) var1.1), bait encoding a truncated 
variant of the protein comprising the JD plus the first UIM (ubiquitin-interacting motif)( 
Gal4BD-2.1N) and the preys encoding human HHR23A, HHR23B and CETN2. Western blot 
confirmed their expression in the yeast (Fig.A4 in Appendix 2). 
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The NER DNA damage recognition complex comprises XPC, HHR23B and CETN2 (Araki et 
al., 2001). The complex is stabilised by the direct interaction of HHR23B and CETN2 
with XPC. To analyse if ATXN3 could bind the other components of the NER complex, 
XPC and CETN2, we prepared the constructs encoding the N-terminal or the C-terminal 
of the protein, Gal4AD-XPC-D1 and Gal4AD-XPC-D2, respectively, since we were unable 
to obtain a full-length clone for the human XPC protein (Fig.4A).  
 
 
 
Figure 4. ATXN3 interacts with XPC. A, schematic 
representation of the prey constructs used in the Y2h 
assay. The N-terminal GAL4AD-fused HHR23A and HHR23B 
proteins comprise an N-terminal ubiquitin-like domain 
(UBL), two ubiquitin associated domains (UBA), and a 
xeroderma pigmentosum complementary group C (XPC)-binding domain. Two fragments of the full-length XPC protein 
were defined: XPC-D1 is an N-terminal fragment; XPC-D2 is the C-terminal fragment, which comprises the known 
HHR23B, DNA and TFIIH binding sites, as depicted in the figure. Schematic drawings are not at scale. B, the yeast two-
hybrid assays between ATXN3 and NER proteins revealed positive interaction with XPC-D1. Two ATXN3 variants were 
used: ATXN3 var1.1 comprises three UIMs and ATXN3 var2.1, which has only two UIMs before the polyQ domain. Two C-
terminal truncations were also assayed, GAL4BD-2.1N, which includes the JD plus the functional UIM1, and GAL4JD 
comprises the JD alone. Yeast co-transformations were plated in high stringency plates, and an interaction was 
considered positive (+) when growth on nutritional selection plates was observed and colonies stained blue, when tested 
for β-galactosidase expression (blue dots); asterisks correspond to protein-protein interactions reported before (Wang et 
al., 2000).NA, interaction not assessed. 
 
 
The results showed that human ATXN3, independently of the cDNA variant expressed, is 
able to bind XPC by its N-terminal region. Moreover, the presence of ATXN3 JD is 
sufficient for the interaction to occur, as positive interactions were observed between 
Gal4BD-2.1N or Gal4BD-JD and Gal4AD-XPC-D1 (Fig.4B); a weaker interaction was also 
detected with the C-terminal fragment of XPC, Gal4AD-XPC-D2 (data not shown). In 
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contrast, no direct interaction was observed between ATXN3 and CETN2. The positive 
interactions found were specific, as the baits did not interact with Gal4AD alone, 
neither the preys with the Gal4BD alone. 
GST pull down assays were performed, which further confirmed the Y2H results, 
regarding ATXN3 and CETN2 results (Fig.5). We were unable to clone XPC full-length 
and to produced the GST-XPC protein; thus we could not confirm this interaction using 
GST pull-down assays.  
 
 
 
 
 
 
 
 
 
 
Figure 5. ATXN3 does not interact with CETN2. A, purified GST-HHR23A and GST-CETN2 were incubated with 6His-
ATXN3. The described interaction of ATXN3 and HHR23A (Wang et al., 2000) was observed in the conditions used 
(asterisk). Inputs lanes represent 10% of 6His-ATXN3 used in the assays. No interaction between ATXN3 and GST-CETN2 
was observed in vitro. GST alone showed no relevant binding in the assays. Black stars indicate protein degradation 
fragments. 
 
 
UV exposure enhances ATXN3 and XPC co-localization in HEK293 cells 
We analysed the expression and localization of both endogenous ATXN3 and XPC 
proteins in HEK293 cells. Using double-immunostaining, we determined if ATXN3 and 
XPC could co-localise in this mammalian cell line. Cells were fixed, permeabilised and 
then immunoastained with monoclonal anti-XPC and polyclonal anti-mjd antibodies. 
Both proteins exhibited a diffuse distribution in the cell (Fig.6, (a)). Nonetheless, 
merged images allowed us to observe that ATXN3 and XPC co-localised primarily within 
the nucleus (depicted by yellow areas). 
Next, we assessed the distribution of ATXN3 and XPC in irradiated cells that were 
allowed to recover and repair the DNA for either 5 min (Fig.6, (b)) or one hour (c).  
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Figure 6. Endogenous ATXN3 and XPC colocalise in HEK293 cells. HEK293 cells were mocked treated (-UV, a) or were irradiated with 20 J/m2 UV (b, c) and then allowed to recover for 5 min 
(b), or 1 hour (c) before fixation. Cells were processed for fluorescence microscopy using anti-mjd and anti-XPC antibodies, followed by secondary antibodies conjugated to anti-rabbit 
AlexaFluor488 and anti-mouse AlexaFluor568: ATXN3 (green) and XPC (red); nuclei were stained with Dapi; merged images depict colocalisation of ATXN3 and XPC. The insets are from the 
delimited areas where the nuclei and nucleoli are better seen (magnifications are indicated); arrows depict areas of colocalisation. 
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Interestingly, we observed that nuclear immunostaining of both proteins increased, as 
well as their co-localization. 
After 5 min of recovery, the immunoastaining showed a higher co-localization signal 
(depicted in yellow) within the nucleus of HEK293 cells. The immunostaining appears to 
be more punctated than in non-irradiated cells, possibly indicating the ATXN3 may be 
localising in the same damage spots, to which XPC has been recruited. Another group of 
cells was also allowed to recover for one hour (Fig.6, c), after the UV exposure. Here, 
the immunoastaining showed a more diffuse expression of both proteins, in comparison 
to 5 min recovered cells period. Nevertheless, the co-localization of ATXN3 and XPC is 
notorious not only in the nucleus, but also in the cytoplasm. These observations, 
together with the Y2H results are compatible with the possibility that ATXN3 interacts, 
in vivo, with XPC in HEK293 cells. 
 
 
 
Discussion 
 
Genomic integrity is crucial for the proper transmission of genetic information. From 
prokaryotes to eukaryotes nucleotide excision repair (NER) is a multistep process 
responsible for removing DNA lesions (cyclobutane pyrimidine dimers (CPD) and (6-4) 
photoproducts (6-4PP)) produced by the shortwave UV component of sunlight and bulky 
chemical adducts. In mammals, two major sub-pathways of NER are defined: global 
genome NER (GGR), which repairs lesions over the entire genome, and transcription-
coupled NER (TCR), which repairs transcription-blocking lesions present in actively 
transcribing DNA strands (Wood, 1997; de Laat et al., 1999) 
 
The HHR23B protein is a key component in the DNA damage recognition complex of the 
NER-GGR. Together with XPC and centrin-2, HHR23B forms the trimeric-recognition 
complex, in which it is responsible for the stabilisation of XPC to the site of repair 
(Araki et al., 2001). The interaction of ATXN3 and HHR23B has been previously explored 
in the perspective that both proteins may be active participants in the ubiquitin-
proteasome system (UPS) for protein degradation. Here, we worked on the possibility of 
ATXN3-HHR23 interactions as clues to other physiological roles of ataxin-3, namely in 
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NER. We first investigated whether ATXN3 could interact with the other components of 
the DNA damage recognition complex, the XPC and CETN2 proteins.  
 
Interestingly, we observed that ATXN3 is able to bind XPC. The Y2H results showed a 
positive interaction between ATXN3 and the fragment of XPC, XPC-D1 (Fig.4). Only the 
interaction with the N-terminal fragment of XPC, XPC-D1 was expected, as the C-
terminal fragment, XPC-D2, comprises the TFIIH, DNA, and HHR23B binding domains. 
The sequential nature of the events (Fig.1, page 23 of “General Introduction”) that 
take place at the DNA damage spot, the formation of the recognition complex and the 
subsequent binding of the repair proteins, makes it possible that ATXN3 may also bind 
the XPC protein through its C-terminal. However, due to the known interaction of 
ATXN3 and HHR23B, it is reasonable to hypothesise that, the interaction with XPC-D2 
results of an indirect, “bridging” effect between the latter and the endogenous RAD23 
protein of yeast. The presence of the JD of ATXN3 (Gal4BD-JD) was sufficient for the 
interaction with XPC-D1 to occur. 
The co-immunoprecipitation of endogenous ATXN3 and XPC from cellular extracts is 
crucial to further validate this novel interaction. The confirmation of mapping of the 
interaction by direct testing of XPC fragments and ATXN3 by, for example, GST pull-
down assay is also mandatory and will dissipate any doubts regarding the XPC region 
through which the interaction is actually occurring. 
 
The interaction between ATXN3 and CETN2 was assessed but both the Y2H and the GST 
pull-down assays revealed no positive interaction between the two proteins (Fig.4B and 
Fig.5). A transient interaction between these two proteins, which we could not detect 
with the methodology chosen, cannot be excluded. 
 
Nevertheless, we believe that these results broaden the participation of ATXN3 in the 
NER recognition complex and suggest that this protein may be participating in the DNA 
repair process, not only in the stabilization of the complex through its interaction with 
HHR23B, but also by interacting with the XPC, which is responsible for the “docking” of 
the complex to damage DNA.  
 
These preliminary observations open new possibilities for the normal function(s) of 
ATXN3. Recently, normal ATXN3 has been described as binding to promoter regions of 
the MMP-2 gene and repressing the transcription of GATA-2-dependent target genes; its 
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ability to bind the histones’ acetylation sites, the direct interaction with HDAC3 and 
chromatin are consistent with ATXN3 acting as a transcription repressor (Li et al., 2002; 
Evert et al., 2006), but may be also as a component of DNA repair complexes.  
In the UPS, ATXN3 may participate in the substrate delivery to the proteasome, by 
acting in conjugation with HHR23B and VCP (Hirabayashi et al., 2001; Kobayashi et al., 
2002; Doss-Pepe et al., 2003; Richly et al., 2005); concomitantly, ATXN3 has been 
assigned as a DUB enzyme with in vitro activity (Burnett et al., 2003; Berke et al., 
2005; Nicastro et al., 2005). The HHR23B is known to stabilise, through its ubiquitin-
associated (UBA) domain, the XPC protein at the damage site (Ng et al., 2003). 
Intriguingly, polyubiquitylation of XPC is not intended for degradation but rather for 
further stabilization of XPC, promoting its availability in case of DNA damage (Sugasawa 
et al., 2005). Though the nature of the polyUb chain conjugated to XPC was unexplored, 
Sugasawa et al., proposed that the ubiquitylated XPC is protected against proteasome-
dependent degradation through its interaction with HHR23B (Sugasawa et al., 2005). 
Others have proposed that UBA domains can inhibit elongation of polyubiquitin chains by 
capping conjugated ubiquitin (Ortolan et al., 2000; Chen et al., 2001). Recently 
Heessen et al., proposed the UBA2 domain as key intrinsic stabilizer, and hypothesized 
that through its interaction with polyUb chains, it could allow HHR23s to interact with 
the proteasome while escaping destruction (Heessen et al., 2005). It could be that the 
association of HHR23B’s UBA2 domain with the polyUb conjugated to XPC may hinder 
the delivery of this substrate to the proteasome. On the other hand, the nature of the 
polyUb chain itself may be protective of degradation: if XPC is conjugated to K63-linked 
chains, for example, it would not be eligible for destruction. Long, K48-linked polyUb 
chains escaping proteasome degradation, although unexpected, also exist. This is also 
the case of yeast Met4 protein, a bZIP (basic leucine zipper) family transcriptional 
activator that can be ubiquitylated, but remains stable. Kaiser et al., showed that yeast 
Met4 can be polyubiquitylated with K48-linked chains, though maintaining its stability. 
This evidence and the fact that XPC is stabilised by HHR23B, a cargo-shuttle of 
ubiquitylated substrates and a proteasome-interacting protein, is compatible with the 
possibility that K48-polyUb chains might conjugate XPC (Kaiser et al., 2006). 
There are three possibilities: (1) ATXN3 may be forming a quaternary complex with the 
HHR23B/XPC/CETN2; (2) it also may be competing with HHR23B for XPC, and the fact 
that both interactions occur through the JD supports this last notion; (3) the possibility 
that XPC may be a substrate of ATXN3 DUB activity should also not be ruled out. In vivo, 
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most of the HHR23B protein is complexed with XPC, to form the damage recognition 
complex (Ortolan et al., 2004). The direct binding of ATXN3 to either XPC or HHR23B 
may disrupt the complex stabilisation equilibrium, inducing the shuttling of the complex 
for degradation in the proteasome, allowing rapid elimination of HHR23B/XPC/CETN2 
when unnecessary. Alternatively, the interaction with ATXN3 and its DUB activity, may 
allow the trimming of the polyUb chains, facilitating the delivery and degradation of 
K48-linked polyubiquitylated XPC in the proteasome. The in vitro ubiquitylation of XPC 
and the analysis of the effect of the addition of recombinant ATXN3 in its catalytically 
active and inactive form (ATXN3C14A) could show if XPC is a substrate of ATXN3. It 
would also be interesting to evaluate if ATXN3 modulates the availability of XPC for 
efficient DNA repair, in vivo. 
 
Although very preliminary, our results could suggest that ATXN3, either as a direct 
interactor of XPC or as an isopeptidase affecting its polyubiquitylation rate might be (1) 
directly modulating the availability of XPC (or HHR23B) or (2) its readiness to act as 
caretaker of the genome, and, thus, ATXN3 could be globally acting as negative 
regulator of the GGR-NER pathway.  
Experiments to address these questions still need to be performed. Using, for example, 
gap repair activity assays (Krishna et al., 2005) in cellular extracts expressing either 
normal ATXN3, its catalytic inactive form [ATXN3(C14A)] or with knockdown of ATXN3’s 
expression (RNAi), we could analyse the effect of the protein in cell’s capacity to 
perform DNA repair. The unscheduled DNA synthesis assay (UDS) (Sanes and Okun, 1972) 
could also be used to monitor in a cell culture the extent of DNA synthesis, in the 
presence of fully active ATXN3 or not (either by expressing ATXN3(C14A) or fully knock-
down ATXN3’s expression), after exposure to DNA damaging conditions. This would offer 
an indirect evidence of the in vivo consequences of ATXN3 expression upon on the cell’s 
ability to repair DNA.  
As a start, we chose to use a simpler animal model, C. elegans, to pursue the biological 
relevance of these findings (Section 1B). 
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Atx-3 and ZK20.3, a conserved interaction  
suggesting a role in the DNA damage response  
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Introduction 
 
Atx-3, the homologue protein of ATXN3 in C. elegans, is 38% identical to its human 
counterpart. The primary structure of atx-3 is conserved, as the Josephin domain (JD) 
and two ubiquitin-interacting motifs (UIMs) are present. This led us to study the possible 
conservation of some of the interactions known for ATXN3. The possibility to carry out 
functional studies in a multicellular yet simpler organism, and the availability of a 
knockout strain for atx-3 in the lab, led us to proceed our studies in C. elegans.  
In this section, it will be described and discussed how the expression of atx-3 in wild-
type animals is affected, when these are subjected to genotoxic stress, namely to ENU 
treatment. The mRNA expression of two transcripts, conceptually involved in DNA repair 
in the nematode, ZK20.3 and xpc-1, was analysed. The role of atx-3 in the worm’s 
response to DNA damage-inducing conditions was also addressed. 
 
 
 
Material and Methods 
 
Antibody 
A novel primary antibody against the RAD23 homologue 2 protein of C. elegans, ZK20.3, 
was obtained externally, in Davids Biotechnologie, by immunization of rabbits. The anti-
ZK20.3 antibody was prepared against a specific peptide (IDNVDEDGNDDLN), located in 
the C-terminal region of the ZK20.3 protein. Competition assays were performed, and 
the specificity of anti-ZK20.3 antibody was proven (Fig.A5 of Appendix). 
 
Yeast expression plasmids  
The constructs expressing normal human ATXN3 (pAS1/MJD2.1(17Q), and 
pAS1G/MJD1.1(14Q)), or expressing a truncated variant of the protein (pAS1/2.1N), as 
well as the empty vectors, pAS1G and pACT2G, are described in Chapter 2. The plasmids 
encoding GAL4AD-HHR23A, GAL4AD-HHR23B and GAL4AD-CETN2 are described before, in 
section 1A of this chapter. The cDNA encoding ZK20.3 was obtained from total RNA 
extracted with Trizol reagent (Invitrogen), from N2, wild-type C. elegans. This cDNA 
fragment was first amplified using SL1 and attB2-ZK20.3 primers, and then with attB1.2-
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ZK20.3 and attB2-ZK20.3; the cDNA fragment isolated encodes a protein lacking its first 
50 amino acids. The cDNA fragment encoding the full-length atx-3 protein was obtained 
as described before (Gales et al., 2005). Subsequently, the atx-3 cDNA was re-amplified 
with the primers attB1-atx-3 and attB2-atx-3. The PCR products were first cloned into 
pDONR207 Gateway vector, and then transferred to pACT2G, or pAS1G. The constructs 
were verified by automated sequencing. For primer sequence, refer to Table A3 of 
Appendix.  
 
Bacterial expression plasmids 
To obtain the plasmid expressing GST-ZK20.3, the attB-PCR product was transferred to 
pDEST15 using the Gateway technology, and then verified by automated sequencing. 
The plasmids expressing the GST-HHR23A and GST-HHR23B are described in section 1A 
of this chapter. The expression and purification conditions of 6His-ATX-3 and 6His-
ATXN3 var1.1 were described before (Gales et al., 2005). 
 
Yeast two-hybrid assay 
The yeast strains Y190 (ATCC, 96400) and Y187 (ATCC, 96399) were transformed using 
the lithium acetate method, as described (Gietz et al., 1995), using a bait:prey plasmid 
DNA ratio of 3:1. Transformations with pAS1G-ATXN3 var1.1 or pAS1-2.1N were grown on 
SC-WLH supplemented with 140 or 170 mM of AT (amino-1,2,3 triazole), respectively; 
the remaining were grown on plates with 20 mM AT. We used as positive controls the 
interactions between TSCII (hamartin) and TSCI (tuberin) (van Slegtenhorst et al., 
1998), or SNF4 and SNF1 (Fields and Song, 1989). Incubations were performed, at 30 ºC, 
for five to ten days. Colony-lift β-galactosidase filter assay was performed according the 
manufacturer’s instructions (Clontech). 
 
Expression of recombinant proteins  
The expression of GST-ZK20.3 was carried out overnight, at 30 ºC, in BL21-SI E.coli 
strain (Invitrogen) with 300 mM NaCl. Harvested cells were ressuspended in 1/10 volume 
of ressuspention buffer (TBS 1X, 10 μg/mL lisozyme, 10 mM EDTA pH8, PMSF 0.5 mM), 
supplemented with EDTA-free protease inhibitors cocktail (Roche). After lysis, the 
supernatant was cleared by centrifugation, and the GST-tagged proteins were purified 
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with glutathione-sepharose™ 4B beads (Amersham Biosciences); elution was carried out 
with 10 mM reduced glutathione in 50 mM Tris-Cl pH 8.  
 
GST pull-down assay 
The assays were carried out as described in the previous section 2A, of this chapter 
(Otera et al., 2000). Briefly, the purified GST or GST-tagged proteins were incubated for 
one hour, at 4 ºC, with 50 μl of glutathione-sepharose™ 4B beads, in 500 μl of in vitro 
binding buffer (IBB). The 6His-ATX-3 was added in IBB without BSA, and incubated for 1-
2 hours, at 4 ºC, on a rotator. Bound fractions were washed with IBB without glycerol 
and BSA, eluted by boiling in 50 μl of 2X SDS sample buffer, and then resolved by SDS-
PAGE (12%). Immunoblottings were performed using goat anti-GST (1:7500, GE 
Healthcare), mouse anti-6His (1:2000, GE Healthcare) or rabbit anti-303JSP (1:2000). 
Secondary HRP-coupled anti-goat antibody (Sc-2020, Santa Cruz Biotechnology) was 
diluted at 1:20000, anti-mouse (Santa Cruz Biotechnology Calbiochem), at 1:10000, and 
anti-rabbit (401393, Calbiochem) at 1:20000. The anti-goat and anti-rabbit dilutions 
were prepared in 3% SM/TBST (3% skimmed milk, Tris-buffered saline (TBS) 1X, 0.05% 
Tween 20), whereas anti-mouse antibody was diluted in 1% SM/TBST. Detection was 
carried out with ECL (GE Healthcare). 
 
C. elegans mutagenesis  
Wild-type (Bristol N2) and atx-3-/- knockout (VC346, atx-3(gk193)V.) strains from 
Consortium Gene Center (CGC) were maintained using standard procedures (Brenner, 
1974). The atx-3-/- strain was backcrossed two times. Synchronized L4 stage worm 
cultures were mutagenized with N-ethyl-N-nitrosourea (ENU), with incubations on ENU 
solutions at the appropriate concentration, or in modified M9 for control animals, 
according to the conditions defined by (De Stasio and Dorman, 2001). Afterwards, 
animals were plated, overnight, in seeded NGM plates to allow recovery. For the brood 
size analysis, P0 animals were singly plated and scored as described below.  
 
Brood size test 
The analysis of the progeny of mutagenized relative to control animals was performed 
as described previously (De Stasio and Dorman, 2001), with some modifications: briefly, 
the P0 animals were transferred singly to a new seeded NGM plate each day, up to six 
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days post-mutagenesis. Scoring of the progeny laid in each plate was done at L2/L3 
larval stages.  
 
Determination of C. elegans ZK20.3, xpc-1 and atx-3 expression by semi-
quantitative RT-PCR 
Total RNA was obtained from synchronized cultures. Mutagenized or control C. elegans 
were collected, and total RNA was extracted using Trizol (Invitrogen), as described 
http://cmgm.stanford.edu/~kimlab/germline. Three micrograms of total RNA were 
used in the first-strand synthesis with Superscript II (Invitrogen), accordingly to 
manufacturer’s intructions. Amplification of the selected genes was carried out 
simultaneously with co-amplification of the actin-1 transcript (NM_073418), used as 
internal standard gene. Definition of the appropriate cycle number for both genes was 
defined empirically. The ZK20.3 amplification was carried out with ZK20.3-F1 and 
ZK20.3-R1 primers, as follows: 5 min at 95 ºC, 20 cycles of 1 min at 95 ºC, 1 min at 56 
ºC, and 2 min at 72 ºC. Amplification of xpc-1 was performed with xpc-F1 and xpc-R1 
primers in the following conditions: 5 min at 95 ºC, 29 cycles of 1 min at 95 ºC, 1 min at 
53 ºC, and 2 min at 72 ºC. For atx-3 gene, we used atx-3-F1 and atx-3-R1 primers as 
follows: 5 min at 95 ºC, 23 cycles of 1 min at 95 ºC, 1 min at 60 ºC, and 1 min at 72 ºC. 
All the PCR reactions were set with a final extension of 5 min at 72 º C, and the 
amplification of the actin-1 was carried out with ceact-1F and ceact-1R primers. PCR 
products were loaded onto 2% agarose gel, and then stained with ethidium bromide. 
Densitometry analysis was determined as band volume, using the Image Quantification 
software program (Amersham). The relative expression for each gene target represents 
the ratio of the target gene and actin-1 expressions. Primer sequences in Table A1 of 
Appendix 2. 
 
Protein extraction from C. elegans 
Protein extracts of C. elegans were prepared from L4 larval-stage synchronized 
cultures. Worms were collected with M9, and washed two to three times to wash-off 
bacteria (for mutagenesis assays, the worms were first treated as described using ENU 
solution at 1 mM). Proteins were then extracted from the worm pellets, by adding an 
equal volume of worm lysis buffer [WLB, 100 mM Tris pH6.8, 2% SDS, 15% glycerol, 1X 
complete protease cocktail inhibitors (Roche)], boiled for 5-10 min in a water bath, with 
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occasional shaking, and then spinned at 3200 rpm, for 20 min, at 4 ºC. The supernatants 
were collected and protein concentration determined by Bradford method (Bradford, 
1976).  
 
Data Analysis 
Progeny (n=15), semi-quantitative RT-PCR (n=5 or 6) are expressed as arithmetic means 
± S.D. n, number of independent experiments performed. The statistical difference 
between the groups and condition tested was analysed by Student's t test for 
independent samples. In a 95% of confidence interval (CI), a p value of <0.05 was 
considered significant. 
 
 
 
Results  
 
The interaction of ATXN3 and HHR23 proteins is conserved in C. elegans 
Atx-3 interacts with C. elegans ZK20.3 protein, the homologue of HHR23 
proteins 
We initially cloned the ZK20.3 protein in order to perform yeast two-hybrid assays. 
Experimental attempts showed us that cloning ZK20.3 using the compiled sequences 
information at the Wormbase (www.wormbase.org/db/gene, WBGene00013924) and the 
theoretical ATG of the sequence posted was not possible. Comparative analysis of the 
primary sequence of several RAD23 homologues (Fig.7A) led us to re-design the cloning 
strategy in order to obtain M50 as the first amino acid in the ZK20.3 protein. 
The expressed C. elegans ZK20.3 protein contains, as predicted, an ubiquitin-like 
domain (UBL), two ubiquitin associated domains (UBA1 and UBA2) and one stress-
inducible phosphoprotein (STI1) binding domain (Fig.7B).  
 
We initially determined if the interaction observed between human ATXN3 and HHR23 
proteins, could be conserved in C. elegans. The yeast constructs expressing atx-3 and 
ZK20.3, the protein homologues of ATXN3 and HHR23 were prepared, evaluated for 
auto-activation of the Y2H system reporter genes and for toxicity.  
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Figure 7. Multiple alignments of HHR23A and HHR23B, worm homologue of RAD23 protein (ZK20.3) and yeast RAD23 
protein. A, columns showing a global similarity score over 60 %, calculated from all groups are framed in grey, and amino 
acid positions fully conserved in all species are black-shaded, whereas identical amino acid are written in bold. The dark 
grey and light grey lines highlight the domains of human and C. elegans proteins, respectively: UBL, UBA1 and UBA2; a 
XPC-binding domain is present in human HR23 proteins, whereas a STI1 motif is defined in the C. elegans counterpart. In 
the worm, ZK20.3 is predicted to possess an N-terminal region that shows no similarity with the other proteins (light 
grey-shade). Sequence alignments and colouring were performed with T-Coffee (Notredame et al., 2000) and ESPrit 
(Gouet et al., 1999) programs, respectively. The dots above the aligned sequences represent groups of ten amino acids 
each, considering the first sequence, HHR23A. B, a schematic drawing depicts UBL, UBA1, UBA2 and STI domains in the 
predicted and expressed ZK20.3 protein, discussed in this work (herein, the ZK20.3 protein consider is the expressed 
ZK20.3); amino acid scale in the bottom.  
 
 
The results showed that atx-3 interacts with ZK20.3, supporting the biological 
importance of this interaction. Interestingly, human ATXN3 was also able to interact 
with ZK20.3, independently of the ATXN3 variant expressed (data not shown), denoting 
conservation of this protein’s structure in the nematode. Moreover, we observed that 
ATXN3 was able to bind ZK20.3 through its N-terminal, since a positive interaction was 
observed with Gal4BD-2.1N protein, suggesting that the most N-terminal portion of 
ATXN3 is sufficient for the interaction.  
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C. elegans atx-3 was also able to bind the human HR23 proteins, HHR23A and HHR23B, 
in the Y2H system. Our results thus suggest that atx-3 structure is conserved in the 
nematode (Fig.8). However, no interaction of atx-3 and human XPC-D1 fragment and 
CETN2 was observed in the Y2H assays performed. 
 
 
 
 
 
 
 
 
 
 
 
Figure 8. The atx-3 of C. elegans interacts with HHR23 proteins and with their homologue in the worm, the ZK20.3 
protein. Gal4BD-ATXN3 construct corresponds to the human cDNA variant encoding normal ATXN3 var1.1, comprising 
three UIMs. A construct comprising a fragment of ATXN3, pAS1-2.1N, was also tested, which encodes for JD plus the 
functional UIM1. Gal4BD-atx-3 corresponds to the bait fusion of C. elegans homologue of ATXN3 that contains only two 
UIMs and two glutamines in the repetitive segment of this protein. Gal4AD-tagged constructs encoding human HHR23A, 
HHR23B, CETN2 and XPC-D1 were used as prey interactors. The Gal4AD-ZK20.3 corresponds to the prey fusion of C. 
elegans RAD23 protein. Yeast co-transformations were plated in high stringency plates; an interaction was considered 
positive (+) when growth on nutritional selection plates was observed, and colonies stained blue, when tested for 
β−galactosidase expression (blue dots); asterisks correspond to protein-protein interactions reported before (Wang et al., 
2000). 
 
 
The results obtained with the Y2H system were confirmed by in vitro GST pull-down 
assays (Fig.9). Binding of 6His-ATXN3 and 6His-atx-3 to different GST-tagged proteins 
was evaluated. The interactions between ATXN3 and GST-HHR23A or GST-HHR23B were 
tested and replicated (Wang et al., 2000) under the conditions used, serving as positive 
controls (Fig. 9). The in vitro results showed that atx-3 is able to interact with ZK20.3, 
indicating that this is a direct interaction. Interestingly, HHR23 fusion proteins, GST-
HHR23A and GSTHHR23B also pulled-down 6His-atx-3 in the assay, validating the 
interaction also observed in the Y2H. It is, therefore, highly probable that atx-3 
maintains the same 3D-structure as its human counterpart, enabling the conservation of 
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the interactions in two different methods. No direct interaction was observed between 
atx-3 and human CETN2, supporting the results obtained in the Y2H assays. 
Figure 9. Atx-3 interacts with ZK20.3, the C. elegans homologue of HHR23B protein. The GST pull-down assays 
showed direct interaction of atx-3 with the C. elegans homologue of RAD23 protein, ZK20.3, as well as HHR23A and 
HHR23B, its human homologues. Inputs lanes represent 10% of 6His-atx-3 used in the assays. The C. elegans homologue, 
atx-3, was pulled-down by both HHR23 proteins, HHR23A (A, B) and HHR23B (A), as well as by its C. elegans homologue, 
ZK20.3 (B). No interactions between atx-3 with GST-CETN2 was observed in vitro. GST alone showed no binding in the 
assays. Black stars indicate protein degradation fragments. 
 
 
ZK20.3 expression throughout C. elegans development 
Since we have cloned ZK20.3 for the first time, we assessed its expression during C. 
elegans development. ZK20.3 is expressed in all developmental stages of the worm 
(Fig.10). 
Semi-quantitative RT-PCR analysis showed a higher expression of ZK20.3 in eggs and in 
worm adults. Interestingly, the same pattern has been described for atx-3 (Rodrigues et 
al., 2007), further strengthening the hypothesis that these proteins may be biological 
partners. The highest levels of ZK20.3 are observed in the egg-laying adults (with 126h 
post-hatching), probably due to a cumulative effect of the ZK20.3 expression specific of 
eggs and adult before the egg-laying (76h post-hatching). The dauer, a stall stage 
induced under stressing conditions, also showed high expression levels of ZK20.3, 
significantly different from the pre-dauer (L2) and post-dauer (L3/L4) larvae stages.  
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Figure 10. ZK20.3 is expressed throughout C. elegans development. Semi-quantitative RT-PCR analysis showed 
expression of ZK20.3 in all developmental stages, more significantly in egg-laying adults (Ad-126h) and dauer larval-
stage. The gel image is representative of two RT-PCR and the graph shows normalized ratios of atx-3 expression, using 
act-1 as internal standard gene. (C-), negative control. 
 
 
KO atx-3-/- animals are more resistant to ENU 
The conservation of the atx-3 and ZK20.3 interaction in C. elegans, the ability of atx-3 
to interact with human HHR23 proteins, and vice-versa, led us to perform functional 
assays to further evaluate the biological relevance of the interaction, namely the role of 
atx-3 in the nematode when subjected to DNA damage-inducing conditions. 
In order to analyse the putative role of ATXN3 in DNA repair, namely in NER, we 
analysed the biological effect of a genotoxic chemical, the alkylating agent ENU (N-
ethyl-N-nitrosourea), upon the brood size of wild –type (N2) and atx-3-/- nematodes. ENU 
promotes the formation of bulky adducts in the DNA, inducing the NER response in cells 
(Costa et al., 2003). The conditions of optimized ENU mutagenesis in wild-type C. 
elegans have been defined (De Stasio and Dorman, 2001). In order to determine the 
concentration of ENU to be used in the atx-3-/- strain with minimum toxicity, but 
maintaining a significant rate of mutagenicity, we assayed three ENU concentrations 
(0.3, 0.6 and 1 mM), and scored the progeny of up to 15 animals for each genotype (N2 
and atx-3-/-) (Fig.11A). 
The results showed a progressive reduction of the progeny of both worm genotypes, in 
the presence of ENU, when comparing with the untreated controls. Nonetheless, no 
significant statistical difference was observed in the progeny of N2 or atx-3-/- when  
 
  
 
Figure 11. Effect of alkylating mutagen ENU upon wild-type (N2) and atx-3-/- animals. A, effect of ENU exposure upon the progeny of wild-type and atx-3-/- animals; three different 
concentrations of ENU were tested (0.3, 0.6 and 1 mM), in 15 independent animals (P0) of each genotype; standard deviation bars are derived from statistical analysis of duplicate experiments. 
Semi-quantitative RT-PCR analysis of atx-3 (B), ZK20.3 (C) and xpc-1 (D) expression in wild-type and atx-3-/- animals in the presence or absence of the 1 mM of mutagen (+ENU); standard 
deviation bars were obtained from statistical analysis of n independent experiments: xpc-1 (n=6), ZK20.3 (n=6) and atx-3 (n=5). *, p<0.05 and **, p<0.01. 
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mutated with 0.3 mM or 0.6 mM ENU, relatively to the control animals. A concentration 
of 1 mM ENU exerted the strongest effect, provoking a notorious reduction of brood 
sizes for both genotypes (Fig.11A). Although both N2 and atx-3-/- genotypes were 
drastically affected, we observed that mutagenized atx-3-/- animals showed higher 
brood size than mutagenized wild-type (N2) worms. Statistical analysis of the data 
conferred significance to the experimental difference observed in brood size (p<0.05). 
Surprisingly, the absence of atx-3 seemed to confer a higher resistance of worms to the 
detrimental effects of ENU, producing more viable progeny. 
 
To explore the role of atx-3, ZK20.3 and xpc-1 in DNA repair, we analysed the 
expression of these transcripts in normal and in DNA damage-promoting conditions by 
semi-quantitative RT-PCR. Synchronised L4 larvae-stage worm cultures were prepared 
and total RNA was extracted using the Trizol method. The cDNA synthesis was carried 
out using Superscript II (Invitrogen). 
 
Expression of atx-3 is induced in worms exposed to ENU 
The analysis of atx-3 in mutagenised wild-type animals (1 mM ENU) showed a significant 
induction (16.6% more) of atx-3 expression (p<0.01), when compared to non-treated, 
control animals. This may indicate a potential role of atx-3 in the biological responses 
to mutagenesis engaged by C. elegans, such as DNA repair (Fig.11B).  
 
Expression of xpc-1 and ZK20.3 is reduced in the absence of atx-3 
The analysis of xpc-1 expression in N2 and atx-3-/- animals showed an overall significant 
interaction between ENU and the genotype in xpc-1 expression (ANOVA, p<0.05). The 
results showed a significant difference in xpc-1 expression, between wild-type and 
untreated atx-3-/- animals (p=0.02); in basal conditions, atx-3-/- worms seem to express 
less xpc-1 than wild-type (15.0% less); xpc-1 expression in atx-3-/- worms, was even 
more significantly reduced (36.6% less) comparing to the wild-type, when the animals 
were subjected to ENU treatment (p=0.004). Hence, there is a significant difference 
between the genotypes, in the absence or presence of the mutagenic agent, ENU 
(Fig.11C).  
ZK20.3 expression analysis in N2 and atx-3-/- also showed us a significant effect of 
genotype upon this transcript (p<0.05). In the presence or absence of ENU (1 mM), the 
absence of atx-3 affects significantly ZK20.3 expression (p<0.05), when compared to the 
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wild-type. In non-mutagenised animals, the atx-3-/- showed a 23.4% decreased 
expression of ZK20.3; whereas, in the presence of ENU, even less ZK20.3 expression was 
detectable in atx-3-/- animals, a 31.2% reduction was observed when comparing to ENU-
treated wild-type animals (Fig.11D).  
No significant differences in xpc-1 and ZK20.3 expression were observed for either 
genotype (N2 or atx-3-/-) when comparing ENU-treated (+ENU,1mM) to untreated control 
animals (both, p>0.05), indicating that, counterintuitively, the presence of ENU seems 
to have no significant effect upon xpc-1 and ZK20.3 mRNA expression in animals, 
although they were subjected to DNA damaging condition (Fig.11C, D). Though a 21.6% 
expression increase of xpc-1 was observed, when wild-type animals were treated with 
ENU, no statistical significance was found in this variation (p=0.06) (Fig.11D). 
 
 
ENU produces no overall alteration of the ubiquitylation pattern in C. elegans  
Total protein extracts of wild-type and atx-3-/- animals were obtained and further 
analysed to determine if the ubiquitylation and neddylation patterns of these were 
altered when the worms were subjected to DNA damage-inducing conditions (1 mM 
ENU). No apparent differences were observed in the ubiquitylation pattern of KO 
animals (atx-3-/-) when comparing to wild-type; likewise, no differences were identified 
in the ubiquitylation pattern of the protein expression profile of mutagenised animals 
(Fig.12A). The absence of atx-3 did not seem to modify the overall level of protein 
ubiquitylation.  
 
Differentially neddylated proteins in wild-type worms  
We also analysed the global neddylation pattern in these animals, upon the conditions 
described. Although no overall difference was observed in protein neddylation when 
comparing untreated and ENU-treated animals, the analysis revealed the presence of 
four neddylated proteins, which are less abundant in the neddylation profiles of       
atx-3-/- protein extracts (Fig.12B, arrowheads). No obvious difference was observed in 
these neddylation targets when worms were subjected to ENU alkylating mutagenic 
agent.  
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Figure 12. Analysis of neddylation pattern revealed four neddylation targets less abundant in atx-3-/- animals. 
Synchronised worm cultures of wild-type (N2) and atx-3-/- were grown in the absence or presence of 1 mM ENU. The 
protein extracts were subjected to SDS-PAGE and visualized with Western blot analysis using (A) anti-ubiquitin antibody 
(BIOMOL, PW8810) to detect ubiquitylated proteins or (B) anti-Nedd8 antibody (BIOMOL, PW9340) for proteins modified 
by neddylation; anti-β-actin (A, B) was used as loading control. 
 
 
 
Discussion 
 
Our group has recently reported the first molecular characterization of atx-3, the C. 
elegans homologue protein of ATXN3 (Rodrigues et al., 2007). The relatively high 
sequence conservation of atx-3 and the fact that it showed deubiquitylating activity in 
vitro as its human counterpart, does led us to hypothesise that this protein should 
maintain similar protein-protein interactions, and have the same or similar cellular 
function(s).  
Our results showed a positive direct interaction between atx-3 and ZK20.3, the C. 
elegans homologues of ATXN3 and HHR23. The conservation of this interaction 
throughout evolution denotes its high importance and, putatively, the biochemical 
pathway in which the two proteins are participating as interacting partners. 
Importantly, the conserved interaction with the C. elegans proteins allows us to 
conclude that atx-3 has conserved the relevant biological structure, crucial for the 
interactions. This hypothesis was reinforced, when we observed that atx-3 of C. elegans 
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binds HHR23A and HHR23B and, conversely, that ATXN3 binds ZK20.3, namely through 
the N-terminal region of the human protein. 
 
Although no interaction was observed between human ATXN3 and CETN2, these negative 
results obtained from the Y2H and in vitro assays, do not allow us to exclude 
inequivocally the possibility of this interaction is occurring in the worm. The interaction 
with centrin, the C. elegans homologue of human CETN2, needs to be tested, as well as 
the hypothesis of the conservation of the xpc-1/centrin/ZK20.3/atx-3 complex in C. 
elegans.  
 
The study of the worm protein interactions, led us to clone, for the first time, the 
coding sequence of the ZK20.3 protein, the C. elegans homologue of HHR23 proteins.  
 
The ZK20.3 expression analysis throughout the C. elegans development showed that this 
message is highly represented in all stages of the animal. Interestingly, ZK20.3 is 
expressed, abundantly, in the same stages (adults) as atx-3 (Rodrigues et al., 2007), 
which reinforces the possibility of an interaction between the encoded proteins, atx-3 
and ZK20.3, in the nematode. 
Of notice is the higher ZK20.3 expression observed in the dauer stage. There is no direct 
evidence of the participation of ZK20.3 in DNA repair. However, this possibility was 
strengthened recently, as the direct interaction between ZK20.3 and the C. elegans 
homologue of XPC, xpc-1, was reported as possible in a genome-wide predictive analysis 
of the C. elegans interactions (Zhong and Sternberg, 2006). 
During the C. elegans development and whenever the condition are adverse to life (lack 
of food, low humidity, temperature alterations, animal overcrowding, etc), the animal 
may endure such harsh environmental conditions by switching to a facultative reversible 
stall stage called dauer (Fig.13). In this “lethargus” stage, the feeding and the 
locomotion are arrested indefinitely, and morphological modifications in animals are 
visible, as shedding of cuticle (Cassada and Russell, 1975). Increased oxygen uptake 
during this stall stage has been ascribed to an increase in metabolic activity during this 
period, perhaps associated with the developmental changes observed during the 
transition to the dauer stage. Due to its higher metabolic rate, dauer-larvae may 
produce more reactive oxygen species, hence be more susceptible to oxidative stress 
and, ultimately, to endogenous DNA damage. Interestingly, it is in this stall stage that 
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we observed the highest ZK20.3 expression. The maintenance of cell and genome 
integrity in dauer stage is crucial for animal’s survival upon its re-entering in the normal 
life cycle. Therefore, the efficient DNA repair in this metabolic stage is determinant, 
and the high expression of ZK20.3, may indicate an active role of this protein in genome 
maintenance.  
 
 
Figure 13. Life cycle of C. elegans. The life cycle of C. elegans comprises the embryonic stage, four larval stages (L1-
L4) and adulthood (names of the stages are shaded in light grey). At 22ºC, it takes approximately 45-50 hrs from the 
hatching until the reproductive adult stage. The duration of each developmental stage (defined in hours) varies. Upon 
environmental stress, the worm may enter a reversible, life-sustained stage (dauer stage). As dauer, the life of the 
animal may be extended up to months, until the conditions are normalised.  
(Adapted from www.wormatlas.org/handbook/anatomyintro/anatomyintro.htm). 
 
 
With this work we have shown that (1) the atx-3 and ZK20.3 interaction is conserved in 
C. elegans; (2) atx-3 is able to cross-interact with human HHR23 proteins, suggesting 
structural conservation of the interaction determinants and (3) we observed that     
atx3-/- animals express less ZK20.3 and xpc-1 (4) are able to produce significantly more 
progeny, than wild-type when exposed to 1 mM ENU. (5) Atx-3 expression is induced 
upon DNA damaging conditions. At this point, we do not have experimental evidence 
supporting the existence of an interaction between worm atx-3 and xpc-1. 
Nevertheless, the prediction of the interaction between ZK20.3 and xpc-1 (Zhong and 
Sternberg, 2006), supports the xpc-1/centrin/ZK20.3/atx-3 complex possibility in the 
nematode.  
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We analysed the role of some of these proteins when the nematodes were subject to 
DNA damage-inducing conditions. 
The expression analysis showed that when subjected to mutagenic agent ENU, the C. 
elegans increases atx-3 expression. Previously, Jelinsky et al., showed that several 
yeast genes involved in DNA repair and in ubiquitin/proteasome system were induced in 
response to DNA damage caused by MMS (methyl methanesulfonate) (Jelinsky et al., 
2000). Indeed, we observed that atx-3 is an ENU-responsive gene, thus suggesting a 
direct link between its expression and the response to DNA damage. Whether atx-3 
increased expression is due to (1) a direct participation in the DNA repair response 
driven under such conditions, (2) as a modulator of the availability of DNA repair 
effectors such as xpc-1 and ZK20.3 or (3) due to its participation in UPS as a 
deubiquitylating enzyme needs further clarification.  
We and others have pointed out that ATXN3 interacts with HHR23 proteins (Wang et al., 
2000) and XPC. Indeed, this instigated us to characterise the xpc-1 and ZK20.3 
expression, under ENU-induced genotoxic conditions, in wild type (N2) and atx-3-/- (KO) 
animals. To our surprise, we did not find a significant induction of the xpc-1 and ZK20.3 
expression rates when wild-type animals were subjected to ENU-genotoxic stress 
(Fig.11C, D). Although the results seem paradoxical, we believe that effective 
mutagenesis assays, hence DNA damaging conditions, were performed (we followed the 
C. elegans ENU mutagenesis protocol established by (De Stasio and Dorman, 2001)). 
Indeed, in the progeny assay, using 1 mM ENU (the concentration later on established 
for all expression analysis) we observed a significant reduction in the number of viable 
descendents, both in wild-type (N2) and atx-3-/- strains. Although indirectly, these 
results support the effectiveness of the protocol used. Despite the statistical non-
significance of the results obtained herein, we still observed an increase in the 
expression of xpc-1 and ZK20.3 when the animals were mutagenised, comparing to the 
controls, which we cannot assume, peremptorily, has no biological relevance.  
One possible reason for the apparent absence of a strong increase in the xpc-1 and 
ZK2.3 transcripts is perhaps we have “looked” for the expression of these transcripts, 
too late in time. The mutagenesis assay takes an incubation period of four hours, with 
the ENU solution. This is a crucial step as the thick, resistant C. elegans’ cuticle 
demands longer periods of exposure than other systems, for the treatments to be 
effective. Thus, the rather quick response that is known to occur in eukaryotic cell 
cultures may have been lost, and may be we have just analysed the rebound phase of a 
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potentially stronger response to the ENU genotoxic stress. Assuming this, atx-3 may 
represent a later response, then still detectable. 
 
We also characterised the xpc-1 and ZK20.3 expressions in wild-type (N2) and atx-3-/- 
animals, in normal or ENU-treated conditions.  
The analysis showed a significant reduction of the transcripts’ expression in atx-3-/- 
animals under normal growth conditions, when comparing to wild-type. Such difference 
was more apparent when the animals were subjected to DNA damage conditions. The 
XPC protein is stabilised by HHR23B, in mammalian cells (Ng et al., 2003). Based on the 
evidence that the majority of XPC is complexed with HHR23B in eukaryotic cells, once a 
reduction of ZK20.3 was observed, we were expecting a similar variation in the xpc-1 
expression levels, in C. elegans. 
 
The C. elegans xpc-1 and ZK20.3 proteins may have similar biochemical functions to 
their human counterparts because (1) we show here that atx-3 is able to interact also 
with ZK20.3 and (2) the interaction between xpc-1 and ZK20.3 proteins is conserved in 
the worm (Zhong and Sternberg, 2006). 
The loss of atx-3 caused a reduction in xpc-1 and ZK20.3 expression; this is consistent 
with the hypothesis raised before that ATXN3 could be acting as a deubiquitylating 
enzyme (DUB), hence a negative regulator of the GGR-NER sub-pathway. Acting as a 
DUB, ATXN3 may degrade the XPC-conjugated polyUb chain, diminishing its stability. 
The results obtained in C. elegans reinforce this possibility: in the absence of the DUB 
atx-3 and its potential isopeptidase activity, the xpc-1 is more stable, hence less 
expression of xpc-1 and ZK20.3 mRNA is necessary.  
It would be interesting to evaluate the effect of the overexpression of the endogenous 
atx-3 or its human counterpart encoding normal ATXN3, in the expression of these 
transcripts. Will the differences observed invert? Or will they accentuate? And the 
expression of a catalytic inactive atx-3(C20) or ATXN3(C14) protein will sustain these 
observations? These questions must be address in the future. 
 
Selective degradation of abnormal proteins is essential for cellular functions. The 
ubiquitin conjugating system provides a mechanism that enables the distinction of these 
abnormal proteins from correctly folded and modified proteins. The functional 
equilibrium between the UPP and molecular chaperones ensures the efficiency of the 
Chapter 1: Section 1B 
 88 
protein quality control systems, avoiding the highly deleterious accumulation of 
damaged proteins. 
ATXN3 is known to possess in vitro hydrolase activity either for ubiquitin (Burnett et al., 
2003; Berke et al., 2005) or NEDD8 (Chapter 2); the C. elegans counterpart, atx-3, also 
exhibits in vitro isopeptidase activity against ubiquitin and interacts with NEDD8 
(Chapter 2). We analysed the ubiquitylation and neddylation patterns in basal and DNA 
damaging conditions, in atx-3-/- and wild-type. In the conditions tested, no overall 
difference was observed in the ubiquitylation pattern. Though apparently, the loss of 
atx-3 and/or the presence of ENU do not disturb the overall ability of C. elegans to 
ubiquitylate/deubiquitylate proteins, we may not state definitely, that a variation in 
the protein degradation signalling is indeed absent, nor can we exclude an alteration in 
the ubiquitylation pattern of specific proteins. Interestingly, the absence of atx-3 
revealed some differences in the neddylation pattern observed, namely four proteins 
were reduced or absent in neddylation pattern of atx-3-/-, when comparing to wild-type. 
We showed that the human ATXN3 may interact with NEDD8, and exerts deneddylase 
activity, in vitro. Further testing is required to assess the deneddylase activity of C. 
elegans homologue. The differences observed in the endogenous neddylated proteins 
must be analysed; but this in vivo evidence seems to strengthen the participation of 
ATXN3 in the modulation of post-translational modifications in the cellular environment. 
 
Together with atx-3, C. elegans has another Josephin-related protein (WP:CE32996). 
This evidence makes us wonder if the modest effects observed in the experiments we 
undertook may not be a result of redundancy between the two proteins. Thus, we 
believe that all these questions must also be addressed in the atx-3-/-/josephin-/- 
double-knockout animals. 
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Abstract 
 
Machado-Joseph disease (MJD/SCA3) is an autosomal dominant neurodegenerative 
disease caused by the expansion of a CAG tract in the coding portion of the ATXN3 
gene. The presence of ubiquitin-positive aggregates of the defective protein in affected 
neurons is characteristic of this and most of the polyglutamine disorders. Recently, the 
accumulation of the neural precursor cell expressed developmentally down-regulated 8 
(NEDD8), a ubiquitin-like protein, in the inclusions of MJD brains was reported. Here, we 
report a new molecular interaction between wild-type ataxin-3 and NEDD8, using in 
vitro and in situ approaches. Furthermore, we show that this interaction is not 
dependent on the ubiquitin-interacting motifs in ataxin-3, since the presence of the 
Josephin domain is sufficient for the interaction to occur. The conservation of the 
interaction between the Caenorhabditis elegans ataxin-3 homologue (atx-3) and NEDD8 
suggests its biological and functional relevance. Molecular docking studies of the NEDD8 
molecule to the Josephin domain of ataxin-3 suggest that NEDD8 interacts with ataxin-3 
in a substrate-like mode. In agreement, ataxin-3 displays deneddylase activity against a 
fluorogenic NEDD8 substrate. 
 
 
 
Introduction 
 
Machado-Joseph disease (MJD/SCA3) is the most common dominantly inherited 
cerebellar ataxia worldwide (Schols et al., 2004). The disease is caused by the 
expansion of a CAG repeat in the coding region of the gene ATXN3. This gene encodes 
ataxin-3 (ATXN3), a 42 kDa ubiquitously expressed protein, which has the polyglutamine 
tract located in the C-terminal region (Kawaguchi et al., 1994; Schmidt et al., 1998). 
The repeat segment that normally consists of 12-44 CAG is expanded from 61 up to 87 in 
patients (Maciel et al., 2001). A striking feature of the polyglutamine diseases is the 
presence of neuronal inclusions in the affected brain regions; in MJD, the inclusions are 
both nuclear and cytoplasmic and typically ubiquitylated (Paulson et al., 1997). These 
intracellular inclusions contain proteasome subunits and chaperones, which suggests an 
attempt of the cell to either reduce the amount of non-native protein and restore 
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protein homeostasis or eliminate the inclusions (Schmidt et al., 2002). The physiological 
role of ATXN3 is not yet established.  
 
Recently, it was noticed that the Josephin domain of ATXN3 (JD) contains conserved 
amino acids reminiscent of the catalytic domain of a member of the deubiquitylating 
cysteine protease UCH (ubiquitin C-terminal hydrolases) and USP (ubiquitin-specific 
protease) families (Scheel et al., 2003) and later, in vitro assays showed that ATXN3 
displays Ub hydrolase activity (Burnett et al., 2003; Berke et al., 2005). Strikingly, it 
was found that ATXN3 suppresses polyglutamine neurodegeneration in Drosophila, and 
this suppressing activity is dependent on its interaction with ubiquitin and on its 
protease activity (Warrick et al., 2005). Recent data showed the presence of neural 
precursor cell expressed developmentally down-regulated gene 8 (NEDD8), an ubiquitin-
like protein (UBL), in Ub-reactive neuronal and glial inclusions of several 
neurodegenerative diseases, namely MJD (Mori et al., 2005). An active role was 
suggested for NEDD8 in the formation of the ubiquitylated inclusions through the 
ubiquitin-proteasome system (UPS). 
 
NEDD8 is an 81 amino acid polypeptide, weighting 8 kDa, and shows the highest identity 
with Ub (58%) of all UBL proteins (Kamitani et al., 1997). Like most UBL, de novo NEDD8 
is synthesised as a pre-protein; in the processing of NEDD8, a short C-terminal peptide is 
cleaved, generating the mature UBL with a reactive G76 at its most C-terminal, 
essential for the conjugation reactions. The UCH-L3 enzyme was identified as capable of 
both ubiquitin and NEDD8 processing (Wada et al., 1998), an evolutionarily conserved 
property (Frickel et al., 2007). In a process known as neddylation, the mature NEDD8 is 
covalently linked to substrates, by the establishment of an isopeptide bond between its 
glycine at the C-terminal and the ε-amide group of the substrate’s lysine (Kamitani et 
al., 1997). In a process similar to ubiquitylation, a heterodimeric E1-like activating, 
complex comprising the amyloid precursor protein-binding protein (APP-BP1) and UBA3 
protein, initiates the neddylation, whereas UBC12 (an E2-like conjugating enzyme) 
promotes NEDD8 conjugation to substrates (Osaka et al., 1998). Transfer of NEDD8 to 
substrates is mediated by an E3-like ligase, but NEDD8-specific E3 enzymes are now 
starting to be unveiled. 
Cullins were the first NEDD8 substrates to be discovered. Cullins are evolutionarily 
conserved from yeast to mammals (Petroski and Deshaies, 2005); several cullins (CUL1, 
CUL2, CUL3, CUL4A, CUL4B, CUL5 and CUL7) and cullin-like proteins (PARC and APC2) 
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are expressed in human cells (Petroski and Deshaies, 2005). Cullins are components of 
SCF-like complexes; these are E3-based ubiquitin ligases that regulate cullin-dependent 
ubiquitylation. These cullin-based E3 ligases are multimeric complexes comprising 
several subunits: a cullin or cullin-like protein, a E3 ligase protein, an adaptor protein 
and a substrate receptor. The specificity of the cullin-based complexes is conferred by 
the adaptors and substrate receptors bound to the cullin. The multitude of 
combinations between adaptors, substrate receptors bound to all possible cullin denotes 
the complexity of this system (Petroski and Deshaies, 2005; Hermand, 2006; Kerscher et 
al., 2006). The E3-ligases proteins can be of two different mechanistically types: RING 
(really interesting new gene) finger proteins and HECT (homologous to E6-AP carboxyl 
terminus) proteins. In multimeric RING finger complexes, the RING finger protein binds 
the E2-conjugating protein, while the substrate receptors together with the adaptor 
bind the substrate to the complex. The HECT-domain E3s are unique in that Ub is 
transferred to a conserved cysteine residue of the E3 in a thiolester linkage, and then 
the E3 transfers the Ub to the substrate, also, directly bound to the E3 ligase. This 
function as a covalent intermediary in the transfer of Ub is not found in other classes of 
E3 proteins (reviewed in (Chiba and Tanaka, 2004)). 
 
Several deubiquitylating enzymes can catalyse deneddylation, the removal of 
conjugated NEDD8 from substrates: USP21 (Gong et al., 2000), the COP9 signalosome 
(CNS), through the metalloprotease JAMM motif of CSN5 subunit (Cope et al., 2002) and 
DEN1 (aka NEDP1 or SENP8) (Parry and Estelle, 2004). CAND1 (aka, p120) is a cullin 
interacting protein, with specific affinity for deneddylated cullins (Liu et al., 2002); 
CAND1 seems to regulate negatively the cell’s cullin-based ubiquitylation by rendering 
cullins to an inactive state. The UBC12-mediated covalent attachment of NEDD8 to the 
C-terminal of cullins promotes E3 ligase activity of the complex by mediating the total 
displacement of CAND1 and enabling binding of the adaptor proteins (e.g. Skp1 binding 
to CUL1 in SCF complex) and substrates recognition subunits (e.g. F-box loaded with 
specific substrate in SCF complex), further activating cullins, recruiting ubiquitin-loaded 
E2s and consequently the proper substrate ubiquitylation. It is the cycling process of 
neddylation/deneddylation of cullins that is thought to be essential in the regulation of 
ubiquitylation mediated by cullin-E3 ligases (Pintard et al., 2003; Petroski and Deshaies, 
2005). Moreover, unless neddylated cullins are recycled by the CSN-promoted 
deneddylation, they undergo degradation, suggesting that this “on-off” state of 
neddylated/deneddylated cullins enables the maintenance of intracellular free NEDD8 
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and cullin pool. As importantly, this tight equilibrium prevents cell’s excessive 
ubiquitylation (Wu et al., 2005).  
NEDD8 is highly conserved and it has been demonstrated to be essential for mice 
embryonic development (Tateishi et al., 2001) and C. elegans larvae-viability (Kurz et 
al., 2002). Interestingly, neddylation of cul-3 has been shown essential for the proper 
axonal arborisation and dendritization in Drosophila (Perez et al., 2005). This might 
suggest a role of neddylation in neuroplasticity, with potential relevance in 
neurodegenerative diseases, namely in the mechanisms that the brain may adopt to 
circumvent its inherent cell death. 
Another target for neddylation is the cell cycle regulator, p53. Xirodmas et al., 
demonstrate that neddylation of p53 is dependent of mdm2 activity (Hdm2 in humans), 
an E3 RING-finger ubiquitin ligase with the capability of self-neddylation (Xirodimas et 
al., 2004). Neddylation of p53 was shown to be determinant in the inhibition of 
transcriptional activity of p53 (Xirodimas et al., 2004). Moreover, both mdm2-mediated 
neddylation and ubiquitylation of p53 modifications was dependent of the same cysteine 
residue of the E3 RING-type ligase (mdm2), unveiling that mdm2 could function also as 
an E3-NEDD8 ligase. This dual activity of E3-ubiquitin ligases had been reported before 
by Morimoto et al., whom suggested that ROC1 RING protein (aka RBX1, HRT1) could 
behave as an E3-NEDD8 ligase, by promoting CUL1 neddylation (Morimoto et al., 2003). 
Recently, another neddylation target has been identified. Oved et al.. reported that 
neddylation of epidermal growth factor receptor (EGFR) mediated its lysosomal 
degradation (Oved et al., 2006); ubiquitin and NEDD8 may share the c-Cbl RING-
containing E3 ligase involved and UIM-containing proteins (e.g. Epsin15), at least in the 
c-Cbl- and ligand-dependent degradation process (Oved et al., 2006). The synphilin-1, a 
major component of inclusion bodies found in the brains of patients with 
neurodegenerative α-synucleinopathies, including Parkinson’s disease, was also reported 
to be a target of NEDD8 modification (Tanji et al., 2006). All together, these results 
suggest high functional diversity for RING finger E3 ligases that may either behave as E3-
ubiquitin and E3-NEDD8 ligases and a tight regulation of both neddylation/ubiquitylation 
in the protein degradation pathways. Surely, neddylation and its ensuing regulation play 
no minor role in the cellular protein homeostasis. 
 
The fact that ATXN3 interacts with the UBL domain of HHR23 proteins (Wang et al., 
2000) and the recent finding that NEDD8 is present in ubiquitylated inclusions in the 
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brain of MJD patients, led us to investigate whether ATXN3 could interact with NEDD8. 
In this study, we demonstrate in vitro and in situ that ATXN3 is able to establish a direct 
interaction with NEDD8, through its Josephin domain (JD). Interestingly, the 
Caenorhabditis elegans homologue of ATXN3, atx-3, also interacts with NEDD8, 
indicating that this protein interaction is evolutionarily conserved and, thus, of 
functional relevance. Furthermore, ATXN3 is able to cleave a fluorogenic substrate, 
NEDD8-AMC, which indicates that ATXN3 also has deneddylase activity. 
 
 
 
Material and Methods 
 
Antibodies 
Primary antibody against ataxin-3 variant MJD1-1 (Swiss Prot no. P54252-2 VSP_002784) 
was raised in rabbits, by immunization with normal full-length recombinant 6His-ATXN3-
var1.1, anti-MJD1.1, (David Biotechnologies). Competition assays were performed to 
verify the antibody specificity (Fig.21).  
 
Yeast two-hybrid assays 
The yeast strain Y190 (96400) was purchased from ATCC. The original vectors pAS1-2 
and pACT2 (kindly provided by Dr S. Elledge, Baylor College of Medicine) were 
converted into yeast two-hybrid Gateway® vectors pAS1G and pACT2G, respectively, 
following the manufacturer’s instructions (Invitrogen). The pAS1G-ATXN3 var1.1 coding 
for normal ATXN3, pAS1G-JD, pACT2G-JD, pAS1G-NEDD8, pACT2G-NEDD8 plasmids were 
generated using the Gateway cloning system®. The pAS1-ATXN3 var2.1 (17Q) (Swiss-Prot 
no. P54252 VAR_013690) and pAS1-ATXN3-2.1N were prepared using classical cloning 
techniques (Sambrook and Russel, 2001). The yeast transformations were performed 
using the lithium acetate method (Gietz et al., 1995). Transformants of pAS1G-JD, 
pAS1G-ATXN3 var1.1 or pAS1-ATXN3-2.1N were grown on SC-WLH supplemented with 
130, 140 or 170 mM of amino-1,2,3 triazole (AT), respectively; the remaining were 
grown on plates with 20 mM AT. The interaction between SNF1 and SNF4 encoded by 
pSE1112 and pSE1111, respectively, was used as positive control (kindly provided by Dr 
S. Elledge, Baylor College of Medicine). Incubations were performed at 30 ºC for five 
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days. Colony-lift β-galactosidase filter assays were performed according to the 
manufacturer’s instructions (Clontech).  
 
Expression plasmids and recombinant proteins  
GST-tagged proteins- For generation of GST-NEDD8 protein, NEDD8 cDNA was amplified 
from a human brain cDNA library using attB1-NEDD8  
and attB2-NEDD8 primers. GST-Ub expression construct was obtained from the IMAGE di-
ubiquitin (UBB) cDNA clone (4126622) by amplification of the monomeric Ub cDNA using 
attB1-UB and attB2-UB primers. GST-221cATXN3 expression construct was obtained 
using pAS1G-ATXN3 var1.1 plasmid as template, attB1-221cATXN3 forward primer, and 
attB2-MJD1.1 reverse primer The cDNA for human HHR23A was reverse transcribed from 
total RNA of HeLa cells extracted with Trizol (Invitrogen) using attB1-HHR23A and  
attB2-HHR23A primers; gene-specific sequences are underlined. RT-PCR reactions were 
performed with Superscript RT kit (Invitrogen) according to the manufacturer’s 
instructions. The aforementioned PCR products were first cloned into pDONR201 or 
pDONR207 vectors and then transferred to pDEST15 using the Gateway cloning system 
(Invitrogen) (Hartley et al., 2000) according to the supplier’s instructions. 
6His-tagged proteins- The bacterial constructs expressing 6His-tagged ATXN3-var1.1, 
6His-atx-3 and 6His-tagged Josephin domain (JD) were obtained and expressed as 
described (Gales et al., 2005). The 6His-D1 construct (Fig. 2(a)) was obtained by 
introducing a stop codon at position 787 in ATXN3 cDNA using the QuikChange site-
directed mutagenesis kit (Stratagene) and protein expression was carried out as 
described (Gales et al., 2005). All clones were confirmed by automated sequencing. The 
eukaryotic 6His-Ub plasmid and the 6His-NEDD8 constructs were gifts from Dr D. 
Bohmann, Univ. of Rochester and Dr R. Hay, Univ. of St Andrews (Xirodimas et al., 
2004), respectively.  
GFP-tagged constructs- The eukaryotic pEGFP-ATXN3 (28Q) encoding normal ATXN3 in 
fusion with GFP (N-terminal) was a gift of Dr Henry Paulson, Univ. of Iowa. To obtain 
the mammalian pEGFP-JD plasmid encoding the fusion protein GFP-JD, a stop codon was 
introduced at position 548 in ATXN3 cDNA of the pEGFP-ATXN3 (28Q) using the 
QuikChange site-directed mutagenesis kit according to the manufacturer’s instructions 
(Stratagene). All clones were confirmed by automated sequencing. 
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Purification of recombinant proteins 
The expression of GST, GST-NEDD8 and GST-Ub was induced in Escherichia coli strain 
BL21(DE3) (Invitrogen) , whereas GST-221cATXN3 was expressed in BL21(DE3)pLysS 
(Invitrogen), all with 1 mM IPTG. GST-HHR23A was expressed in BL21(DE3)-SI cells 
(Invitrogen) using 300 mM NaCl. The bacterial protein expressions were carried out for 
three hours at 30 ºC. All GST-tagged proteins were purified with glutathione-sepharose™ 
4B beads (GE Healthcare) according to the manufacturer’s instructions and eluted with 
10 mM reduced glutathione in 50 mM Tris-Cl pH 8.  
 
GST pull-down assay 
The purified GST or GST-tagged proteins (2 μg) were incubated rotating for one hour at 
4 ºC with 50 μl of glutathione-sepharose™ 4B beads in 500 μl of in vitro binding buffer 
(IBB) (50 mM Tris-Cl pH 7.5, 150 mM NaCl, 10% glycerol, 1% Triton X-100, 1 mM EDTA, 1 
mM DTT, 1 mM PMSF (Otera et al., 2000)). The 6His-J1, 6His-D1 or 6His-ATXN3-var1.1 
were added and incubated for 1-2 hours at 4 ºC on a rotator. Incubations of 6His-ATXN3-
var1.1, 6His-NEDD8 (UW9225, BioMol) or 6His-atx-3 were performed with 1% or 3% of 
BSA, respectively. Bound fractions were washed with IBB without glycerol and BSA, 
eluted by boiling in 50 μl of 2X SDS sample buffer and then were analysed by SDS-PAGE. 
Immunoblottings were performed using goat anti-GST (1:7500, GE Healthcare), mouse 
anti-6His (1:2000, Qiagen), rabbit anti-MJD1.1 (1:25000) or rabbit anti-NEDD8 (1:200) 
antibodies, all diluted in 1% SM/TBS-T (1% skimmed milk in Tris-buffered saline 1X 
(TBS), 0.05% Tween 20), or with rabbit anti-303JSP (1:2000) antibody (Rodrigues et al., 
2007), diluted in 3% SM/TBS-T. Secondary HRP-coupled antibody incubations were as 
follows: anti-goat 1:30000, anti-mouse (Santa Cruz Biotechnology) both at 1:10000 1% 
SM/TBS-T and anti-rabbit (Santa Cruz Biotechnology) 1:25000 1% SM/TBS-T for ATXN3-
var1.1 or 1:20000 3% SM/TBS-T for atx-3. Detection was carried out with ECL (GE 
Healthcare). 
 
Cell culture and transfection 
HeLa cells were grown (37 ºC, 5% CO2) in DMEM (10938, GIBCO) supplemented with 10% 
of FBS, 100 U/ml penicillin and 500 g/ml streptomycin (Gibco BRL). Cells were 
transfected at 70% cell confluence (5 μg of each expression plasmid) using 
Lipofectamine 2000 (Invitrogen) following the manufacturer’s instructions and rinsed 
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with PBS eight hours later; the DNA concentration was measured by spectrophotometer. 
Forty-eight hours after transfection whole cell protein extracts were prepared in 250 μl 
of lysis buffer [Buffer A (50 mM Tris-HCl pH7.5, 150 mM NaCl, 0.5% Tween 20, 1 mM 
PMSF) plus 1 mM imidazole] supplemented with EDTA-free protease inhibitors cocktail 
(Roche). After sonication lysates were cleared by centrifugation and incubated with 50 
μl of Ni-NTA agarose beads in lysis buffer. Beads were washed three times with washing 
buffer (Buffer A plus 30 mM imidazole) and bound fractions were eluted with 50 μl of 
elution buffer (Buffer A plus 500 mM imidazole). Eluted proteins were subjected to SDS-
PAGE and immunoblotted with rabbit anti-GFP antibody at 1:2000 1% SM/TBS-T 
overnight, 4 ºC. Detection was carried out with ECF detection kit.  
 
Immunofluorescence and immunoprecipitation 
For immunolocalization of endogenous ATXN3 and NEDD8, HEK293 cells were grown on 
coverslips and were fixed for 20 min in freshly prepared 4% p-formaldehyde (Sigma) in 
phosphate-buffered saline (PBS), permeabilized with PBS/0.1% Triton X-100 for 5-7 min, 
washed in PBS and blocked with PBS/10% FBS. ATXN3 was detected with anti-SCA3 (1H9 
clone, Chemicon) at 1:500 and NEDD8 was detected with rabbit anti-NEDD8 (PW9340, 
BioMol) at 1:50. Fluorescent secondary antibodies (AlexaFluor 488-coupled goat anti-
rabbit and AlexaFluor 568-coupled goat anti-mouse, Molecular probes) were used at 
1:1500. DNA was stained with Dapi (Sigma). Images captured were then prepared and 
analysed using Photoshop 5.0LE (Adobe). For immunoprecipitation, HEK293 cells (CRL-
1573, ATCC) were transfected with 10 μg of GFP-NEDD8 using Lipofectamine2000 
reagent (Gibco BRL) following the manufacturer’s instructions; cells were collected 48 h 
after transfection, lysed in buffer A plus protease inhibitors (Roche)), briefly sonicated 
and cleared by centrifuged. The lysates were then pre-cleared with Protein-G-
Sepharose (GE Healthcare) for 1 h at 4°C and then incubated with 9 μl of polyclonal 
anti-NEDD8 antibody (PW9340) overnight at 4 ºC. The immuno-complexes were 
precipitated with Protein-G-Sepharose at 4 ºC for 2 h; the beads were washed two times 
with buffer A, minus the detergent, and finally eluted with 2X SDS sample buffer. The 
eluted proteins were analysed by western blot with anti-SCA3 (1H9) or anti-GFP.  
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Molecular docking prediction 
Models of the JD-NEDD8 and of JD-ubiquitin complexes were built by superimposing the 
structures of the NED1-NEDD8 complex (PBD ID 1xt9 (Reverter et al., 2005)) and of the 
UCH-L3 ubiquitin vinylmethylesther complex (PDB ID 1xd3 (Misaghi et al., 2005)), 
respectively, with the JD domain (PDB ID 1yzb (Nicastro et al., 2005)) using the DALI 
server (Holm and Park, 2000). The structures superpose with JD with Z-scores of 1.8 and 
4.5, and rmsds of 3.4 and 2.9 Å, respectively. The interface between the two proteins 
in the docked complexes was further refined by geometry optimization with CNS 
(Brunger et al., 1998). All images were made with PyMOL 
(http://pymol.sourceforge.net/).  
 
NEDD8-AMC cleavage assays 
The putative deneddylase activity of the proteins was evaluated using the fluorogenic 
substrate NEDD8-AMC, a reagent that allows determination of NEDD8 c-terminal 
hydrolase activity, according to a previously described protocol (Burnett and Pittman, 
2005). Briefly, 300 μl of assay buffer (50 mM HEPES, 0.5 mM EDTA, pH 7.5, with 0.1 
mg/ml BSA and 1 mM DTT) containing 10 μg of ATXN3 or ATXN3C14A, purified as 
described (Gales et al., 2005), was incubated at 37 ºC for 30 minutes. The reaction was 
initiated by adding the substrate to a final concentration of 0.5 μM and the proteins’ 
hydrolytic activities were measured as the release of AMC, after cleavage, for 9 minutes 
using a Perkin Elmer LS 50B fluorimeter. 
 
 
 
Results and Discussion 
 
ATXN3 interacts with NEDD8 
In order to evaluate if ATXN3 interacts with NEDD8, we used the yeast two-hybrid 
system (Y2H) and GST pull-down assays.  
For this study, several Y2H constructs of ATXN3 were made, coding for the entire 
protein (Gal4BD-ATXN3 var1.1), the JD (Gal4BD-JD) or the JD plus the first UIM 
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(ubiquitin-interacting motif) (Gal4BD-2.1N). A second variant of ATXN3, ATXN3 var2.1, 
in which UIM3 is absent, was also tested (Fig.14).  
The results showed that ATXN3 interacts with NEDD8, in the Y2H assay (Fig.15). No 
difference was observed when isoform ATXN3 var1.1 or ATXN3 var2.1 were tested, 
indicating that the third UIM in ATXN3 does not influence its ability to interact with 
NEDD8. 
To pinpoint the region in ATXN3 responsible for the interaction with NEDD8, two 
truncated fragments of ATXN3 were tested (Fig.15). The results obtained with the 
different fragments of ATXN3 showed that the JD is sufficient to establish the 
interaction with NEDD8. We tested also the reverse interaction between GAL4BD-NEDD8  
and GAL4AD-JD, and a positive interaction was observed. Co-transformations of the bait 
or prey constructs with the pACT2 and pAS1 Y2H empty vectors, respectively, showed 
no positive interactions (Fig.15). 
 
 
Figure 14. Sequence alignment of the human and Caenorhabditis elegans ataxin-3 proteins. Three isoforms of non-
expanded human ataxin-3 have been studied: ATXN3 var2.1, ATXN3 var1.1 and ATXN3 var1a. The Machado-Joseph 
disease-like protein of C. elegans is here referred as atx-3. The Josephin domain (JD) and the UIM (ubiquitin-interacting 
motifs) of all proteins are delimited by two-head arrows (dark grey for the human isoforms and light grey for atx-3). The 
human isoforms ATXN3 var2.1 and ATXN3 var1a contain only two UIM1 and UIM2 (dark grey arrows) located before the 
repetitive segment of glutamines (shaded in medium grey). The MJD1.1 isoform comprises another UIM (UIM3, italicized). 
The atx-3 protein contains UIM1 and UIM2 (light grey arrows). Notice that atx-3 contains only two glutamine residues. 
Sequence alignments and colouring were performed with Clustal W (1.83) and ESPrit (Gouet et al., 1999). 
 
 
The results obtained with the Y2H analysis were confirmed using in vitro pull-down 
assays, by monitoring the binding of GST-NEDD8 to several 6His-tagged constructs of  
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Figure 15. ATXN3 interacts with NEDD8 in the yeast two-hybrid system. The schematic representation depicts all 
yeast expression plasmids used. Two cDNA variants encoding normal ataxin-3 were used: GAL4BD-ATXN3 var1.1 and 
GAL4BD-ATXN3 var2.1, which lacks UIM3. Two constructs comprising fragments of ATXN3 were also tested: pAS1G-JD 
encodes GAL4BD fusion to Josephin domain and pAS1-2.1N encodes JD plus functional UIM1. The reverse interaction 
between GAL4BD-NEDD8 (crossed rectangle) and GAL4AD-JD was also tested; the filled rhombus represents the GAL4BD 
tag. An interaction was considered positive (+) when growth on nutritional selection plates was observed and colonies 
stained blue when tested for β-galactosidase expression (β-Gal assay). 
 
 
ATXN3 (Fig.16(a)). The direct interaction between ATXN3 and Ub was also tested, given  
the high identity between NEDD8 and Ub, and the fact that ATXN3 has been previously 
described to bind polyubiquitin (Burnett et al., 2003; Chai et al., 2004). As shown in 
Figure 16(b), full-length ATXN3 interacts in vitro with NEDD8, further indicating that 
ATXN3 can bind NEDD8 directly.  
In order to evaluate whether the interaction between ATXN3 and NEDD8 is 
evolutionarily conserved, we tested if the C. elegans atx-3 could also interact with 
human NEDD8. Interestingly, we observed a positive interaction between human NEDD8 
and atx-3 protein (Fig.16(c)). The high degree of JD conservation, despite an overall 
identity of only 36% between atx-3 and human ATXN3, may explain this direct 
interaction (Fig.14). In C. elegans, ned-8 has been shown to be crucial for nematode 
development. The absence of ned-8 resulted in embryonic lethality or severe 
developmental abnormalities (Jones and Candido, 2000). The conservation of the      
atx-3/NEDD8 interaction throughout evolution suggests a biological and functional 
relevance for this protein pair. 
 
 
  
 
Figure 16. ATXN3 interacts with NEDD8 in vitro. The GST pull-down assays show direct interaction of ATXN3 with NEDD8 and ubiquitin. (a) Schematic representation of 
recombinant proteins used in the assays: 6His-ATXN3 var1.1 represents the full-length of ataxin-3 variant 1.1 with three UIMs; 6His-D1, comprises the JD plus two UIMs; 6His-JD 
comprises only the JD; GST-221cATXN3 comprises all domains of ATXN3 var1.1 except JD, and 6His-atx-3 represents the ataxin-3 of C. elegans. Expected molecular weights for all 
proteins are stated (brackets). Purified GST-NEDD8 and GST-Ub were incubated with ATXN3 full-length (b), 6His-D1 ((d), (h)), 6His-JD ((e), (f), (i)) or atx-3 (c); GST-221cATXN3 was 
incubated with 6His-NEDD8 ((f)). Interaction between GST-HHR23A and 6His-ATXN3 was observed under the conditions established ((b)). Input lanes show 10% of the 6His-tagged 
protein used. GST-NEDD8 pulled-down ATXN3 (b), its fragments 6His-D1 (d) and 6His-JD ((e), (f)) and atx-3 (c), but failed to interact with GST-221cATXN3 (f). The monomeric Ub 
showed interaction only with ATXN3 full-length ((g). GST alone showed no binding in any assay. Bands identified with cardinals (#) are protein degradation products. 
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As a control experiment, we tested the interaction between ATXN3 and HHR23A 
(Fig.16(b)), and under the conditions used, we were able to replicate the interaction 
reported before (Wang et al., 2000). Our results also suggest that ATXN3 is able to  
interact more efficiently with NEDD8 and HHR23A, than with monomeric Ub, since a 
higher amount of GST-Ub was needed to pull-down a quantity of ATXN3 similar to those 
obtained with NEDD8 and HHR23A (Fig.16(b), (g)).  
We also mapped the minimum domain required for ATXN3 to interact with NEDD8, using 
the pull-down assays. Truncated fragments of ATXN3 corresponding to the JD plus UIM1 
and UIM2 (6His-D1), the JD alone (6His-JD) or a C-terminal fragment comprising all 
ATXN3 domains except JD (GST-221cATXN3) were produced and assayed for binding to 
GST-NEDD8 or to GST-Ub. We did observe interaction between GST-NEDD8 and 6His-D1 
or 6His-JD proteins (Fig.16(d), (e)), but no interaction was observed between          
GST-221cATXN3 and 6His-NEDD8 (Fig.16(f)). No interactions between the D1 or JD 
fragments of ATXN3 and monomeric Ub were observed in these in vitro studies (Fig.16 
(h), (i)). 
Thus, we conclude, that the JD of ATXN3 is sufficient, and necessary, for the 
interaction with NEDD8, in agreement with the results obtained in the Y2H assay (Fig. 
2). In control experiments we could not detect any binding of ATXN3 or its truncated 
forms to the beads alone, or to beads containing GST, indicating that the interactions 
observed with NEDD8 or monomeric Ub are specific (Fig.16(b-i)).  
Taken together, the results obtained, using the Y2H system and GST pull-down assays, 
indicate that ATXN3 interacts with NEDD8 through its JD. 
 
 
ATXN3 and NEDD8 co-localise and interact in mammalian cells  
The subcellular expression of endogenous ATXN3 and NEDD8 proteins was determined in 
HeLa cells, using immunofluorescence analysis. Cells were fixed, permeabilized and 
then immunolabelled with anti-SCA3 (1H9) and anti-NEDD8 (PW9340) antibodies. Both 
proteins have nuclear and cytoplasmic diffuse distribution (Fig.17(a)). Incubations with 
secondary antibodies alone did not produce specific staining (data not shown). Merged 
images show co-localization of ATXN3 and NEDD8, both in the nucleus and cytoplasm, 
which is compatible with the possibility that the two proteins are interacting partners. 
 
  
 
Figure 17. Ataxin-3 interacts and colocalize with NEDD8 in eukaryotic cells. (a) Immunofluorescence analysis showed nuclear and cytoplasmatic colocalization of endogenous ATXN3 and 
NEDD8. ATXN3 was detected with anti-SCA3 (1H9) and probed with AlexaFluor 568-coupled goat anti-mouse antibody (red); NEDD8 was detected with polyclonal anti-NEDD8 antibody 
revealed by AlexaFluor 488-coupled goat anti-rabbit fluorescent antibody (green); nuclei were stained with Dapi (Sigma). (b) Schematic representation of GFP-JD used in mammalian cell 
transfection; the expected molecular weight is stated (brackets); filled star represents the GFP tag. (c) ATXN3 interacts with NEDD8 in mammalian cells. The 6His-NEDD8 or 6His-Ub proteins 
were co-expressed with GFP-JD (lanes 7, 9) or empty vector (lanes 8, 10) in HeLa cells. Lanes 1-6 were loaded with 5% of the total protein input of each assay. GFP-JD pulled-down (black 
star) by 6His-NEDD8 or 6His-Ub were detected by western blotting using the anti-GFP antibody (SC-8334). (d) Endogenous ATXN3 is immunoprecipitated by GFP-tagged NEDD8. Supernatants 
obtained from cells expressing GFP-NEDD8 were incubated overnight with anti-NEDD8 antibody (+) or without the antibody (-); immunocomplexes were subsequently separated by SDS-PAGE 
and immunoblotted with anti-SCA3 or anti-GFP antibodies. 
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In order to investigate whether ATXN3 can bind NEDD8 or Ub in the context of a 
mammalian cell, the interactions were analysed in transfected HeLa cells. Briefly, 6His-
NEDD8 or 6His-Ub was co-expressed either with GFP-JD or GFP alone (Fig.17(b)). His-
tagged proteins were purified under non-denaturing conditions, and the purified 
samples were subsequently immunoblotted with an anti-GFP antibody (Fig.17(c)). 
Cells transfected only with pEGFP-JD or pEGFP were used as controls. The interaction of 
6His-NEDD8 with the JD (Fig.17(c), lane 7) was detected in this assay, supporting the 
previous results. No binding of GFP alone to NEDD8 was detected (lane 8), indicating 
that JD fusion protein was specifically co-purified with NEDD8. It should be noted that, 
the purified GFP-JD protein detected using the anti-GFP antibody has the molecular size 
corresponding to unmodified GFP-JD, suggesting that this domain is not neddylated, but 
rather that it interacts with NEDD8. 
The interactions between 6His-Ub and GFP-JD were also tested. GFP alone showed no 
binding to monomeric Ub in this assay (Fig.17(c), lane 10). When 6His-Ub was co-
expressed with GFP-JD, the anti-GFP antibody detected a protein corresponding in size 
to the GFP-tagged JD (lane 9). The fact that this interaction could not be detected in 
the GST pull-down assay (Fig.16(i)) suggests that the interaction occurs with 
polyubiquitylated proteins.  
To further confirm the occurrence of this new interaction in vivo, HEK293 cells were 
transiently transfected with a construct expressing GFP-NEDD8. When the cell lysates 
were incubated with polyclonal anti-NEDD8 we were able to co-immunoprecipitate the 
endogenous ATXN3 (Fig.17(d)). No ATXN3 was detected in the negative control 
(omission of the anti-NEDD8 antibody). An immunoblot assay with anti-GFP confirmed 
that GFP-NEDD8 protein was efficiently immunoprecipitated. Altogether, these results 
suggest that endogenous ATXN3 specifically interacts with NEDD8. 
 
Costa et al., has reported the expression pattern of murine ATXN3, which is expressed 
ubiquitously since early embryonic stages, at least in E11.5 (do Carmo Costa et al., 
2004). Interestingly, previous mRNA studies showed that the highest expression of the 
NEDD8 occurs at the E11 stage; moreover, Kamitani et al., (Kamitani et al., 1997) have 
proposed that proteins expressed in the heart and skeletal muscle or in early 
development would be good candidates for NEDD8 interaction. Strikingly, mouse ATXN3 
shows prominent expression in these particular tissues (do Carmo Costa et al., 2004). All 
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these data support a biological relevance for the ATXN3/NEDD8 interaction, not only in 
differentiated tissues, but also since early stages of development. 
 
NEDD8 interacts with ATXN3 in a substrate-like mode 
Recently, the structure of JD of ATXN3 has been determined by NMR (Mao et al., 2005; 
Nicastro et al., 2005), revealing that it shares a significant structural homology with the 
DUB enzymes, human UCH-L3 (Misaghi et al., 2005) and yeast YUH1 (Johnston et al., 
1999). Those studies allowed mapping of the active site (Q9, C14, H119, N134) and 
revealed that the binding site for the N-terminal UBL domain of HHR23B is comprised of 
an hydrophobic surface located opposite to the catalytic site of the JD (Nicastro et al., 
2005). The binding site of Ub as a substrate has been proposed to be located just above 
the active site, in a cleft bordered by the central catalytic subdomain and by a flexible 
helical hairpin that is likely to move to better accommodate the substrate (Mao et al., 
2005; Nicastro et al., 2005). Our data shows that ATXN3 interacts specifically with 
NEDD8, and that the interaction site involves its catalytic JD. The high sequence and 
structural similarity between NEDD8, Ub and the UBL domain of HHR23B raises two 
possible scenarios: i) NEDD8 could interact with ATXN3 JD via its exposed hydrophobic 
surface used for the HHR23B interaction (Nicastro et al., 2005) or ii) NEDD8 could 
interact with ATXN3 in a substrate-like mode, meaning that ATXN3 could have 
deneddylase activity.  
 
We have analysed the surface distribution of conserved and divergent residues between 
the UBL domain of HHR23B and NEDD8, and between Ub and NEDD8, in an effort to 
identify the structural basis of their differential binding to ATXN3. The hydrophobic 
HHR23B-UBL surface relevant for the interaction with the JD is not strictly conserved in 
NEDD8 and we can predict that the NEDD8 interaction site on the JD is likely to be 
different. We predict that NEDD8 interacts with the JD in a substrate-like manner. 
 
Our docking model of Ub and NEDD8 at the putative substrate-binding site of the JD was 
built based on the structural homology between Ub/NEDD8 hydrolases and JD. For both 
complexes the C-terminus -GG76 motif, common to NEDD8 and Ub, is bound deep in the 
narrow catalytic canyon, close to the catalytic C14 of ATXN3 (Fig.18). Accommodation 
of either NEDD8 or Ub involves small structural changes both in the JD and in the 
docked molecules (data not shown), in regions that have been shown, by chemical shift 
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perturbation, to be relevant for the JD-Ubiquitin interaction (Mao et al., 2005). In these 
models, the negative electrostatic surface potential of the JD is complemented by the 
positive charge of the docked molecules (Fig.18(a) and (b)) and docking is further aided 
by surface complementarity.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 18. NEDD8 and ubiquitin share the same binding site on ATXN3 catalytic domain. Solid surface representation 
of the JD, NEDD8 and Ub coloured according to the electrostatic potential (blue for positive, red for negative). JD is 
complexed (a) with NEDD8 (green) and (b) with Ub (violet). The pictures on the left (a) and (b) figures show solid surface 
representations of NEDD8 and Ub rotated ~90º along the horizontal axis in the figure plane, in comparison with their 
position in the docked complex. The docking surfaces of NEDD8 and Ub are predominantly basic and complement the 
acidic character of the substrate-binding cleft of the JD. The overall surface complementarity is notorious in both 
complexes.  
 
 
Our modelling studies clearly show that both NEDD8 and Ub should bind in a substrate-
like mode. In agreement, ATXN3 has NEDD8 C-terminal hydrolase activity against the 
fluorogenic substrate NEDD8-AMC (7-amino-4-methylcoumarin) (Fig.19).  
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Figure 19. Hydrolysis of NEDD8-AMC by ATXN3 requires the C14 residue. ATXN3 displays C-terminal hydrolase activity 
against NEDD8-AMC (Boston Biochemicals). Recombinant ATXN3 or mutant ATXN3 (ATXN3C14A) were incubated with 
NEDD8-AMC (7-amino-4-methylcoumarin) for a total of 9 minutes, and their proteolytic activities measured from the AMC 
release extent, after cleavage. No cleavage was observed when only the assay buffer was present (grey line) or the 
mutant ATXN3C14A (orange line). However, when ATXN3 was present in the reaction a time-dependent release of AMC 
could be observed (blue line) indicating the hydrolytic activity of ATXN3 on NEDD8-AMC. The slope for the ATXN3 and 
ATXN3C14A activities were 0.037 s-1 and 0.0032 s-1, respectively. 
 
 
Furthermore, our results clearly show that the deneddylase activity of ATXN3 is 
dependent on the cysteine at position 14. The mutant ATXN3 (C14A) does not show 
deneddylase activity against NEDD8-AMC (Fig.19). However, this activity loss is not due 
to loss of interaction between these proteins since NEDD8 is still able to interact with 
mutant ATXN3 JD(C14A) (Fig.20). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 20. NEDD8 interacts with mutated ATXN3 (JD(C14A)) in vitro. The 6His-JD(C14A) construct was obtained by 
introducing a substitution of cysteine (C) by an alanine (A) at position 42 using the QuikChange site-directed mutagenesis 
kit (Stratagene). Protein expression was carried out as described (Gales et al., 2005). The GST pull-down assay was 
performed as described (“Material and Methods” section). Bands identified with cardinals (#) are protein degradation 
products. 
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Figure 21. Characterization of a new rabbit polyclonal antibody produced against normal full-length recombinant 
6His-ATXN3-var1.1, anti-MJD1.1. Five micrograms of the following 6His-tagged proteins were separated on a 12% SDS-
PAGE gel: 1, JD, josephin domain alone; 2, JD plus UIM1 and UIM2; 3, full length ATXN3 var1.1. Proteins were transferred 
to a nitrocellulose membrane, stained with Ponceau S and subsequently immunoblotted as follows: A, anti-MJD1.1 at 
1:20000; in B, anti-MJD1.1 was previously pre-incubated with 60 μg of 6His-ATXN-3 var1.1 for one hour at 37 ºC and then 
used at 1:20000 dilution; C, secondary antibody alone at  1:30000. These immunoblots against different recombinant 
6His-tagged protein demonstrated that the anti-MJD1.1 antibody detects specifically ATXN3 full length as well as, its 
fragments comprising the JD plus UIM1 and UIM2 (A, 2) as it fails to detect recombinant 6His-JD (A, 1). 
 
 
In conclusion, in this study, we identified a novel molecular partner of ATXN3, NEDD8. 
We demonstrated that the interaction between NEDD8 and ATXN3 is specific and 
independent of the presence of the UIM domains and the polyglutamine tract, since it 
occurs through its JD. The specific interaction between the JD and NEDD8 prompted us 
to build a theoretical model of the complex, which shows, that monomeric Ub and 
NEDD8 could share the same binding site. Moreover, we show that ATXN3 has a 
deneddylase activity dependent on the cysteine residue at position 14. 
 
The NEDD8 protein is essential for the activity of SCF-like ubiquitin ligase complexes. 
These complexes determine the degradation of several substrates and consequently 
pace the pathways in which they participate. Our group has recently reported a 
transcriptomic analysis of atx-3 knockout C. elegans strains (Rodrigues et al., 2007) 
where we showed down-regulation of several genes encoding subunits of the SCF 
complex. Additionally, a recent analysis of genetic interactions in C. elegans by Zhong 
and Sternberg (Zhong and Sternberg, 2006), pinpointed several genes encoding UPS-
related proteins and components of SCF-like complexes as genetic interactors of atx-3 
in the worm. Together with these results, the identification of NEDD8 as a new ATXN3 
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interacting protein adds a new perspective to the possible physiological role of ATXN3 
modulating the activity of the UPS. 
 
Further studies will be needed to explore the nature and specificity determinants of this 
newly identified interaction, to clarify its physiological role and the biological relevance 
of the putative deneddylase activity of ATXN3. 
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The function of most of disease-causing polyglutamine proteins is largely unknown. 
Apart from the polyQ domain, there is virtually no sequence homology between polyQ 
proteins. In this work, we focused on the normal function of ATXN3, the smallest of all 
polyQ proteins. 
 
ATXN3 role(s) in the cell  
Evidence gathered about ATXN3 subcellular localisation and interactions raised several 
possibilities for the biological function(s) of ATXN3 in the cell, though a definite 
conclusion remains elusive.  
ATXN3 may be involved in transcriptional regulation by interacting directly with 
transcription factors, CBP, p300 and pCAF, or indirectly, by inhibiting histones 
modifications (Li et al., 2002). Moreover, ATXN3 was also shown to interact with HDAC3 
and NCoR, leading to an increased histone deacetylase activity, dependent of ATXN3’s 
intact UIMs (Evert et al., 2006), and thus reinforcing its role as a transcriptional 
repressor. 
ATXN3 may also participate in the cellular DNA damage response, specifically in NER-
GGR. The interaction of ataxin-3 with the HHR23 proteins (Wang et al., 2000), and with 
XPC (our work, Chapter 2), further strengthens this hypothesis. Apart from our initial 
work presented in here, however, there is no other biological evidence that ataxin-3 is 
directly involved in DNA repair. 
The larger body of evidence until known suggest that ATXN3 participates in the protein 
surveillance mechanisms. It has been shown that it functions as a polyubiquitin chain 
hydrolase (Burnett et al., 2003; Chai et al., 2004; Berke et al., 2005; Mao et al., 2005), 
in a C14 residue-dependent manner. The interaction between ATXN3 and VCP, a 
chaperone involved in the translocation of misfolded protein to the 26S proteasome, is 
dependent on polyQ length and reinforces its participation in the cell quality control 
systems (Hirabayashi et al., 2001; Kobayashi et al., 2002; Doss-Pepe et al., 2003; 
Nakayama, 2003; Boeddrich et al., 2006; Zhong and Pittman, 2006). The modulation of 
this interaction the polyQ domain of ATXN3 may affect its deubiquitylating activity (Mao 
et al., 2005). In fact, normal ATXN3 is recruited into the aggregates of several polyQ 
diseases, through interaction with its mutant counterpart or with other polyQ proteins 
(Perez et al., 1998). Moreover, overexpression of normal ATXN3, in a Drosophila model 
of MJD, suppressed polyQ toxicity. Such neuroprotective role was dependent of the 
deubiquitylating activity of ATXN3 and of the proteasome (Warrick et al., 2005).  
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Given the uncertainty about the physiological role of ATXN3, we decided to approach 
this question through the identification of ATXN3’s molecular interactors. 
 
 
 
Library screening  
 
The initial strategy set for this work, a large genetic screening for molecular interactors 
of normal ATXN3 in a brain-cDNA library, did not produce the results that could have 
been expected. Though the quality of the library screened should be considered the 
major drawback in the success of this strategy, we still feel that the power of screening 
should have been higher. If more independent clones had been screened, we would 
definitely maximize our probabilities of finding a true positive interactor, and perhaps 
overcome the redundancy of the tested library. In light of our current experience, we 
also think that, some of the seven candidates selected from that screening should be 
cloned in the correct frame, and further tested, independently of the final validation 
outcome. Nevertheless, with this work we implemented the yeast two-hybrid system 
routinely in our lab, which is now being used to study interactions of the C. elegans and 
mouse orthologues of ATXN3 and we prepared, and characterised, new molecular tools 
for continuing the study of protein-protein interactions, either by designing a new 
library screening, or by analysing direct protein interactions. 
 
Conversely, the direct protein-protein interaction analysis turned out to be a successful 
strategy. We could prove that normal ATXN3 interacts with XPC, a repair factor crucial 
in the early steps of GGR-NER, and NEDD8, an ubiquitin-like protein, involved in the 
cullin-dependent ubiquitylation system. The specific interaction between the JD and 
the HHR23 proteins (Chapter1), which in addition to their role in DNA repair are also, 
proteasome-binding factors, reinforces the role of ataxin-3 as an active participant in 
protein surveillance mechanisms of the cell, as is the interaction observed between 
normal ATXN3 and NEDD8; the clues obtained in vitro regarding its deneddylating 
activity may sustained the participation of ATXN3 in the regulation of UPS activity 
(Chapter 2).  
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ATXN3 and DNA repair 
 
Back in 2000, the discovery of the interaction between ATXN3 and the HHR23A and 
HHR23B proteins (Wang et al., 2000) led to significant research regarding the role of 
this interaction, in the protein quality control systems of the cell (Hirabayashi et al., 
2001; Kobayashi et al., 2002; Doss-Pepe et al., 2003; Nakayama, 2003; Boeddrich et al., 
2006; Zhong and Pittman, 2006). Yet, we set as our objective to define another 
functional context for this interaction. The interaction of ATXN3 and the HHR23 
proteins raised the possibility that this interaction could also have some relevance for 
DNA repair, namely the GGR-NER pathway.  
As discussed in chapter 2, the HHR23 proteins bind and function as stabilizers of XPC to 
the damage recognition complex (Sugasawa et al., 1996; Li et al., 1997; Sugasawa et 
al., 1997; Ng et al., 2003; Sugasawa et al., 2005; Park and Choi, 2006). Moreover, XPC 
polyubiquitylation stabilizes this complex and promotes its availability to the damage 
site (Sugasawa et al., 2005). The mechanism through which XPC stabilisation occurs 
remains elusive, but the intrinsic characteristics of the interactor HHR23 seem to play a 
pivotal role (Ortolan et al., 2000; Chen et al., 2001; Madura, 2002; Wang et al., 2003; 
Heessen et al., 2005; Sugasawa et al., 2005). 
This new interaction between ATXN3 and XPC has to be further validated, and its 
structural determinants and functional significance must be further studied. The 
preliminary immunofluorescence experiments with irradiated HEK293 cells are 
promising. The observed induced colocalisation of ATXN3 and XPC that occurs post-UV 
irradiation strengthens the possibility that ATXN3 may be participating in GGR-NER in 
vivo. The significant induction of the expression of atx-3 in ENU-treated worms is 
compatible with this assumption. Thought we think that this is strong evidence, worthy 
of attention, we may only speculate, at this point, about the possible role(s) of ATXN3 
in this pathway.  
We have raised three hypotheses: ATXN3 may either be (1) binding the 
HHR23B/XPC/CETN2 ternary complex and acting directly in GGR-NER. or (2) it may be 
competing with HHR23B for XPC (and the fact that both interactions occur through the 
JD supports this last notion); the direct binding of ATXN3 to either XPC or HHR23B would 
disrupt the complex stabilisation equilibrium, inducing the shuttling of the complex for 
degradation in the proteasome, and allowing rapid elimination of HHR23B/XPC/CETN2, 
when unnecessary. (3) The possibility that XPC may be a substrate of ATXN3, as a 
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deubiquitylating enzyme (DUB), must also be considered. The nature of the polyUb 
conjugated to XPC is still unknown. Although K63-linked polyUb chains are known to be 
involved in DNA repair (and this has not been ruled out for XPC), the fact that XPC is 
complexed with a proteasome-interacting protein (HHR23B) raises the possibility that it 
may be conjugated to K48-linked polyUb chains. Nevertheless, and independently of the 
nature of the polyUb chain conjugated to XPC, it is a possible substrate of ATXN3, as 
ATXN3 has in vitro DUB activity upon both K63- and K48-linked chains {Burnett, 2003 
#813; Chai, 2004 #818 and H. Paulson, personal communication).  
As for its nature, little is known about the size of the XPC-conjugated ubiquitin chain 
optimal for efficient GGR-NER. The interaction with ATXN3 may allow the 
“proofreading” of the XPC polyUb chain to optimal sizing, or it may be acting as a 
negative regulator of GGR-NER, by destabilising XPC, by degrading the polyUb below the 
putative optimal size and addressing it to proteasome degradation.  
The results obtained with C. elegans, in the progeny assay, sustain the latter 
hypothesis. This assay showed that, in the absence of atx-3 expression (atx-3-/-), the 
knockout animals were able to produce significantly more viable progeny than the wild-
type strain, when treated with ENU. It seems that, upon DNA damage-inducing 
conditions, the absence of atx-3 expression confers a higher resistance to genotoxic 
stress, either enabling the animals to repair more efficiently the damages induced. This 
and the remaining observations, such as the significant differences observed in the xpc-
1 and ZK20.3 expressions, between wild-type and atx-3-/- animals, upon basal and ENU-
treated conditions, seem to support the hypothesis that ATXN3, or its worm 
counterpart, may be acting as a negative regulator of GGR-NER.  
Recently, Wang et al. (2005) showed that, upon UV irradiation, XPC is modified by 
SUMO-1 in a XPA and DDB2-dependent manner. Sumoylation seems to enhance 
stabilization of XPC, as yeast studies showed that ubc9-1  strain (with deletion of Ubc9, 
the specific SUMO-1 E2 conjugating enzyme) had low RAD4 levels and increased UV 
sensitivity, in comparison to the normal strains {Ramsey, 2004 #988}. Sumoylation can 
also alter target’s interactions (Johnson, 2004) and it may be modulating XPC’s 
interactions throughout the NER reaction, for example, sensing the moment of its 
dissociation of repair complex. Interestingly, SUMO-1 has been reported as an ATXN3 
interactor (Shen et al., 2006), another evidence that may potentially link ATXN3 to XPC 
and, ultimately, to NER.   
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In summary, we gathered more evidence supporting the putative involvement of ATXN3 
in GGR-NER, through a participation in XPC complex-remodelling activity that may 
modulate the rate or efficiency of this repair system in vivo. 
 
The isopeptidase activity of ATXN3 
Depending on their catalytic mechanism, proteases may be divided into five classes: 
aspartic, metallo, serine, threonine, and cysteine proteases. DUBs are cysteinic or 
metalloproteases. Furthermore, the cysteinic DUBs, depending of the active catalylic 
center, may be sub-divided into four classes: ubiquitin-specific proteases (USP), 
ubiquitin C-terminal hydrolases (UCH), ovarian tumor-related proteases (OTU), and 
Machado-Joseph disease proteases (MJD). The metalloproteases have a JAMM 
(JAB1/MPN/Mov34 metalloenzyme) motif at their catalytic centre (Amerik and 
Hochstrasser, 2004; Nijman et al., 2005). DUBs catalyse the cleavage between the C-
terminal glycine-76 of ubiquitin and the substrate.  
Though DUB’s function is not fully understood, they may be responsible for (1) the 
processing of the ubiquitin and UBL precursors, (2) the proofreading of the conjugated 
polyUb chains, either from mistakenly ubiquitylated proteins, or (3) from specific 
polyubiquitylated substrates, (4) retrieving polyUb chains before the substrate’s 
proteolysis in the proteasome, (5) disassemble the ubiquitin oligomers (unanchored 
polyubiquitin chains), or (6) deubiquitylating of membrane proteins tagged for 
lysosomal/vacuole-dependent degradation or trafficking (Amerik and Hochstrasser, 
2004). DUBs are essential for the maintenance of the ubiquitin cycle of conjugated and 
non-conjugated ubiquitin, sustaining the pool of free ubiquitin, necessary for new 
ubiquitylation reactions.  
ATXN3, namely its JD domain, contains conserved amino acids reminiscent of the 
catalytic domain of a member of the deubiquitylating cysteine protease UCH and USP 
family (Scheel et al., 2003; Amerik and Hochstrasser, 2004; Mao et al., 2005; Nicastro 
et al., 2005; Nicastro et al., 2006), displays Ub hydrolase activity, and binds ubiquitin-
aldehyde in vitro (Burnett et al., 2003; Berke et al., 2005).  
The protein atx-3 is the homologue of ATXN3 in C. elegans. Similarly to its human 
counterpart, it conserves the catalytic triad characteristic of cysteinic proteases and 
has deubiquitylating activity in vitro. The knockout animal for atx-3 (atx-3-/-) showed no 
obvious phenotypic alterations, compared to the wild-type (Rodrigues et al., 2007). This 
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suggests that atx-3 is not an essential protein and, as a putative DUB, atx-3 may not be 
contributing significantly for the essential free ubiquitin pool within the cell; rather, it 
may be acting upon specific substrates, without significant repercussions to the cell. 
The same result was obtained for another C. elegans UCH (R10E11.3), UCH46 in humans, 
the knockdown expression of which led to a normal phenotype. Based on several pieces 
of evidence, Nijman et al. suggested that most DUB target specific substrates (Nijman 
et al., 2005).  
The biochemical characterisation of atx-3 as an enzyme is very incomplete. Yet, given 
the similarity between the homologues and the known in vitro preference of human 
ATXN3 for polyUb chains containing four or more Ub moieties, it is licit to speculate 
that these two proteins are also not involved in the processivity of ubiquitin or UBL 
proteins precursors, reinforcing their role in the regulation of ubiquitylation pattern of 
specific substrates. The results of ubiquitylation pattern analysis corroborate this 
hypothesis. No obvious difference was observed in the global ubiquitylation pattern of 
protein extracts from atx-3-/- animals, when compared to the wild-type and, as seen 
before (Santos, 2005), nor even upon heat-shock (Rodrigues, A.J. personal 
communication) or ENU-treatment. 
ATXN3 seems to be a weak DUB in vitro (K. Wilkinson, personal communication), which 
anticipates the difficulties that should be encountered in the in vivo validation of its 
activity and, concomitantly, in the identification of its substrates. Nevertheless, the 
identification of specific targets of this polyQ protein is mandatory.  
 
Nevertheless, much has been done in the last decade, and a rather intricate net of 
experimental and bioinformatic evidence has been obtained for ATXN3. Identifying its 
biological target(s) will shed some light upon the biological pathways which ATXN3 is 
acting in, and, hopefully, will help to elucidate its normal function(s). With this work, 
we propose a novel putative target of ATXN3 activity, the XPC protein. Undoubtedly, 
further studies must be carried out, to better understand to what extent the 
polyubiquitylation of XPC and, extensively, the GGR-NER system are modulated by 
ATXN3 or any other DUB. 
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“DUBling” the chances: ubiquitin or NEDD8?  
Several pieces of evidence showed that some predicted DUBs might also be active 
toward ubiquitin-like proteins. USP21 and UCH-L3 cleave both Ub and NEDD8; USP18 has 
been proposed to specifically cleave ISG15, another UBL (Wada et al., 1998; Gong et 
al., 2000; Malakhov et al., 2002). Additionally, SENP8/NEDP1/DEN1, a cysteinic 
protease known to be involved in the proteolysis of SUMO, has also been reported to be 
a NEDD8-specific protease (Gan-Erdene et al., 2003; Wu et al., 2003).  
As described and discussed in chapter 2, we have contributed to the identification and 
characterisation of a novel molecular interactor of ATXN3, NEDD8. Hence, we identified 
ATXN3 as another cysteinic DUB that displays affinity for NEDD8, in vitro and in vivo. 
This interaction is dependent on the JD domain of ATXN3, and modelling studies led us 
to predict that NEDD8 interacts with the JD in a substrate-like manner. In agreement, 
cleavage activity assays confirmed the structural hypothesis, as ATXN3 exhibits catalytic 
properties against NEDD8-AMC, a fluorogenic substrate; Costa el at. (unpublished data) 
verified the evolutionarily conservation of the deneddylase activity, since the murine 
homologue of ATXN3 is also able to cleave NEDD8-AMC, in vitro. The ATXN3’s 
deneddylase activity is dependent of the cysteine residue (Cys14) at the catalytic triad 
in the JD, as the mutant protein, ATXN3C14A, displays no deneddylase activity against 
the fluorogenic substrate. Importantly, the activity loss is not due to the abrogation of 
the interaction, as JD(C14A) is still able to interact with NEDD8. The C14 residue is, 
crucial for the catalytic function, itself, of the active site of ATXN3; the importance of 
this residue, as a potential modifier for the disease, still needs to be evaluated. It is 
known that the catalytically inactive form of ATXN3 leads to the accumulation of 
ubiquitylated proteins in the cell (Berke et al., 2005). It would be interesting to 
evaluate if an alteration at this position, and/or at any other of the catalytic triad, has 
any clinical relevance, for example, for the age-at-onset of the MJD. 
The presence of NEDD8 in neuronal and glial inclusions reactive to ubiquitin has been 
reported for several neurodegenerative diseases, including MJD. Whether the presence 
of NEDD8 is a consequence of its interaction with ATXN3, or if it indicates the presence 
of neddylated proteins, remains unknown. The new animal model for MJD that is being 
developed in our lab (Costa et al., in preparation) will allow, for example, the analysis 
of the composition of ubiquitylated and neddylated inclusions aiming at the 
identification of possible targets of ATXN3, either as DUB or deneddylase. The analysis 
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of the protein expression patterns from the C. elegans atx-3-/- knockout strain or from a 
ATXN3 knockdowned cell line, may also be used to identify ATXN3 targets. 
ATXN3 may therefore interplay with both the ubiquitylation and neddylation pathways. 
Currently, it is still unknown which residues or motifs are important for these proteases, 
and how they distinguish between ubiquitin and the remaining UBL proteins (substrate 
type specificity), or the conjugated target protein (target specificity). Clearly, more in 
vitro and in vivo analysis of DUBs and UBL proteases are necessary. Probably a combined 
strategy relying on the recognition of both the specific target, the nature of the 
attached UBLs and the domains present in the protease (e.g. UIM, UBA, PAZ-
polyubiquitin associated zinc finger) determines their overall specificity (Amerik and 
Hochstrasser, 2004; Nijman et al., 2005). 
The interaction of ATXN3 with NEDD8 is dependent of the JD domain. In contrast, the 
interaction with Ub seems to be dependent of the presence of the UIM domains, 
although the catalytic centre is at the JD (Berke et al., 2005; Mao et al., 2005). The 
presence of the UIM positioned outside the catalytic domain may therefore confer 
differential specificity towards the ubiquitylated targets.  
The importance of sequences outside the catalytic domains in the determination of the 
inherent specificity of the proteases has been reported. The deubiquitylating enzyme 
USP5 (aka isopeptidase T) comprises two UBA domains. In vivo, USP5 disassembles 
unanchored K48-linked chains (Amerik et al., 1997); in vitro, the human USP5 showed 
comparable activity against all of the chains tested, Lys48-Ub4, Lys63- and Lys29/6-Ub4 
and monoubiquitin; however, its isolated UBA2 domain showed substantial affinity for 
monoubiquitin. The ectopic expression of the UBA2 from HHR23A, which binds 
preferably Lys48-Ub4, altered the specificity of the chimeric USP5, and biased its 
preference for the K48-Ub chains. Although the UBA2 domain of this DUB may not be the 
sole determinant of the enzyme’s specificity, it may have a regulatory role in the 
protease activity (Raasi et al., 2005).  
The biophysical properties of both ATXN3 interactions need to be determined, and 
together with the analysis of the enzyme kinetics, may elucidate the substrate towards 
which ATXN3 shows a higher affinity, i.e., the specificity of the isopeptidase activity. 
Our preliminary results show that 6His-NEDD8 inhibits ATXN3’s DUB activity against 
polyUb chains, in vitro. The competitive nature of the inhibition is not unexpected, as 
NEDD8 binds directly to JD, the catalytic domain of ATXN3.  
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A proposed model: linking E3 ligases, NEDD8, UPS and genotoxic stress 
DUBs and E3 ligases are often found in protein complexes together. Several interactions 
have been reported: USP7 and HDM2 (Canning et al., 2004); USP15 and Rbx1 (Hetfeld et 
al., 2005), and USP20 and pVHL are just some of these. The ultimate example is A20, 
which possesses simultaneously DUB and E3-ligase activity (Wertz et al., 2004). 
Independently of the purpose of these interactions - E3-ligase stabilization, differential 
regulation of the targets or the DUB itself, or definition of the target specificity - they 
seem to establish the proper conditions for the degradation of the right protein.  
ATXN3 itself is known to be associated with some E3-ligases such as parkin (Tsai et al., 
2003), CHIP (Jana et al., 2005), p300 which strongly ubiquitylates p53 (Grossman et al., 
2003) and PCAF, the p300–CBP-associated factor which has been recently described as 
an atypical E3 ligase (Li et al., 2002; Linares et al., 2007).  
The model proposed in Fig.22, adapted from the work by Huang et al. (2006), fits many 
aspects discussed in this work.  
In vivo, DDB2 has ubiquitin ligase activity, which is modulated by UV exposure, and,  as 
referenced before, XPC is polyubiquitylated by DDB2 (Sugasawa et al., 2005).  
DDB is a heterodimeric complex, comprising DDB1 and DDB2. Although the mechanism 
remains poorly understood, DDB participates in the recognition steps of GGR-NER, 
together with the trimeric complex XPC/CETN2/HHR23B. DDB, itself, forms a complex 
with a SCF-like complex, which comprises cullin-4A, RBX1/ROC1, and is negatively 
regulated by CSN (COP9/signalosome), which can deconjugate both ubiquitin and 
NEDD8-modified cullin4A (Groisman et al., 2003). Upon DNA damage, CSN dissociates 
from the SCF-like complex, allowing cullin4A to be neddylated, and thus the activation 
of the ubiquitin ligase complex. Therefore, in the basal conditions (Fig.22A), the DDB 
E3-ligase complex (DDB1, DDB2, CUL4A and ROC1 (E3-ligase RING domain)) is 
inactivated due to the interaction with CSN, the negative regulator of the complex.  
 
Upon DNA damage (Fig.22B), the activated/neddylated DDB ligase complex translocates 
to the DNA lesion, recruiting the XPC/CETN2/HHR23 complex to the lesion site. During 
GGR-NER of low distorting lesions, the DDB complex helps the XPC complex to sense the 
damage spot (Fitch et al., 2003a; Fitch et al., 2003b). The polyubiquitylation of XPC is 
mediated by DDB2 (Sugasawa et al., 2005); although the concomitant ubiquitylation of 
cullin4A and self-ubiquitylation of DDB2 is promoted by the same E3 ligase complex 
(Fig.22C), these proteins have different fates. Polyubiquitylation of XPC stabilizes it 
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and stimulates NER, whereas polyubiquitylated DDB2 is degraded, and the remaining 
ubiquitylated DDB ligase complex (polyubiquitylated CUL4A) is displaced from the lesion 
(Fig.22D). In the absence of ubiquitylation and inhibition of the proteasome, DDB2 is 
not degraded and the XPC binding to the damage site is compromised, as is NER 
efficiency (Wang et al., 2005). Therefore, the DDB complex seems to not only to help 
XPC complex to sense the damage site, but also to promote its ubiquitylation.  
The DNA repair mechanism comprises several proteins and multiple spots of regulation. 
The precise timing of protein association and dissociation during NER may be regulated 
by post-translational modifications. It is suggested by the authors that regulation of this 
pathway might involve negative regulators, as deubiquitylating enzymes (DUB), that ae 
able to “reset” the mechanism. 
It is the nature of the post-translational modifications in this model, polyubiquitylation, 
neddylation and sumoylation, which makes it worthy of attention. 
Based on the known properties of ATXN3, and on the results from this work, there are 
several steps of NER, which ATXN3 may negatively regulate. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 22. Proposed model of how ATXN3 may be linking E3-ligases, neddylation, UPS and DNA repair.  
Legend: C, centrin-2; CSN, COP9/signalosome; N, NEDD8; Ub, ubiquitin; DUBs, deubiquitylating enzymes. Adapted from 
(Huang and D'Andrea, 2006). 
 
 
General Discussion 
127 
As depicted in Fig.22, ATXN3 is able to interact, through its JD domain, with both 
HHR23 proteins and XPC. ATXN3 may be competing with HHR23B for XPC, or vice-versa, 
thus disrupting the stabilisation of HHR23B/XPC/CETN2 complex.  
The hypothesis that XPC may be a substrate of ATXN3 DUB activity should also be 
considered. The interaction with ATXN3 may be proofreading XPC’s polyUb chain, 
destabilising XPC. Since the interaction with XPC occurs through the catalytic domain of 
ATXN3, reinforces this hypothesis. The competition for HHR23B, which is shields XPC 
from degradation in the proteasome, may also be occurring at this stage. 
Although the CSN seems to be the only negative regulator of CUL4A neddylation known 
to date in this pathway, the results obtained with this work suggest the possibility that 
ATXN3 may also deneddylate cullin4A. The neddylation of cullins stimulates the E3 
ligase activity of SCF complexes; if ATXN3 would be able to deneddylate cullin4a, it 
would be promoting the deactivation of E3 ligase, the CSN binding to DDB complex and 
shutting down the mechanism. Further evidence support this possibility: murine ataxin-3 
interacts directly with the C-terminal of mouse cullin-1 (MC Costa, personal 
comunication), a region that is conserved in Cul4A; interestingly, cullins are typically 
neddylated at the C-terminal region of cullins. Moreover, recently its was reported that 
worm cul-1 may participate in NER regulation (Gao, M., personal communication). The 
authors knockdowned the expression of cul-1 in C. elegans and observed an increased 
ENU-induced germ line apoptosis. Since cullin-1 is a component of the Skp1/Cullin1/F-
box (SCF) complex, it seems that the apoptosis induced by ENU is negatively regulated 
by neddylation through SCF. Altogether, all this evidence supports the possibility that, 
as a deneddylase, ATXN3 may be a negative regulator of NER. 
Apart from the polyubiquitylation on XPC stabilization, XPC is also modified, by SUMO-1, 
upon UV irradiation (Wang et al., 2005), in a DDB2-dependent manner. Interestingly, 
ATXN3 interacts also with SUMO-1. It would be interesting to evaluate if ATXN3 has any 
participation on the decision of whether or when, DDB2 ubiquitylates or sumoylates 
XPC. 
 
The hypotheses raised still lack experimental validation. Nevertheless, we believe we 
have contributed to the further understanding of the normal function of ATXN3, and 
suggest it may be a factor that connects E3 ligases, neddylation, UPS and NER.  
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Conclusions 
 
We have contributed to the understanding of the normal function of the protein 
involved in Machado-Joseph disease, ATXN3, by identifying and studying a new 
molecular interactor of normal ATXN3.  
 
In chapter 1, we established a link between ATXN3 participating or the modulation of 
DNA repair, namely the GGR pathway:.  
 
 In the study of direct protein-protein interactions of some putative interactors of 
normal ATXN3, we identified the XPC protein as a direct interactor of normal 
ATXN3. 
 Immunofluorescence assays showed that the co-localisation of the two proteins, 
in mammalian cells, was enhanced upon UV radiation. 
 No direct interaction could be observed between ATXN3 and the centrin-2 
protein, the third component of NER’s trimeric recognition complex. A transient 
interaction between the two proteins could not be ruled out. 
 The conservation of some of the human interactions observed by the C. elegans 
protein homologue of ATXN3, atx-3, allow us to conclude that the atx-3 protein 
conserves a similar structure to its human counterpart, thus of biological 
relevance. 
 Atx-3 is an ENU-responsive gene, as wild-type animals (N2) showed a significant 
upregulation of atx-3 expression, when exposed to a mutagenic agent, ENU. 
 Absence of atx-3 affects the expression levels of two potential DNA repair genes, 
ZK20.3 (RAD23 homologue) and xpc-1, and increases resistance to DNA-damaging 
conditions. 
 
 
Consistent with a role for ATXN3 in UPS regulation, we showed in chapter 2, with in 
vitro and in vivo evidence, that ATXN3 interacts, through its JD, with the neural 
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precursor cell expressed developmentally down-regulated gene 8 (NEDD8), an ubiquitin- 
like protein implicated in cullin-dependent ubiquitylation.  
The C. elegans homologue of ATXN3, atx-3, also interacts with NEDD8, indicating that 
atx-3 maintains the structural requirements for functionality, similar to the human 
protein’s. Additionally, we gathered the first evidence that ATXN3 is potentially a 
deneddylase:  
 
 We identified a novel molecular partner of normal ATXN3, NEDD8, an      
ubiquitin-like protein.  
 The interaction between NEDD8 and ATXN3 is specific and dependent of its JD; in 
contrast, interaction with monomeric ubiquitin requires the full-length ATXN3.  
 The specific interaction between the JD and NEDD8 led us to build a theoretical 
model of the complex, showing that monomeric Ub and NEDD8 could share the 
same binding site in ATXN3, which may adopt a substrate-like structure.  
 Normal ATXN3 has deneddylase activity in vitro. 
 The deneddylase activity of ATXN3 is dependent of the cysteine residue at 
position 14 (Cys14), as the mutant ATXN3C14A does not exert deneddylase 
activity in vitro, albeit the interaction with NEDD8 is maintained. 
 
 
The biological implications of these findings are being further investigated, and 
hopefully will deepen our understanding of the MJD pathogenesis. 
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Appendix 1 
 
Screening for proteins that interact with ataxin-3 using 
the yeast two-hybrid system 
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Introduction 
 
Protein interactions are intrinsic to virtually all cellular process. In cells, long-lasting or 
transient protein interactions are engaged in the control and modulation of several 
cellular processes (Van Criekinge and Beyaert, 1999). At the starting point of this work, 
little was known about the ATXN3 protein, its physiological function, or the biological 
pathways it could be involved in. Most of the information came indirectly from the 
analysis of post-mortem material of MJD patients and lymphoblastoid or neuronal cell 
lines, all largely exploring the expression and localization of ATXN3. Information 
regarding the normal sub-cellular localisation of ATXN3 pointed out that it was present 
in the nucleus and associated with the inner nuclear matrix (Tait et al., 1998), but also 
in the cytoplasm, within mitochondrial compartments (Trottier et al., 1998). All the 
clues gathered from the other polyglutamine proteins, could only provide a more 
general scenario for these types of proteins, but a more specific protein network for 
ATXN3 was still unveiled. The study of typical ubiquitylated ATXN3-containing 
aggregates in MJD brains showed the presence of proteasome subunits and chaperones 
(Schmidt et al., 2002), as well as CREB-binding protein (CBP),mastermind-like-1 or 
splicing factor SC35 (McCampbell et al., 2000; Chai et al., 2001). 
The study of normal or altered protein interactions of a given disease-related protein 
may extend our understanding of that disease. The identification, characterization and 
manipulation of protein interactions engaged by the disease-causing protein may 
eventually, lead to a therapeutic strategy. This prompted our search for the ATXN3 
biological interactome. 
 
The first known direct interacting-partners of ATXN3, HHR23A and HHR23B, were 
identified based on the yeast two-hybrid (Y2H) methodology (Wang et al., 2000). 
Confident that there were still more interactions to be unidentified, we set to perform 
an yeast two hybrid screening with normal ATXN3, in order to find new interacting 
partners that could give additional functional clues and, potentially, provide links to the 
biological pathway engaged by ATXN3. A Gal4-based yeast-two-hybrid system was used, 
in which a fusion protein comprising the DNA-binding domain of the yeast transcription 
factor Gal4 and ATXN3 (Gal4BD/ATXN3, bait) was used to screen a Gal4-activation 
domain (Gal4AD) fused to cDNAs from a human brain library (prey). Many eukaryotic 
transcription factors comprise physically separated transcription domains: the DNA 
binding domain and the activation domain. The full transcriptional activity may be 
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restored, if these transcriptional domains are brought into close proximity in the 
promoter region. Hybrid proteins comprising two interacting partners in fusion with 
binding domain and activation domain may activate the transcription of reporter genes 
under the control of a Gal4-reponsive promoter. Hence, in the system used here, a 
positive interaction would be able to activate the expression of both reporter genes 
GAL1-LacZ and GAL1UAS-HIS3, generating β-galactosidase expressing and histidine 
prototrophic (His+) yeast colonies. 
 
 
 
Methods  
 
Yeast strains 
In the yeast two-hybrid assays, Y190 (MATa, ura3-52, his3-200, ade2-101, lys2-801, 
trp1-901, leu2-3, 112, gal4Δ, gal80Δ, cyhr2, LYS2::GAL1UAS-HIS3TATA-HIS3, URA3::GAL1UAS-
GAL1TATA-lacZ) and Y187 (MATα, ura3-52, his3-200, ade2-101, lys2-801, trp1-901, leu2-
3, 112, gal4Δ, gal80Δ, met-, cyhr2, URA3::GAL1UAS-GAL1TATA-lacZ) yeast strains were 
used for the library screening and mating assays, respectively (Harper et al., 1993). The 
Y190 strain contains two different reporter genes, regulated by different GAL4–
dependent promoters, reducing leakiness of gene expression. The HIS3 reporter is under 
the control of GAL1UAS and a minimal promoter, containing both TC (constitutive) and 
TR (regulated) HIS3 TATA boxes (Flick and Johnston, 1990). The LacZ reporter is highly 
regulated by the intact GAL1 promoter (including the GAL1UAS and GAL1 minimal 
promoter). 
 
Yeast culture media 
All media used for yeast growth and manipulation were prepared as described in the 
Yeast Protocols Handbook (Clontech). Selection media were prepared with all amino 
acids except tryptophan (W), leucine (L) or histidine (H or His) (SC-aa). These nutrients 
were added separately depending on the necessary selection medium. The leaky HIS3 
expression on the yeast strains was controlled by including 3-amino-1, 2, 4-triazole (AT) 
in the medium to suppress background expression of IGP dehydratase (HIS3 gene 
product). The necessary concentration of AT for each yeast two-hybrid construct used 
was determined empirically. 
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Yeast two-hybrid bait constructs 
The bait plasmids used for the library screen, pAS1-2/ATXN3 var2.1/14Q) and pAS1-
2/ATXN3 var2.1/40Q) were prepared using classical cloning techniques (Sambrook and 
Russel, 2001). The complete coding sequences of isoform 1 ATXN3 (aa 1-364) (referred 
as ATXN3 var2.1) with a normal range of 14 or 40 glutamines residues were cloned in 
frame with GAL4BD domain of the pAS1-2 vector (kindly provided by Dr S.Elledge). The 
cDNA inserts were completely digested from initial pBluescript(SK) vector using BamHI 
and XhoI restriction sites and cloned in frame into BamHI and SalI site, a complementary 
XhoI site in pAS1-2 vector. An N-terminal fragment of ATXN3 pAS1/2.1N (aa 1-247) was 
also generated. The initial cDNA insert in pBluescript(SK) encoding full-length ATXN3 
was completely digested with BamHI and BglII was sub-cloned into BamHI in order to be 
in frame in GAL4BD coding sequence of pAS1. These bait constructs have a TRP1 gene 
that allows auxotrophic Y190 yeast strain to grow in media lacking tryptophan. The bait 
constructs were confirmed by automated sequencing and tested for its toxicity in the 
yeast and self-activation of the two reporter genes, HIS3 and LacZ. 
 
Self-activation assay 
In order to assess the ability of the bait and prey constructs to self-activate Y190 
reporter genes, pre-transformed yeasts were spread or plated as dots in selective drop-
out media SC-WH or SC-LH, supplemented with a initial concentration of 20 mM AT, 
incubated at 30 ºC, for five days, and then assayed for β-galactosidase expression. For 
the bait or prey constructs that showed initial self-activation properties, the proper AT 
concentration to eliminate this property were determined empirically. 
 
Yeast protein extraction and analysis 
To prepare protein extracts for immunoblotting, yeasts were grown in the respective 
drop-out media (SC-aa), to mid-log phase (OD600=0.5-1.5), and proteins were extracted 
using the glass beads disruption protocol as described (Dunn and Wobbe, 1993). Briefly, 
a 600 μl-yeast pellet was resuspended in three volumes of glass bead disruption buffer 
[20 mM Tris-HCl pH7.9, 1 mM EDTA, 10 mM MgCl2, 5% glycerol, 300 mM (NH4)2SO4, 1 mM 
DTT, 4 mM PMSF and yeast inhibitors concentrate (100 mM benzamidine, 10 mg/mL 
leupeptin, 10 mg/mL aprotinin)] and 150 μL of acid-washed glass beads. Then, six cycles 
of 1 min vortexing/1 min ice incubation were performed. After centrifugation, 
supernatants were recovered and the pellets were resuspended with 400 μL of 
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ressuspention buffer B (8 M urea, 0.1 M NaH2PO4, 10 mM Tris-Cl pH6.8). Proteins were 
diluted with sample buffer 2X or 4X, as necessary, and analysed by SDS-PAGE and 
immunoblotted. 
 
Western blots: yeast expressed proteins 
The expression of the bait and prey proteins was confirmed by western blot analysis. 
Protein extracts were obtained as described in the previous section. Proteins were 
separated by SDS-PAGE, transferred to a nitrocellulose or PVDF membrane (GE 
Healthcare) and immunoassayed. Generally, prey Gal4AD-fusion proteins were detected 
with anti-HA antibody (sc-7392, Santa Cruz Biotechnology), unless otherwise stated. The 
bait proteins were detected with a specific antibody. The blocking reaction of the 
membrane was generally performed with 5% SM/TBS-T (5% skimmed milk in Tris-
buffered saline 1X (TBS), 0.05% Tween 20), for 1 hour, at 4 ºC. Antibody dilutions were 
carried out as described in Table A4. Incubations of primary antibodies were performed 
overnight, at 4 ºC, unless otherwise stated. Detection was carried out with ECL (GE 
Healthcare). 
 
Human library screening 
The human brain cDNA library used in the yeast two-hybrid screen, “Human brain 
MATCHMAKER cDNA library” in BNN132 E. coli (Clontech) and was kindly provided by Dr. 
Peter Heutink, Amsterdam. The cDNAs were primed with XhoI-(dT)15 oligo from a pool of 
mRNAs obtained from a whole brain and directionally cloned into the XhoI-EcoRI sites of 
pACT2 vector. The library cDNA size range was 0.5-4.2 kb, with an average cDNA size of 
2.0 kb. The library had been re-titered to 2.0x108 cfu/mL, representing 3.5x106 
independent clones. The optimal transformation efficiency and the total number of 
transformants screened with each construct were determined; two serial dilutions (1/40 
and 1/80) of the transformation, using three micrograms of the library DNA and each 
construct, were plated in SC-WL plates, yield 1.2x104 - 1.5x104 cfu/μg DNA, between the 
two bait constructs tested.  
After the heat-shock, cells were plated in selective plates (SC-WLH/20 mM AT), 
incubated at 30 ºC, for six days, scored, and then re-incubated for a total of ten days, 
to detect weaker interactions. The positive colonies were re-plated on selective 
medium, analysed for LacZ activation, and the transformants that became blue were 
selected to be further studied.  
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Yeast transformation 
Y190 and Y187 were transformed using the lithium acetate method (Gietz and Woods, 
2002). An average-size yeast colony (0.5-2 mm) of Y190 or Y187 was used to inoculate 
rich YPAD medium and was grown at 30 ºC overnight; pre-transformed yeasts were 
grown in drop-out medium to keep selective pressure on the plasmid. Overnight cultures 
were diluted in YPAD to an OD600=0.3 and then allowed to reach logarithmic growth, 
OD600= 0.5-0.6. Harvested cells (2000 rpm) cells were washed twice with sterile water, 
and resuspended in 1.2 volumes of fresh made 100 mM lithium acetate (LiAc). The 
following reagents were added, in this order, to 50 μL competent yeast suspension: 240 
μL of 50% PEG 3350 (m/v), 36 μL LiAc 1 M, 50 μL sheared salmon sperm DNA 2 mg/mL, x 
μL of plasmid (1-5 μg) and 50-x μL of sterile water. Each tube was vortexed vigorously 
for 1 min, or until the pellet was completely resuspended, and then the cells were 
allowed to recover at 30 ºC, for 30 min. Cells were then heat-shocked at 42 ºC for 30-40 
min. Finally, cells were briefly centrifuged (2000 rpm, 2 min), resuspended in 800 μL of 
YPAD and plated onto the appropriate selective medium. 
 
β-galactosidase colony-lift filter assay 
The β-galactosidase assay (Breeden and Nasmyth, 1985) was performed by colony-lift 
filter assay. The assay was either performed directly on fresh plates with single colonies 
or with dots of yeast transformants (WH+, LH+ or WLH+), grown on selective medium, 
supplemented with the sufficient AT concentration. A dry nylon membrane was placed 
over the grown plate surface to be assayed; when the membrane was evenly wetted, it 
was lifted and submerged in N2 (l) for 10 s, to allow cell permeabilisation. Afterwards, it 
was thawed at room temperature and placed, colonies side up, in a filter paper pre-
soaked with Z-buffer (16.1 mg/mL Na2HPO4.7H20, 5.5 mg/mL NaH2PO4.H2O, 0.75 mg/mL 
KCl, 0.25 mg/mL M2SO4, pH 7.0), supplemented with 1 mg/mL X-Gal (5-bromo-4-chloro-
3-indolyl-β-D-galactopyranoside) and 38.6 mM β-ME (final). Filters were incubated 1-24 
hours at 30 ºC, and then analysed for the presence of blue colonies (LacZ+ 
transformants). 
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Yeast plasmid segregants 
In order to evaluate if the putative positive HIS+/blue transformants obtained in the 
library screening were theresult from a true positive interaction, dependent of both 
bait and library plasmid, it was necessary to obtain yeast plasmids segregants containing 
only the library “fished” plasmids. For this, the plasmids DNA mixture (bait + library 
cDNA plasmids) was isolated, using zymolyase method, then they were used to 
transform E. coli, from which they were subsequently isolated, and used to re-transform 
yeast cells. These prey segregants were tested for specificity on the activation of Y190 
reporter genes when co-transformed with the bait plasmid or with the empty bait 
vector, pAS1. 
 
Yeast plasmid DNA extraction by generation of spheroplasts 
The H+/blue yeast transformants were grown overnight, at 30 ºC, on the appropriate 
liquid selective medium. All centrifugations were carried out at 14000 rpm at 4 ºC. Cells 
from overnight cultures (1.5 mL) were harvested, washed with 1 mL of Z-buffer and 
then re-centrifuged. Cells were then resuspended with 200 μL Z-buffer/0.1% β-
mercaptoethanol/zymolyase and incubated 1 hour, at 37 ºC. Cells were further lysed by 
adding 400 μL of lysis buffer (0.2 M NaHO/1% SDS) and incubated on ice for 5 min. 
Proteins were then precipitated with 3 M KCH3COO pH 5.5 and separated by 
centrifugation. An equal volume of phenol:cloroform:isoamyl (25:24:1) was added to the 
colleted supernatant and the DNA was precipitated from the aqueous phase with 2-
propanol for 30 min at -20 ºC. DNA was washed with 70% ethanol and air-dried. TE-
dissolved DNA was used for transformation of E. coli by electroporation. 
 
Yeast mating 
For the yeast mating assay (Bendixen et al., 1994), fresh average-size yeast colonies 
(0.5-2 mm) of each mating type were used to inoculate 500 μL of YPAD; inoculums were 
vigorously vortexed and incubated overnight at 30 ºC with high shaking. Afterwards, 10 
to 20 μL of the mating culture were spread or platted as dots (5-10 μL) in selective SC-
WLH/AT plates and incubated, at 30 ºC, for four to five days to allow selection of 
diploid cells with a positive interaction. 
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Results 
 
Study of ATXN3 encoding bait constructs for yeast cell toxicity and self-activation 
properties 
Three yeast two–hybrid bait constructs were prepared for the screening of a human 
brain cDNA library (Table A1). The pAS1-2 plasmid (kindly provided by Dr S. Elledge) 
was used for the construction of the expression vectors pAS1/2.1N, pAS/ATXN3 
var2.1(14Q) and pAS1/ATXN3 var2.1(40Q). The bait plasmids encode for Gal4BD N-
terminal-fusion proteins of (1) a N-terminal fragment of ATXN3 including 247 amino 
acids (Gal4BD-2.1N), (2) full-length ATXN3 protein with 14 glutamines (Gal4BD-ATXN3 
var2.1(14Q)), and (3) full-length ATXN3 protein with 40 glutamines (Gal4BD-ATXN3 
var2.1(40Q)). To determine if the constructs were appropriate for an Y2H screening or 
for direct interaction assays, their effect upon yeast growth (toxicity) was evaluated. 
Yeast were transformed with each bait construct and allowed to grow on selective 
media SD-W, during five days, at 30 ºC; the average diameter was evaluated for the 
grown colonies, during this period. The fusion control interacting partners, Gal4BD-TSCII 
and Gal4AD-TSCI (van Slegtenhorst et al., 1998), or Gal4BD-SNF4 and Gal4AD-SNF1 
(James P et al., 1996), were previously reported not to affect yeast growth. Both 
pAS1/2.1N and pAS1/ATXN3 var2.1(40Q) bait plasmids did not affect significantly the 
yeast growth (Table A1); however, yeast transformed with pAS1/ATXN3 var2.1(14Q) 
grew less in SC-W plates, denoting some toxicity of the GAL4BD-ATXN3 var2.1(14Q) 
protein over-expression in yeast.  
The bait constructs were also evaluated for their ability to self-activate the 
transcription of the reporter genes, GAL1UAS-HIS3 and GAL1-LacZ. It should be noted 
that, Y190 reporter yeast strain is marginally prototrophic for histidine, but the addition 
of a competitive inhibitor of the HIS3 product (IGP dehydratase), 3-aminotriazole (AT), 
strengthens the sensitivity of the reporter gene, rendering Y190 auxotrophic to histdine 
(Brent and Finley, 1997). Yeast transformed with the bait plasmids were plated in 
selective plates, SC-W-H, supplemented with 20 mM of 3-aminotriazole (SC-WH/20AT) 
and incubated, for five days. Self-activation of GAL1-LacZ expression induced by the 
bait plasmids was also evaluated, and the assay for β-galactosidase (β-gal) activity 
performed in the colonies grown in SC-WH/20AT.  
Yeast transformants expressing Gal4BD-ATXN3 var2.1(14Q) and Gal4BD-ATXN3 
var2.1(40Q) were unable to grow in selective SC-WH/20AT plates, but those expressing 
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Gal4BD-2.1N (ATXN3 N-terminal fragment), were able to significantly activate the 
GAL1UAS-HIS3 reporter leading to visible growth of large (1mm diameter) yeast colonies 
in SC-WH/20AT plates.  
The β-galactosidase assays confirmed that none of the bait constructs encoding full-
length ATXN3 could activate the Y190 reporter genes, whereas pAS1/2.1N bait could 
(Table A1). Ideally, the bait plasmids should not be able to autonomously activate the 
GAL1UAS-HIS3 and GAL1-LacZ reporter genes. Hence, the pAS1-2.1N was not used in the 
Y2H library screening. Later, the histidine auxotrophy of pAS1-2.1N transformants was 
restored with 140 mM 3-aminotriazole, and this bait plasmid was used in direct protein 
interactions assays; an interaction was considered positive when generating colonies in 
SC-WLH/140AT selective medium turned blue in β-gal assay. 
 
SC-WH/20AT 
Bait construct SC-W 
Growth (Ø) β-gal assay 
pAS1/2-1N +++ +++ (1 mm) B 
pAS1/ATXN3 var2-1(14Q) + ± (<0.5 mm) W 
pAS1/ATXN3 var2-1(40Q) +++ ± (<0.5 mm) W 
 
 
Table A1. Evaluation of bait toxicity in yeast growth and reporter gene self-activation. Yeast toxicity of 
each construct is reported in SC-W column, where the average diameter (Ø, mm) is indicated; the self-
activation of the nutritional reporter gene (GAL1UAS-HIS3) by the bait Gal4BD-fusions was evaluated in 
selective plates (SC-WH/20AT); the self-activation of the second reporter gene GAL1-LacZ was assessed by 
colony−lift filter β-galactosidase assay. Legend: +, growth; B, blue; W, white. 
 
 
The expression of the bait constructs in yeast was confirmed by western blot (Fig.A1), 
using monoclonal anti-Gal4 DNA-BD antibody (Clontech) and specific polyclonal anti-
MJD2.1 antibody produced in our lab (Fig.A5 of Appendix 2). The full-length Gal4BD-
ATXN3 var2.1(40Q) and the Gal4BD-2.1N fusion proteins were expressed and presented 
the expected molecular weights. However, the expression of the Gal4BD-ATXN3 
var2.1(14Q) protein could not be detected, even though, the pAS1 vector used in the 
cloning process has a strong ADH1 promoter, which induces high-level expression of 
sequences cloned downstream (Ammerer, 1983). Automated sequencing confirmed that 
the ATXN3 insert was in frame with the Gal4BD sequence; we assumed that the Gal4BD-
ATXN3 var2.1(14Q) protein was correctly expressed albeit at very low levels, due to its 
toxicity in yeast. Previous studies showed that ATXN3 was able to interact with two 
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proteins, HHR23A and HHR23B, in the Y2H system (Wang et al., 2000). To confirm that 
pAS1/ATXN3 var2.1(14Q) was indeed expressed in the yeast and, therefore, suitable for 
the two-hybrid assays regardless of its inherent toxicity, the direct interaction between 
Gal4BD-ATXN3 var2.1(14Q) and Gal4AD-HHR23B was tested. We observed a positive 
interaction between the two Gal4-fusion proteins, ATXN3 and HHR23B, showing that the 
ATXN3 bait constructs obtained by us could be used in the yeast library screening.  
 
Screening for molecular interactors of ATXN3 
In order to identify new human proteins that could interact with ATXN3, we screened a 
human brain cDNA library with both pAS1/ATXN3 var2.1(14Q) and pAS1/ATXN3 
var2.1(40Q) plasmids encoding full-length ATXN3 with a normal-sized polyQ region.  
 
 
Figure A1. Western blotting analysis of bait 
Gal4BD-fusion proteins in Y190 yeast. 
Protein extracts were resolved by SDS-PAGE, 
transferred to nitrocellulose membrane and 
immunoblotted with polyclonal anti-MJD2.1, 
or monoclonal anti-Gal4 DNA-BD (Clontech). 
The Gal4BD-fusion proteins expressed in yeast 
showed the expected molecular weights: 47 
kDa for the N-terminal fragment of ATXN3 
(Gal4BD-2.1N) and 67 kDa for the Gal4BD-
ATXN3 var2.1(40Q) with; Gal4BD alone showed 20 kDa as expected. The Gal4BD-ATXN3 var2.1(40Q) fusion-
protein could not be detected by western blot. Y190 indicates the lane corresponding to protein extracts of 
untransformed yeast. Detection was carried out with ECL (GE Healthcare). 
 
 
Since the pAS1/ATXN3 var2.1(14Q) showed some toxicity in yeast cells, co-
transformations of this bait plasmid with the library prey clones were done, rather than 
sequential transformations. The high transformation efficiency obtained for this 
construct (1.5x104 cfu/DNA), indicates that co-expression with a prey plasmid seems to 
decrease toxicity of pAS1/ATXN3 var2.1(14Q). As a positive control of the system, we 
used the direct interaction between the Gal4-fusions of tuberin (pGBT9/TSCII) and 
hamartin (pGAD/TSCI) involved in tuberous sclerosis, in which they are known to 
interact (van Slegtenhorst et al., 1998). 
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Yeast co-transformed with pAS1/ATXN3 var2.1(14Q) or pAS1/ATXN3 var2.1(40Q) and 
with Gal4AD-tagged cDNA expression library were plated in SC-WLH/20AT selective 
plates. A total of 4.3×104 library cDNAs were screened with pAS1/ATXN3 var2.1(14Q), 
and 3.3×104 with pAS1/ATXN3 var2.1(40Q) bait plasmid. After a six day period of 
incubation, five His+ colonies were picked pAS1/ATXN3 var2.1(14Q) and four His+ were 
detected from pAS1/ATXN3 var2.1(40Q) screening plates, and re-streaked in fresh SC-
WLH/20AT plate (masterplate). The original screening plates were re-incubated for 
another four days, to allow the growth of transformants comprising weaker interactions. 
After a ten day period of incubation, a total of ten and six His+ prototrophics were 
obtained from the library screenings, with pAS1/ATXN3 var2.1(14Q) and pAS1/ATXN3 
var2.1(40Q), respectively. These 16 His+ co-transformants were replated in fresh SC-
WLH/20AT and then evaluated for the activation of the LacZ reporter using the β-gal 
assay; all the preys exhibited β-galactosidase activity, and were considered true 
His+/blue positive clones (Fig.A2). 
 
Isolation and identification of the putative prey interactors 
To identify and characterise the protein interactors of ATXN3, isolated in the library 
screening, the prey plasmids were purified from yeast. Since more than one prey 
plasmid could be present in the same His+/blue positive clone, it was necessary to 
extract yeast library cDNAs and generate yeast segregants. 
 
 
Figure A2. Yeast two-hybrid interactions of ATXN3 identified in the library screen. Positive interactions 
were identified by colony growth in selective SC-WLH/20AT medium and β-galactosidase assay. A total of 16 
of putative interactors were identified using normal-sized ATXN3 var2.1. Interaction between tuberin (TSCI) 
and hamartin (TSCI) was used as positive control of the assay.  
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His+/blue positive clones were grown in liquid SC-WL and the cDNA prey plasmids were 
extracted from these cultures, using zymolase method and then subsequently 
electroporated into HB10 E.coli. Three colonies of each bacterial transformation  were 
picked, and the prey plasmids were digested with BglII for insert excision. Comparison 
of the digestion patterns of the prey plasmids led to the selection of several cDNA 
clones (e.g. 1a, 1b and 1c sub-clones). The cDNA plasmids presenting different digestion 
patterns were selected, in order to further understand the difference obtained.  
A total of 14 different prey plasmids were defined from the initial His+/blue clones 
obtained from the screen with pAS1/ATXN3 var2.1(14Q); 10 prey plasmids were chosen 
from the restriction digestion analysis of cDNA from the His+/blue clones isolated in the 
pAS1/ATXN3 var2.1(40Q) screening. All prey plasmids were re-transformed in yeast, and 
none of these prey segregants showed yeast toxicity or self-activated the expression of 
HIS3 and LacZ reporter genes by itself. Hence, the direct interactions between each 
prey segregant and the original bait constructs were assessed. Only four out of the 14 
yeast segregants expressing a prey plasmid (sub-clones) retrieved from screening 
performed with pAS/ATXN3 var2.1(14Q) bait were able to reproduce the initial results, 
indicating that, six out of the initial ten His+/blue clones identified (Fig.A2) represented 
false positive interactions. The four prey segregants, which reproduced the initial 
positive interactions with the pAS1/ATXN3 var2.1(14Q), also exhibited positive 
interaction with pAS1/ATXN3 var2.1(40Q); yeast co-transformation of these prey 
plasmids and the pGBT9/TSCII control bait produced no positive interaction, reinforcing 
the specificity of the His+/blue positive interactions found.  
For further confirming, yeast mating assays were performed between Y187 (Matα) 
expressing each of the prey plasmid and Y190 (Mata) expressing Gal4BD/ATXN3 
var2.1(14Q). Two of the mating diploids were negative for the expression of both 
reporter genes (His-/white).  
In the case of the yeast segregants expressing prey plasmids isolated from the library 
screening performed with pAS/ATXN3 var2.1(40Q), all, with the exception of one, 
reproduced positive interactions. Hence, five out of six His+/blue clones isolated from 
the initial screening were potentially true positive interactors of ATXN3.  
 
In conclusion, from the initial 16 putative interactors selected from the library 
screening with Gal4BD/ATXN3 bait plasmids, only seven were found to potentially 
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encode a true interactor of normal-sized ATXN3. For simplicity, a flowchart of the work 
performed is presented in Figure A3.  
 
 
Yeast two-hybrid screening 
 147 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure A3. Flowchart representing the yeast two-hybrid analysis performed in this work. Two bait constructs 
encoding normal ATXN3 were designed, characterized and used to screen a yeast two-hybrid human brain cDNA library. 
Sixteen positive clones were isolate; further analysis confirmed that, seven of these could encode true positive 
interactors of normal ATXN3. Automated sequencing and bioinformatic searches were used to further identify, and 
characterized the DNA and/or protein sequences of each of these seven positive prey clones. 
Bait constructs design and characterisation 
test yeast toxicity + HIS3/Lacz gene reporter self-activation 
bait protein expression in yeast: WB 
pAS1/ATXN3 var2.1(14Q) pAS1/ATXN3 var2.1(40Q) 
 His+ prototrophic blue colonies 10 6 
Yeast DNA extraction (spheroplasts generation) 
HB101 E. coli transformation by electroporation 
Confirmation of His+/blue positive colonies: 
Replating in fresh SC-WLH/20AT plates + β-gal assay 
Selection of three isolated colonies per yeast prey DNA and minipreps 
BglII restriction pattern analysis: excision of prey 
Selected patterns for each prey isolated (sub-clones): (left and right boxes) 
1b 
2c 
3c 
4c 
5a, c 
6a, b, d 
8a, b, e 
9c 
10a 
Total: 14 
1Ea, b 
2Ea 
3Ea, b 
4Ea, c 
5Ea 
6Ea 
Total: 9 
5c 
6a 
Total: 2 
1Eb 
2Ea 
3Ea 
4Ec 
6Ea 
Total: 5 
Protein (Blastx) and nucleotide (Blastn) and database bioinformatic searches 
Theoretical ORF definition with Expasy proteomics tools 
pACT2 library co-transformation 
SC-WLH/20AT growth during 10 days + β-gal assay assay 
1b 
2c 
3c (&) 
4c (&) 
5c (#) 
6a (&, #) 
8a 
9c 
10a 
Total: 9 
1Eb (&) 
2Ea (&) 
3Ea (&) 
4Ec (&) 
5Ea 
6Ea (&) 
Total: 6 
Confirmation of His+/blue phenotype of double transformants: 
Automated sequencing: some sub-clones had to the same DNA sequence 
- 5a=5c, 6a=6b=6d, 8a=8b=8e 
- 1Ea=1Eb, 3Ea=3Eb, 4Ea=4Ec 
Yeast re-(co)transformation (positive assay = &) and mating assays (positive assay = #) of bait and selected prey 
Growth in SC-WLH/20AT + β-gal assay 
.Positive prey clones confirmed.  
Appendix 1 
148 
Sequence analysis of prey plasmids  
Automated sequencing of all prey plasmids revealed that most sequences originated 
from the initial His+/blue clones corresponded to the same sequence. Using the BLASTx 
program, the protein databases were blasted with the translated prey, in order to 
identify the protein encoded. Some of the sequences did not show any similarity with 
any known protein sequence, at the time of the analysis. In these cases, a BLASTn 
search was performed. Initially, a control test for the quality of the cDNA library used 
was performed; PCR-amplification of the library DNA with specific primers for the 
coding sequence of HHR23 protein revealed that this gene was indeed represented in  
the library. However, none of the prey sequences identified corresponded to HHR23 
encoding sequences. The results are summarized in Table A2. 
The BLASTn search of the prey sequences, revealed some of the alignments to be 
potentially interesting, such as the human PPP2R2B gene implicated in spinocerebellar 
ataxia type 12 (SCA12) (Holmes et al., 1999) (prey clone 4Ec). PPP2R2B gene encodes 
for a brain-specific regulatory subunit B, isoform β of protein PP2A, a serine/threonine 
phosphatase involved in cell cycle regulation, cell morphology, development and 
regulation of specific signal transduction (Janssens and Goris, 2001). The PPA2 had been 
suggested to modulate GSK-3β−dependent phosphorylation pathways in Wnt signalling 
(Ikeda et al., 2000). Interestingly, GSK-3β another serine/threonine phosphatase, has 
been recently reported to interact directly with ATXN3, leading to its phosphorylation 
(Fei et al., 2007). 
The prey clone 2Ea aligned with the 3’-UTR of WW-domain containing protein 2 (WWP2) 
encoding sequence. WWP2 protein is a member of the E3 HECT-type ubiquitin ligase 
family (Xu et al., 2004). Interestingly, WWP2 has been reported to interact with 
atrophin-1 (Wood et al., 1998) and more recently this interaction has been replicated in 
an high-thoughtput screening for protein involved in hereditary ataxias and disorders 
with Purkinjie cells associated-degeneration. Close proximity between the ATXN3- and 
ATN1-specific interaction clusters, the latter comprising WWP2 protein (Lim et al., 
2006), was observed. 
The prey clone 5c isolated with the Gal4-ATXN3 var2.1 (14Q) bait, aligned with the 3’ 
untranslated region of the gene encoding NAP1L1, a nucleosome assembly protein 1-like 
1, which seems to be involved in DNA replication, cellular proliferation and chromatin 
remodelling, acting like an histone chaperone (Park et al., 2005).  
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Table A2. Prey plasmids selected from the library screening. In the table are displayed the prey cDNA clones obtained from the library screening with pAS1/ATXN3 var2-1 (14Q) and 
pAS1/ATXN3 var2-1 (40Q) bait plasmids; a code name was assigned to each prey (second column). All seven preys generating His+/blue positive clones were sequenced; each sequence 
determined (length, bp in the second column) was analysed against nucleotide and/or protein sequence databases, using the BLAST programs. The number of amino acids encoded by each 
cDNA prey plasmid, considering the three open reading frames (ORF), is presented also (fourth column). The theoretical DNA sequence translations were performed with ExPASy proteomics 
tools (http://expasy.org/tools/#translate). 
Prey  Bioinformatic data  Encoded prey 
Bait 
Code name, bp   Results (BLASTn program)   ORF = number of aa 
    
    5c, 395 
  
 NAP1L1 variant 2, mRNA: 3'-UTR alignment  
 
  
+1 = 55 aa-STOP 
+2 = 33 aa-STOP 
+3 = 7 aa-STOP 
    
    
A
T
X
N
3
 
v
a
r
2
-
1
(
1
4
Q
)
 
6a, 406 
  
Alu contamination Warning 
  
+1 = 33 aa-STOP 
+2 = STOP 
+3 = 39 aa-STOP 
    
    
1Ea, 539 
  
Protein G subunit β1/γ2 interacting factor 3, partial cds 
  
+1= 6 aa-STOP 
+2 = 3 aa-STOP 
+3 = 12 aa STOP 
    
    
2Ea, 569 
  
WW domain containing E3 ubiquitin protein ligase 2 (WWP2), variant 1 
and 2, mRNAs: 3'-UTR alignment 
  
+1 = 17 aa-STOP 
+2 = 2 aa-STOP 
+3 = 32 aa-STOP 
    
    
3Ea, 544 
  
Na+/K+ATPase subunit β1 (ATP1B1), mRNA  
  
+1 = 9 aa-STOP 
+2 = 4 aa-STOP 
+3 = 168 aa (from 95 to 262) 
    
4Ec, 558  
  
Phosphatase protein 2 (PPA2), regulator subunit B, isoform β (PPP2R2B), 
neuronal isoform, mRNA   
+1 = 6 aa-STOP 
+2 = 132 aa (from 273 to 404) 
    
A
T
X
N
3
 
v
a
r
2
-
1
(
4
0
Q
)
 
6Ea, 597 
 
Proteasome subunit 26S non-ATPase, 12 (PSMD12), p55 regulatory subunit, 
transcript 1, mRNA    
+1 = 5 aa-STOP 
+2 = 138 aa (from 40 to 174) 
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NAP1L1 has been reported to interact with p300 (Asahara et al., 2002), a known 
interactor of ATXN3 (Li et al., 2002). However, the alignments corresponded to the 3’-
untranslated region of the gene encoding NAP1L1 protein.  
The most promising alignment was obtained with BLASTn for the 3Ea sequence. The 
analysis identified a sodium/potassium-transporting ATPase subunit β1 (Na+/K+ATPase 
subunit β1). However, when we determined the aminoacidic sequence encoded by 
frame +1, the frame in which the cDNA prey clone was actually being translated in 
yeast, we recurrently found that it did not correspond to the coding sequence of the 
gene identified by the BLASTn search, i.e., the alignments identified by BLASTn were 
not corresponding the fusion proteins being expressed. Some BLASTn alignments were 
obtained also with untranslated regions of databases sequences or even with Alu 
elements, which are genomic, transcriptionally silent sequences (Hagan et al., 2003). 
We explored the possibility that the library had some systematic construction error 
inducing a frameshift by reverse-sequencing all the preys identified; we could not 
identify such a systematic alteration, like an insertion or deletion, in the upstream 
sequence of the prey vector (pACT2) that could explain the truncated peptides found. 
 
 
 
Discussion 
 
Several methodologies have been established in order to assess protein-protein 
interactions. Among the high-throughput tools for the study of protein-protein 
interactions, the yeast two-hybrid system (Y2H) is an in vivo technology that enables 
the identification of interacting proteins, confirm putative interactions, and define the 
directly involved interacting domains (Fields and Song, 1989). Being a scalable assay, it 
makes possible the screening of interactions among a large pool of encoded proteins, in 
a rather fast way (Fields, 2005).  
The most striking advantage of the Y2H assays is the immediate access to the gene 
encoding the interacting, “fished” proteins. This is also a sensitive method, able to 
detect stable as well as transient interactions. As an in vivo tool, proteins tested by the 
Y2H, are more likely to be in their native conformations, thus enabling the detection of 
physiological significant interactions. The major drawback associated with this 
technique is the high percentage of false positives (and negative) ~50% (Deane et al., 
Yeast two-hybrid screening 
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2002) among the interactions retrieved. The Y2H detects protein interactions depicted 
by (1) overexpressed bait and prey proteins (2) fused to transcriptional activators, (3) in 
yeast nucleus. Therefore, Y2H may identify protein interactions potentially occurring in 
an unnatural environment and the absence of some post-transcriptional modifications 
which may not occur in the yeast may lead to protein interactions with no biological 
significance or, in contrast, lead to false negative results.  
Since its first version, the Y2H system has been constantly improved. The incorporation 
of multiple independent reporter genes to measure transcription activation, the design 
of different DNA-binding sequences at the promoters of the different yeast reporter 
genes, the use low-copy number vectors circumventing the protein overexpression and, 
importantly, the retesting interacting pairs in fresh yeast, allowed a significant 
improvement of the data quality gathered in the Y2H experiments (Cusick et al., 2005). 
Despite the skepticism regarding Y2H, when it is coupled to complementary and 
confirmatory experiments as the GST-pull-down, co-immunoprecipitation and co-
localisation assays of the endogenous proteins, the improved Y2H systems are a valuable 
tool and still largely applied in protein-protein interactions studies.  
The complete genome sequencing of several organisms enabled the high throughput 
analyses and led to the comprehensive determination of all protein–protein interactions 
characteristic of an organism, at a given time, the interactome. For organisms as 
Sccharomyces cerevisiae (Uetz et al., 2000; Ito et al., 2001), Helicobacter pylori (Rain 
et al., 2001), C. elegans (Walhout et al., 2000; Li et al., 2004), Drosophila 
melanogaster (Giot et al., 2003) and Homo sapiens (Colland et al., 2004; Rual et al., 
2005) drafts of the protein-protein interactions maps were possible using integrated 
high throughput Y2H-based screens coupled with other experimental procedures. 
Moreover, the definition of the interactome of polyQ proteins as huntingtin (Goehler et 
al., 2004; Kaltenbach et al., 2007) and ataxin-1 (Lam et al., 2006) has recently 
successfully been achieved applying a Y2H-based approach.  
 
Here, we performed a yeast two screening in order to identify molecular partners of 
ataxin-3 in human brain tissue using two bait plasmids encoding proteins of different 
polyQ lengths. Considering the high titre of the re-amplified cDNA library used and the 
suitability of the plasmids prepared, it was expected that some novel interaction(s) 
would be identified. Unfortunately, this was not the case. From the initial His+/blue 
clones isolated in the screening, 56% (9 out of 16) were false positive, i.e., were unable 
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to reproduce the screening interactions observed with the baits when re-tested by co-
transformation and mating assays. Although high, this value is, unfortunately, consistent 
with the literature (Deane et al., 2002).  
The remaining seven clones showed consistent interactions, and interestingly, some 
with both bait proteins. With the subsequent bioinformatic analysis against protein or 
nucleotide databases, however, we were confronted with very disappointing results. 
The prey sequences isolated were recurrently interacting through small peptide 
fragments, which did not correspond to the open reading frame of the genes found to 
correspond to the prey sequence after a BLASTn search. In most of the preys, soon after 
the Gal4BD, the frame had a premature stop codon. No sequence alteration was 
identified upstream the multiple cloning site of pACT2 that could, somehow, be causing 
the frameshifts of the prey sequences isolated. Of course, if the bait choice and its 
characterisation are critical for the success of a yeast two-hybrid screening, the quality 
of the cDNA library used should not be undervalued and this was the main pitfall of our 
study. The fact that we found a cDNA sequence that aligned significantly with Alu 
elements, led us to suspect that the cDNA library was contaminated with genomic 
sequences, evidencing its poor quality. Albeit the number of the independent clones 
screened should had been higher, two normal-sized ATXN3 proteins were used, which in 
a sense could be considered as if the library was screened twice, independently, and 
less false positives should be expected. After automated sequencing, we observed that 
most of the clones selected corresponded to the same cDNA sequence. Again, this fact 
led us to suspect about the quality of the library used, namely its high redundancy, 
where a cloning bias towards the more frequent cDNA transcripts cannot be ruled out.  
Hence, and since we had validated our prey constructs, we considered it more 
strategical to address a set of candidates interactors based on current hypothesis set for 
ataxin-3 function (described in chapter 1 and chapter 2).  
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Primer name Sequence 5’→ 3’ 
attB1-HHR23A GGGGACAAGTTTGTACAAAAAAGCAGGCTGGATGGCCGTCACCATCACGCTG 
attB2-HHR23A GGGGACCACTTTGTACAAGAAAGCTGGGTCTCACTCGTCATCAAAGTTCTG 
attB1-HHR23B GGGGACAAGTTTGTACAAAAAAGCAGGCTGGATGCAGGTCACCCTGAAGACC 
attB2-HHR23B GGGGACCACTTTGTACAAGAAAGCTGGGTCTCAATCTTCATCAAAGTTCTG 
attB1-MJD GGGGCAAGTTTGTACAAAAAAAGCAGGCTGGATGGAGTCCATCTTCCACGAG 
attB1-221cATXN3 GGGGACAAGTTTGTACAAAAAAGCAGGCTGGATGTTAGACGAAGATGAG 
attB2-MJD1.1 GGGGACCACTTTGTACAAGAAAGCTGGGTCTTATTTTTTTCCTTCTGTTTT 
attB2.1-XPC-D1 GGGGACCACTTTGTACAAGAAAGCTGGGTCTTAATAGAGGCTGGTCTTTTTCAT 
attB1-XPC GGGGACAAGTTTGTACAAAAAAGCAGGCTGGATGGCTCGGAAACGCGCGGCCGGC 
attB2-XPC GGGGACCACTTTGTACAAGAAAGCTGGGTCTCACAGCTTCTCAAATGGGAACAG 
attB1.2-XPC-D2 GGGGACAAGTTTGTACAAAAAAGCAGGCTGGATGGCCGTCACCATCACGCTG 
attB1-P8HHR23B GGGGACAAGTTTGTACAAAAAAGCAGGCTGGACGGTGAAAGCACTGAAAGAGAAG 
attB1.2-ZK20.3 GGGGACAAGTTTGTACAAAAAAGCAGGCTGGATGGTTTTGTCCGTTACATTC 
attB2.1-ZK20.3 GGGGACCACTTTGTACAAGAAAGCTGGGTCTTATTCCTCATCGAGGTTGCTGAAAATAAAG 
CETN2-F1 GTACACGTCGGTTGCCTAAC 
CETN2-R1 TTCTTCACGCTTGTGTGCTC 
attB2-CETN2 GGGGACCACTTTGTACAAGAAAGCTGGGTCTTAATAGAGGCTGGTCTTTTTCAT 
attB1.2-CETN2 GGGGACAAGTTTGTACAAAAAAGCAGGCTGGATGGCCTCCAACTTTAAGAAGG 
attB2-MJD2.1-JD(199) GGGGACCACTTTGTACAAGAAAGCTGGGTCTAGTTGTGCTAATTCTTCTCCA 
SL1 GGTTTAATTACCCAAGTTTGAG 
ZK20.3-F1 TGAAGATCAGACGATTGCGG 
ZK20.3-R1 AATAAAGTTGATAGCGGCTTCCTCG 
attB1-NEDD8 GGGGACAAGTTTGTACAAAAAAGCAGGCTGGATGCTAATTAAAGTGAAGAC 
attB2-NEDD8 GGGGACCACTTTGTACAAGAAAGCTGGGTCTCACTGCCTAAGACCACCTC 
attB1-Ub GGGGACAAGTTTGTACAAAAAAGCAGGCTGGATGCAGATCTTCGTGAAGA 
attB2-Ub GGGGACCACTTTGTACAAGAAAGCTGGGTCTCAACCACCTCTCAGACGCAGG 
xpc-R1 TAGCGATCGATGCTTTGG 
xpc-R2 ATCCGACAACTGCTGGAATG 
atx-3-1R ACTTTTGGCGGTACAACTGG 
atx-3-1F AAAATCCTGCGATGGTGGAC 
ceact-1F GTCGGTATGGGACAGAAGGA 
ceact-1R GCTTCAGTGAGGAGGACTGG 
Table A3. Nucleotide sequences of the primers used along this work. The attB-primers were used with the Gateway 
cloning system.   
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table A4. List of all yeast two hybrid bait and prey constructs made and used in this work. For all constructs, the potential toxicity for yeast cells or self-activation properties were 
analysed. The expression of the Gal4BD- and Gal4AD-fusion proteins in the yeast was also confirmed. ATXN3 bait plasmids pAS1/2.1N, pAS1/ATXN3 var2.1(14Q) and pAS1/ATXN3 var2.1(40Q) 
(light gray) were described and characterized for the yeast two hybrid screening. Blocking reactions were performed overnight, at 4 ºC, unless stated otherwise. Legend: *, optimised 
aminotriazole (AT) concentration to eliminate the construct’s self-activation property; XG, construct obtained with Gateway cloning technology; -, absence; +, presence; ND, not 
determined; SM, skimmed milk; a) blocking was performed with 1% SM/TBS-T 1h, 4 ºC. 
Assay Western blot analysis 
Constructs 
Toxicity Self-activation 
Fusion Protein 
Primary antibody Dilution (%SM) HRP-conjugated secondary antibody Dilution (%SM) 
WB 
Baits         
pAS1G - ± (20 mM AT)* Gal4BD anti-GAL4BD 1:500 (1%) anti-mouse 1:10000 (1%) + 
pAS1/JD - - Gal4BD/JD anti-HA 1:200 (1%) anti-mouse 1:2000 (1%) + 
pAS1/MJD2-1N  - + (140 mM AT)* Gal4BD/2.1N anti-GAL4BD 1:500 (1%) anti-mouse 1:10000 (1%) + 
pAS1/ATXN3 var2.1(14Q)  + - Gal4BD/ATN3 var2.1(14Q) anti-MJD2.1 1:2000 (3%) anti-rabbit 1:10000 (3%) - 
pAS1/ATXN3 var2.1(40Q)  - - Gal4BD/ATN3 var2.1(40Q) anti-MJD2.1 1:2000 (3%) anti-rabbit 1:10000 (3%) + 
pAS1G/ATXN3 var1.1(14Q)  + + (110 mM AT)* Gal4BD/ATN3 var1.1(14Q) anti-MJD1.1 1:3000 (1%) anti-rabbit 1:5000 (1%) + 
pAS1G/atx-3  - - Gal4BD/atx-3 anti-303JSP 1:2500 (1%) anti-rabbit 1:5000 (1%) + 
pAS1G/NEDD8  - - Gal4BD/NEDD8 - - - - ND 
Preys         
pACT2G - ± (20 mM AT)* Gal4AD anti-HA 1:200 (1%) anti-mouse 1:5000 (1%) + 
pACT2G/JD - + (30 mM AT)* Gal4AD/JD - - - - ND 
pACT2G/HHR23B  - - Gal4AD/HHR23B anti-HA 1:200 (1%) anti-mouse 1:2500 (1%) + 
pACT2G/HHR23Bdel21  - - Gal4AD/HHR23Bdel21 anti-HA 1:200 (1%) anti-mouse 1:5000 (1%) + 
pACT2G/HHR23A  - - Gal4AD/HHR23A anti-HA 1:200 (1%) anti-mouse 1:5000 (1%) + 
pACT2G/XPC-D1 ± - Gal4AD/XPC-D1 - - - - ND 
pACT2G/XPC-D2 ± - Gal4AD/XPC-D2 - - - - ND 
pACT2G/CETN2  - - Gal4AD/CETN2 anti-HA 1:100 (1%) anti-mouse 1:5000 (1%) + 
pACT2G/ZK20.3  - - Gal4AD/ZK20.3 anti-ZK20.3 1:1000 (1%) anti-rabbit 1:5000 (1%) + 
pACT2G/Ub  - - Gal4AD/Ub - - - - ND 
pACT2G/NEDD8  - - Gal4AD/NEDD8 a) anti-HA 1:100 (1%) anti-mouse 1:2000 (1%) + 
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Figure A4. Western blotting analysis of bait and prey Gal4-fusion proteins. Protein extracts were analysed by SDS-
PAGE, transferred to nitrocellulose or PVDF membrane and immunoblotted with anti-MJD1.1 (B), anti-HA (C, D, E, G, H; 
Santa Cruz Biotechnology), anti-303JSP (A) or anti-ZK20.3 (F). The yeast expressed fusion proteins showed the expected 
molecular weights (MW): NEDD8, 30 kDa; HHR23B, 64 kDa; Gal4AD-ZK20.3, 56 kDa; Gal4BD protein, 20 kDa; Gal4AD 
protein, 16 kDa. For the remaining Gal4-fusion proteins we found discrepancies between the observed and the expected 
(parenthesis) MWs in the western blots performed: atx-3, 65 (56) kDa; atx3 (14Q) var 1.1, 59 (62) kDa; human CETN2, 40 
(36) kDa; HHR23A, 62 (54) kDa; HHR23B.2, 62 (60) kDa and JD (josephin domain), 47 (43) kDa. Lanes of Y190 or Y187 
correspond to protein extracts of non-transformed yeast. Detection was carried out with ECL (GE Healthcare). 
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Figure A5. The novel primary anti-MJD2.1 and anti-ZK20.3 antibodies are highly specific. (i) The new anti-MJD2.1 
antibody recognizes with high specificity the full-length 6His-ATXN3 var1.1. For characterization of the antibody, the 
recombinant 6His-tagged ATXN3 var1.1 was separated on a 10% SDS-PAGE gel and proteins were either stained in-gel with 
coomassie blue (A) or transferred to a nitrocellulose membrane and immunoblotted with anti-MJD2.1 dilutions (B, C, D). 
B, anti-MJD2.1 at 1:10000; C, anti-MJD2.1 antibody was pre-incubated with recombinant full-length 6His-ATXN3 var1.1 
protein for 1 hour at 37 ºC and then used to prepare a 1:10000 antibody dilution; D, immunoblotting was performed only 
with secondary antibody dilution, 1:30000 (anti-rabbit). (ii) The new antibody anti-ZK203 recognizes specifically the C. 
elegans homologue of RAD23 protein, ZK20.3. Assays to determine anti-ZK20.3 specificity were performed as follows: 500 
μg of N2 protein extract were separated in a SDS-PAGE; proteins were transferred to a nitrocellulose membrane and 
incubated with anti-ZK20.3 dilutions. A, anti-ZK20.3 at 1:10000; B, anti-ZK20.3 was pre-incubated with 50 μg peptide-
antigen, for one hour at 37 ºC, and then used to prepare an 1:10000 dilution; in C, the membrane was incubated only 
with secondary antibody, 1:10000 (anti-rabbit). Both ATXN3 var1.1 and ZK20.3 proteins were detected at higher 
molecular weights then the expected, 42 kDa and 40 kDa, respectively. These abnormal migrations at approximately 50 
and 60 kDa, respectively, may result from post-translational modifications of the proteins. 
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